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ABSTRACT 
The synthesis and properties of a new coupling reagent, 1 -hydroxyl-4-
ethoxycarbonyl- 1,2,3 -triazole (HOCt), were investigated. An efficient synthetic 
protocol with a high and reproducible yield was established. This new reagent was 
applied successfully to the solid phase synthesis of difficult and large peptides. 
Endothelins(ETs) are a novel family of vasoconstrictor peptides, which have 
variety of biological activities and are involved in many cardiovascular disease states. 
The structure activity relationship (SAR) studies of endothelin-1 (ET-1) and its linear 
analogues were carried out. The results indicated that some residues of ET-1 were of 
particular biological significance and several highly selective and potent ETB receptor 
agonists were reported. Conformational studies indicated that a high percentage of 
helical structure is present in most of the linear analogues studied. 
ET-1 is cleaved from the biologically inactive BigET-1 by ECE in vivo. SAR 
studies of the BigET-1 analogues have also been carried out and residues 16-34 were 
found to be important for ECE recognition and several 16-34 analogues were found 
to be potent ECE inhibitors. 
o-Agatoxins have been valuable tools in defining various classes of Ca 2 
channels. Among these, w-agatoxin lilA was of particular importance since it was the 
only known reagent that blocks both L-type and N-type Ca 21  channels. Due to limited 
natural sources, the chemical synthesis of this peptide was of particular interest. An 
attempt was made to fold this peptide into biologically active form, which was a 
difficult task due to the presence of six disulphide bridges. The synthetic peptide was 
found to be heterogeneous in conformation and the biological assay gave an 10 50 of 
lp.M at the R-type Ca2 channel. 
ABBREVIATIONS 
AAIR8 arachidonic acid release at ETB receptor 
Acm acetamidomethyl 
AcOH acetic acid 
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DMIF N,N' -dimethylformamide 
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HMPA hexamethyiphosphotriamide 
HOAt 7-azabenzotriazole 
HOBt 1 -hydrôxybenzotriazole 
HOCt 1-hydroxyl-4-ethoxycarbonyl- 1,2,3-triazole 
HPLC high performance liquid chromatography 
IIDQ - - 1-isobutyloxycarbonyl-2-isobutyloxy-1,2- 
dihydroquinoline 
NGF neural growth factor 
NUR nuclear magnetic resonance 
NOE nuclear overhauser enhancement 
NOESY nuclear overhauser enhancement spectroscopy 
PhAcm phenylaceamidomethyl 
Pmc 2,2, 5,7,8-pentamethylchroman-6-sulphonyl 




RP-HPLC reverse phase HPLC 
SAR structure activity relationship 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
SPPS solid phase peptide synthesis 
StBu tert-butylsuiphenyl 
RT room temperature 
SRTX sarafotoxin 
Tbfmoc tetrabenzo [a, c,g,i]fluorenyl- 1 7-methoxycarbonyl 
TBTU 2-( 1 H-benzotriazole- 1 -yl)- 1,1,3,3 -tetramethyluronium 
tetrafluoroborate 
TCTU 2-( 1 -H-4-ethoxycarbonyl- 1,2,3 -triazole-yl)- 1,1,3,3 - 
tetramethyluronium tetrafluoroborate 
TFA trifluoroacetic acid 
TFE 2,2,2-trifluoroethanol 
TFFH tetramethyifluoroformamidinium hexafluorophosphate 
TFMSA trifloromethanesulfonic acid 
THF tetrahydrofuran 
TIS triisopropylsilane 
TLC thin layer chromatography 
TMSBr trimethylsilyl bromide 




TSTU O-(N-succinimidyl)- I,1,3,3 -tetramethyluronium 
tetrafluoroborate 
UV ultraviolet 
VIC vasoactive instinal contractor 
VSM vascular smooth muscle 
Z benzyloxycarbonyl 
AMINO ACIDS 
Amino acid 3 letter code - 	 - 	 1 letter - code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gin Q 
Glycine Gly G 
Histidine His H 
Isoleucine lie I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proiine Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Vaiine Val V 
cc-amino isobutyric acid Aib - 
-y-methylieucine Mie - 
nor-leucine Me - 
penicilliamine Pen - 
CONTENTS 
- -CHAPTER 1- INTRODUCTION TO PEPTIDE SYNTHESIS AND 
PURIFICATION 
1.1 The History of Peptide Synthesis ....................................................... 1 
	
1.1.1 	Introduction ................................................................................1 
1.2 Stepwise SPPS and solid phase fragment condensation ................ 3 
1.1.3 	Peptide libraries ..........................................................................6 
1.2 Stepwise Solid Phase Peptide Synthesis (SPPS) ................................ 7 
1.2.1 Solid support and the linker ........................................................ 7 
1.2.2 Activation and coupling ..............................................................9 
1.2.3 Side reactions, racemisation .......................................................11 
1.3 Purification and Folding of Peptides and Proteins .......................... 12 
1.3.1 Deprotection and cleavage of peptides ...................................... 12 
1.3.2 Peptide purification, general ...................................................... 13 
1.3.3 Peptide purification by Tbfmoc .................................................. 13 
1.3.4 Peptide/protein folding ............................................................... 15 
1.3.5 Protection/deprotection, reduction/oxidation of cysteine 
the formation of disulphide bonds ........................................16 
1.4 References ......................................................................................... 18 
CHAPTER 2 THE SYNTHESIS OF A NEW COUPLING 
REAGENT AND ITS APPLICATION IN SPPS 
2.1 Introduction ...................................................................................... 20 
1.1 Development of coupling methods and coupling reagents .......... 20 
2.1.2 Monitoring of peptide synthesis ................................................. 24 
2.2 Synthesis and Properties and Application of HOCt ........................ 27 
2.2.1 Development of N-hydroxy heterocyclic compounds as 
potential coupling reagents and the problems involved ............... 27 
2.2.2 Further investigation of the synthesis of HOCt 
---trouble shooting 	...................................................................28 
2.2.3 Attempted synthesis of the HOCt Knorr reagents .......................33 
-  2.2.4 Synthesis of HOCt phosphinate as coupling reagent ....................38 
2.2.5 The HOCt active esters ..............................................................38 
2.2.6 The reaction between HOCt and DIC, NMR study of the 
reaction mechanism ..................................................................42 
2.2.7 Racemisation studies of HOCt ...................................................52 
2.2.8 Application of HOCt ---- 1. the monitoring of the coupling ..........53 
2.2.9 Application of HOCt ---- 2. the synthesis of endothelin 
analogues and difficult peptides ................................................55 
2 .3 Experimental .................................................................................... 59 
2.3.1 Synthesis 	of HOCt 	..................................................................... 59 
2.3.2 Synthesis of the HOCt Knorr reagents ....................................... 61 
2.3.3 Synthesis of the HOCt diphenyl phosphinate .............................. 63 
2.3.4 Synthesis of the HOCt active esters ........................................... 64 
2.3.5 NMR study of the reaction between DIC and HOCt .................. 64 
2.3.6 Monitoring of amino acid coupling ............................................ 65 
2.3.7 Synthesis of the peptides 	............................................................ 65 
2.4 References .......................................................................................... 66 
CHAPTER 3 THE STRUCTURE ACTIVITY RELATIONSHIP 
STUDIES OF ENDOTHELIN-1, BIG 
ENDOTHELIN-1 AND THEIR LINEAR 
ANALOGUES 
3.1 Introduction ...................................................................................... 68 
3. 1.1 EDRF/EDCF and cardiovascular disease, the history of endothelial 
studies........................................................................................68 
3.1.2 Endothelins and their structures .................................................69 
3.1.3 Biosynthesis of ETs, endothelin-converting enzyme (ECE) ........70 
3.1.4 Receptor subtypes ETA and ETB ................................................71 
3.1.5 Physiological and pathological importance of endothelins ...........72 
3.1.6 Development of ET receptor selective agonists/antagonists, 
SAR studies ...............................................................................74 
- 	 3.1.7 Conformational studies, CD, NMR and X-ray diffraction . . . .......79 
3.2 SAR Studies of ET-1 and Its Linear Analogues ...............................80 
3.2.1 Replacement of Met 7 .................................................................80 
3.2.2 Replacement of Cys 1,3"5 ..........................................................82 
3.2.3 Effects of chain length ...............................................................83 
3.2.4 D-amino acid survey at selected positions ..................................85 
3.2.5 N-Acetylation of ET-1 analogues ...............................................88 
3.2.6 SAR study of truncated analogues, 8-21 of ET-1 .......................89 
3.2.7 Comparison among the truncated 6-21, 7-21 and 8-21 
analogues.................................................................................91 
3.2.8 Synthesis and folding of ET-1 ....................................................93 
3.2.9 Conformational studies of ET-1 and its linear analogues ............95 
3.3 SAR Study of Big ET-1 Analogues, ECE Inhibitors ......................103 
3.3.1 Introduction .............................................................................103 
3.3.2 Effects of chain length and important residues ..........................104 
3.3.3 Synthesis of the reduced isostere FmocTrpi(CH 2NH)ValOH.. 105 
3.3.4 The inhibitory activity of the BigET-1 analogues with the 
reduced isostere .....................................................................110 
3.3.5 Substitutions at position 22, the sulphur containing amino 
acidsCys and Pen ....................................................................110 
3.4 Expeimetals ..................................................................................... 112 
3.4.1 	General ....................................................................................112 
3.4.1.1 	Notes ....................................................................................112 
3.4.1.2 Loading of the first amino acid on the Wang resin 
andCl-Trt resin ....................................................................113 
3.4.1.3 Fmoc and Tbfmoc loading tests ............................................113 
3.4.1.4 Solid phase synthesis of the peptides ....................................114 
3.4.1.5 Cleavage, purification and analysis of the peptides ................115 
3.4.1.6 HPLC conditions 	 . 115 
3.4.1.7 	Elimans' 	test 	......................................................................... 116 
3.4.2 	Synthesis of the linear ET-1 analogues ..................................... 116 
3.4.3 	Synthesis of the ET-1 (peptide 60) .............................................. J19 
3.4.4 Attempted synthesis of Fmoc-Trpiy(CH2NH)Va1OH 
through Z-Trp(CH2N(Boc))Val0H, method 1 ..................... 119 
3.4.5 Synthesis of Fmoc-Trp(CH2NH)Val0H, methods 2&3 ......... 122 
3.4.6 Deprotection and oxidation of Cys(Acm), conversion 
of peptide 45 to peptide 045, the BigET-1 .............................. 124 
3.4.7 	Synthesis of FmocPen(Acm) ................................................... 126 
3.4.8 	Deprotection of Pen(Acm) ....................................................... 126 
3.4.9 	Synthesis of BigET-1 	analogues .............................................. 128 
3.4. 10 	Biological 	assays 	................................................................... 129 
3.4.10.1 	Endothelin binding assay .................................................... 129 
3.4.10.2 	Arachidonic acid release (AAR 5) ........................................ 129 
3.4.10.3 	ECE 	inhibiting 	.................................................................... 130 
3.4.11 	CD 	spectroscopy 	................................................................... 130 
3.4.12 	NMlRstudies 	......................................................................... 131 
3.5 	References ....................................................................................... 132 
CHAPTER 4 THE CHEMICAL SYNTHESIS OF co-AGATOXIN 
lIlA 
4.1 Introduction .................................................................................... 137 
4.2 The Synthesis of a-Agatoxin lilA .................................................. 138 
4.2.1 Introduction ............................................................................138 
4.2.2 The first synthesis of a-agatoxin hA utilising DICJHOBt 
couplingmethod .....................................................................139 
4.2.3 The second synthesis of w-agatoxin lilA utilising HOCt as 
couplingmethod .....................................................................142 
4.3 Studies of the Disulphide Pattern .................................................. 144 
4.3.1 Introduction ............................................................................144 
4.3.2 Trypsin digestion of the synthetic co-agatoxin lilA ................. 145 
- 	 4.4 Biological Activity of the Synthetic co-Agatoxin mA .  ................... 147 
4.5 Experimental ................................................................................... 149 
4.5.1 General ....................................................................................149 
4.5.2 The first synthesis of co-agatoxin lilA .......................................149 
4.5.2.1 Synthesis of co-agatoxin lilA using HOBt/DIC 
couplingmethod ...................................................................149 
4.5.2.2 Purification and folding of co-agatoxin lilA ............................150 
4.5.3 The second synthesis of co-agatoxin lilA ..................................151 
4.5.3.1 Synthesis of co-agatoxin lilA using HOCt 
couplingmethod ....................................................................151 
4.5.3.2 Purification and folding of co-agatoxin lilA ...........................151 
4.5.4 Enzyme digestion .....................................................................152 
4.5.5 Biological assay ........................................................................152 
4.6 References ....................................................................................... 153 
Appendix I ..............................................................................................154 
Apendix H ..............................................................................................155 
Appedix Ill .............................................................................................157 
Apendix 1V .............................................................................................159 
CHAPTER 1 
INTRODUCTION TO PEPTIDE SYNTHESIS AND 
PURIFICATION 
1.1 The history of peptide synthesis 
1.1.1 Introduction 
The history of peptide chemistry can be traced back to the turn of the century 
when Curtius made the first amide bond between two cc-amino acids' and Fischer 
made the first free dipeptide. 2 Early attempts to synthesise a variety of small peptide 
substrates for the recently discovered proteolytic enzymes led to the development of 
the first removable protecting group 3 . The discovery of more complex, naturally 
occurring, biologically active peptides stimulated an explosion of synthesis and 
methodology development that lasted through the 1950s and 1960s, and which laid 
the foundation of modern peptide chemistry. However, traditional solution chemistry 
requires labour intensive purification and isolation of each intermediate compound. 
The difficulties experienced in the synthesis of even very small peptides stimulated a 
sustained effort towards improvements in the methodology of peptide synthesis. 
Techniques which allowed facile chain-building by simple, repetitive operations were 
definitely needed. 
In the 1960s, Merrifield published his remarkable work of solid phase peptide 
synthesis (SPPS). 4  The rationale for the SPPS approach was simple. By attaching a 
growing peptide chain to an insoluble polymeric support, it was reasoned that the 
excess reagents and by-products from the coupling reactions could be removed by 
simple filtration and washing steps. This new method of peptide assembly was entirely 
compatible with some of the well developed chemistry of coupling and functional 
group protection in solution which already existed at that time. The simple, repetitive 
methodology also made the mechanisation and automation of the chain building 
process possible, thus greatly reducing the drudgery in execution, especially when 
1 
chains of 50 or more residues have to be constructed. The remarkable idea laid the 
foundation of modern peptide chemistry and it remains viable and alternative to the 
gene engineering technology for the synthesis of peptides. 
Recently, there has been an upsurge in interest in protein chemistry, which, to 
a large extent, has been stimulated by the establishment of a pharmaceutical industry 
based on the production of proteins by genetic engineering. Molecular biology 
research has led to the availability of amino acid sequence data by cloning and cDNA 
sequencing of genes. In many cases, the proteins themselves have never been isolated 
and their properties are largely or completely unknown. Chemical synthesis of peptide 
fragments, or of the whole molecule, can be used to study the properties of such gene 
products and also help redesign known proteins as second-generation products for 
pharmaceutical use. Chemical synthesis has a variety of applications in research on 
biologically active peptides including proof of structure and demonstration that the 
appropriate biological activities reside in a particular molecule, or even a particular 
part of the molecule'. Most importantly, chemical synthesis allows the systematic 
variation of structure with the aim of developing peptides for therapeutic use, the so-
called structure-activity relationship (SAR) study, which can be shown clearly in the 
development of endothelin agonists and antagonists (Chapter 3). 
Recent improvements in the solid phase method itself and in associated 
chemistry have extended the usefulness of SPPS to the routine preparation of peptides 
up to 50 amino acid residues in length. This has made synthetic peptides readily 
available to very large number of biological researchers, and has changed the way in 
which many research problems are approached. 
However, the stepwise synthesis of peptides with more than 100 residues 
remains the big challenge facing the peptide chemists. The synthesis of peptide 
sequences of 50100 residues is normally unpredictable, as side reactions vary from 
case to case and depend not only on the individual amino acid involved, but also on 
the primary sequence. Studies of new coupling reagents and coupling methods, 
protecting groups, mechanism of side reactions and identification of difficult couplings 
thus remain a very active area in peptide research. Several excellent reviews have been 
published on these subjects and can be referred to for more details. 6 ' 7 ' 8 By using a 
new coupling reagent, 1-hydroxyl-4-ethylcarbonyl-1,2,3-triazole (HOCt), which has 
2 
been developed in our laboratory, peptides as long as 170 amino acid residues have 
been synthesised with success 9 . 
R 1 p 
I 
	
No-protecting group I- NH —4H —C —OH 	+ 	linker 
Loading of first 
protected amino acid on to resin 
R1 o 
1 	11 
Nprotecting group 	NH 	H —c —o—flerrin 
Deprotect the amino group 




NH2 —CH _ 
 
No-protecting group - NH 	H - 	activating group 	 coupling 
R2 0 	 R 1 
1 11 1 	11 
Ne-protecting group i- 
Repeat deprotection 
* 	and coupling 
Rn 0 	 R1 o 
1 11 1 	11 
N°-protecting group - (NH __H -C —n NH —CH -C ___0___1iie-_-fin 
Cleave 
Rn o 	 R1 o 
1 11 1 	11 
H (NH —CH _) NH —CH -C - OH + EeJ—_jsin 
Scheme 1.1.1 The general process of stepwise SPPS 
1.1.2 Stepwise SPPS and solid phase fragment condensation 
There are two different synthesis strategies for the assembly of peptide chains 
on solid supports: the stepwise synthesis and fragment condensation. 
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The basic principle of stepwise SPPS is outlined in Scheme 1.1.1. Two 
synthetic methodologies are used routinely for stepwise SPPS today, based on the 
different Nu  protecting groups applied----the base-labile Fmoc .group (1) or the acid-
labile Boc group (2) (Figure 1.1.1): 
0 
HCH2 Q - 
(1) Fmoc- 
CH3 
H3C— C_ 0— C - 
CH  
(2) Boc- 
Figure 1.1.1 The structures of the I'P'-protecting groups, Fmoc and Boc 
The Boc methodology was first introduced by Merrifield and has been used 
successfully as a standard SPPS method ever since.' 0 ' 11 Cleavage of the Boc 
protecting group is achieved using trifluoroacetic acid (TFA), and the final cleavage 
of the peptide from the resin and side chain deprotection requires strong acid such as 
hydrogen fluoride (BF) or trifluoromethanesulphonic acid (TFMSA) (Scheme 1.1.2). 
Protecting group 
'4 	 HF/TFMSA 
R 




= polymer 	L = linker 
Scheme 1.1.2 The deprotection and cleavage in Boc methodology 
Alternative methodology arose out of concern that repetitive TFA acidolysis 
in Boc group deprotection could lead to the alteration of sensitive peptide bonds as 
well as acid catalysed side-reactions. In addition, cleavage and deprotection in the 
Boc strategy also requires the use of dangerous BF, and expensive laboratory 
4 
apparatus. This situation changed with the introduction of the base labile N 
protecting group 9-fluorenylmethyloxycarbonyl (Fmoc),' 2" 3 which can be removed 
with very mild base, i.e. 20% piperidine in DMF, and the hazard acid TFA is only 
required once, at the last stage, to cleave the peptide from the resin and to remove 
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) 	 CH- 1-- NHCHRCO_-® 
(H 
+ CO  + NH2CHRC0- 
Scheme 1.1.4 The mechanism of Fmoc cleavage 
This makes Fmoc methodology more attractive and it is thus adopted in this 
laboratory. The mechanism of Fmoc deprotection is shown in Scheme 1.1.4. 
As an alternative strategy for peptide chain assembly, the solid phase fragment 
condensation method provides a way of overcoming the losses in overall yield which 
accompanies the stepwise approach and also alleviating difficult sequence problem 
5 
found using stepwise SPPS. However, the major problem related to this method is the 
insolubility, and thus the purification, of the protected fragments, which are to be 
coupled to the resin bound peptide intermediate. A newly developed reagent, 
TbfmocCl,14' 15  which provides a totally different method of purification, may solve 
this problem eventually. The principle of fragments condensation is shown in Scheme 
1.1.5. 









Scheme 1.1.5 The principle of solid phasefragments condensation 
1.1.3 Peptide libraries 
A newly developed, rapidly expanding area, the combinatorial library, has also 
found its application in peptide chemistry, the building of peptide libraries. The 
method allows hundreds and thousands of peptide analogues to be synthesised in a 
very short time. This technique will play an important role in the development of 
physiologically important peptides, making SPPS an even more attractive approach. 
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1.2 Stepwise solid phase peptide synthesis (SPPS) 
1.2.1 Solid support and the linker 
In the early work of Merrifield, several different types of polymers were 
investigated. 16  The most promising one was polystyrene with 1% divinylbenzene as 
cross-linking reagent. This resin possessed most of the characters required for the 
SPPS. It was chemically stable, could be easily modified by attachment of a linker and 
also had reasonable swelling properties in the solvent used for SPPS, allowing rapid 
diffusion of the reagents. Despite much research and the development of new 
supports, including the successful application of polyacylamide resins, the original 
chioromethylated polystyrene resin remains the preferred one. 17 
The chioromethylation of the cross-linked polystyrene resin produces an 
arylchloromethyl derivative which can be used as an anchor for the growing chain as 
in the case of Merrifield resin", or more usually as a starting point to which can be 
coupled a variety of handle linkers, which provide different acid labilities for 
subsequent cleavage of the associated peptide from the resin on completion of the 
peptide assembly. 19,20 
The linkers used in this laboratory for the synthesis of peptide acids and 
amides are p-benzyloxybenzylalcohol and dibenzosuberenyl resins which were 
developed by Wang 2' and Ramage22 respectively. However, attachment of Cys and 
His to the Wang resin is associated with high level of racemisation due to the 4- 
dimethylaminopyridine (DMAP). catalysed activation of the carboxyl group 23 . A 
specially designed resin, CI-Trt resin is thus recommended, 24' 25 as DMAP is not used 
for the loading of the first amino acid onto this resin. 
Synthesis of peptide acids with C-terminal Pro can also be problematic. Loss 
of peptide from the resin at the dipeptide stage can be very high as a result of 
diketopiperazine formation 26 . The extreme steric hindrance of the CI-Trt resin can 
completely suppress the formation of the diketopiperazine at the dipeptide stage, thus 
preventing the loss of dipeptide from resin. 27,28,29  As the CI-Trt linker is particularly 
acid labile, CI-Trt resin has also been widely used in the preparation of fully protected 
7 
peptide fragments which can be cleaved under very mild acidic cleavage 
conditions  .24,10  The structures of these resins are shown in Figure 1.2.1. 





Dibenzosulberenyl resin 	C(t)3--OCH 
2-Chiorotrityichioroide resin 
(CI-Trt resin) 
Figure 1.2.1 Structures of the resins used in this laboratory 
OCH3  OH 
Rink resin 
JL 
CH30 	 O—CH2 --- 
NH—Fmoc 
Rink amide resin 
CH3O 
HMPB-BHA resin 	
CH30 	 L ,) 
HOCH2 __~ __O(CH2)3—00NH—CH__(I__Ø 
Figure 1.2.2 Some other resins used for Fmoc SPPS 
There are many other types of solid supports and handles to suit a variety of 
requirements, the detail of which can be found in the literature. Some of them are 
shown in Figure 1.2.2. - 
1.2.2 Activation and coupling 
The formation of an amide bond involves the acylation of an amino group of 
the first amino acid by the carboxyl group of a second amino acid . 3 ' This reaction is 
energy-requiring and thus needs the activation of either the carboxyl or the amino 
group involved. However, whereas the activation of the amino group is a challenging 
problem to which no practical solution has been found to date, activation of the 
carboxyl group thus remains the underlying principle of all coupling methods in use 
(Scheme 1.2.1), where Y is an electron withdrawing group, which can increase the 
electrophilicity of the carboxyl carbon and thus facilitate nucleophilic attack by the 
amino group. The tetrahedral intermediate formed (4) leads to the stabilised amide 
bond by the elimination of Y, which is usually a good leaving group. 
0 ____ 	(O '' ____ 	 ____ 	0 
R-C 	 R-C" N-H 	 R -c-Y 	. R-C' 
OH 	 I 	 I R NH-R'  
(4) 
Scheme 1.2.1 The process of an amide bond formation 
There are four major types of coupling techniques currently employed for the 
stepwise introduction of Naprotected  amino acid in SPPS. 32 ' 33 ' 34 These are 
summarised in Table 1.2.1 and will be discussed in detail in Chapter 2. 
Despite all these alternatives, in practice, almost all peptides bonds are 
currently formed using the coupling reagent, DIC/DCC and HOBt, either for Boc or 
Fmoc methodology, due to the availability and cost. A new coupling reagent has 
recently been developed in our laboratory, 35 which shows better coupling efficiency 
than HOBt. It will be discussed in Chapter 2. 
Table 1.21 Some coupling methods and reagents 
methods reagents comments 
Carbodiirnides 
- 	 (J).N=C =N 	
- Insoluble by-product with 
DCCI 	"-" DCCI, 
C 	N Dehydration of Asn/Gln; / 	DIC Racemisation of His (Trt). 
0 N 
 Improved with the addition of 
(5) HOBt  OH 
HOBt (5). 
Anhydrides 0 	0 Mainly for Boc SPPS; 
R - —0— 
Side-reactions involved; 
Wasteful if R=R' 
Active esters F 	F 
01 'N 
K- -N' 	F-<--O Easy to use, fast in coupling, 
0 • 
(6) R-CO2Bt COR 
	F 	F less side-reactions; 
0 	 (7) R-0O2pfp 
LN_O_COR a--'N  
Not all available; 




(8) R-0O2Dhbt 	(9) R-0O2OAt 
COR 
NPF 	 1 	"N 	
PF 
0111:~f 	 ~d 
6–P-E-N(C44 1 	o 	PEN€I 
] 
3 -' (11)PyBOP (1 0) BOP 
-Br 	 1"N 	PF 
I Cq3P :r4 
Coupling (12)PyBroP 	 6-C[N(CH3)2]2 
(13)HBTU Easy to use; 
Reagents  0 
a r
N 
"N 	BF Less side-reactions; 
Expensive. 






' :NN_o_c[N(cH3)1 	3 2J2 	
" 	
PF& 
BF, 	 0-_KJ 
(16)TNTU (17) B01 
H3d' 
():N '
N 	 C-F PF&  (I-13C)2N' 
(18)HATU 	 (19)TFFH 
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1.2.3 Side reactions, racemisation 
Side reactions are a feature of almost all organic reactions, but they are of 
particular importance in a process such as peptide synthesis where hundreds of 
reactions are involved in the chain assembly. Intensive efforts have been made in the 
identification and correction of side reactions, and most of the problems have been 
solved using carefully adjusted conditions. 6 ' 7'36 
H—N 	 10 N 	Y 
_ _7L o 
I, 	,- 	N 	I 
R' 
I 








Scheme 1. 2.2 The oxazolone mechanism of racemisation 
Racemisation is the most common side reaction which affects all naturally 
occurring amino acids except glycine. A considerable amount of work has been 
carried out in order to understand the mechanism, and thus to prevent it. 11,37 The 
most commonly observed and well studied mechanism of racemisation is oxazolone 
formation which occurs during the activation of the Naprotected  amino acid (Scheme 
1.2.2). 
The tendency for racemisation lies in the ease by which the acidic proton can 
be abstracted by bases from the chiral centre due to resonance stabilisation of the 
carbanion generated in the process. It is thus influenced by the nature of the amino 
acid involved, the solvent used or the presence/absence of tertiary amines. The 
imidazole side chain of His provides an intramolecular amine, hence it is not surprising 
that this amino acid causes most problems in peptide synthesis where racemisation is 
concerned. Fortunately, this tendency for oxa.zolone formation can be completely 
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suppressed in the presence of HOBt, which makes stepwise SPPS a reliable, 
racemisation free synthetic approach in most circumstances. 6 ' 7' 36 
Incomplete acylation at each coupling step gives rise to truncated and deletion 
peptides with properties similar to the target sequence. Optimised coupling condition 
can improve the situation, but not completely cure it. Therefore, quantitative 
termination of the unreacted functional group, requires the so called 'capping' step 
which becomes equally important. This is an area which requires further investigation. 
Apart from the general problems, residue or sequence specific side reactions 
have also been studied. 17,18,39  Some of them, such as the cyclisation and rearrangement 
of Asp/Gly under certain circumstances to give incorrect peptide sequences which are 
very similar to the target peptide, still remain as big challenges facing the peptide 
chemist. 
1.3 The purification and folding of peptides and proteins 
1.3.1 Deprotection and cleavage of peptides 
After complete assembly of the peptide chain on the resin, all protecting 
groups must be removed and the link between the peptide and the resin cleaved in 
order to release the free peptide into solution. TFA, in the presence of scavengers, is 
the normal reagent used in Fmoc methodology. This process is always hampered by 
side-reactions involving certain side-chain protecting groups which are liberated as 
stable cations during the TFA cleavage and deprotection, such as Trt, tBu and Pmc. 
The majority of the side-reactions involve modification of sensitive amino acid 
residues, such as Trp, Tyr, Met and Cys. A number of scavengers are thus included in 
the cleavage mixture to quench all the cations. Optimum cleavage conditions are very 
much dependent on the individual amino acid residues present, it is thus always 
recommended that a small scale cleavage be carried out to find the particular 
conditions suitable for the peptide sequence involved. The most commonly used 
scavengers are ethanedithiol (EDT), H 20, thioanisole, phenol, and triisopropylsilane 
(TIS). 
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1.3.2 Peptide purification, general 
The crude peptide resulting from SPPS contains a variety of by-products, 
which must be removed to afford the pure final product. In principle, purification 
should be carried out by the consecutive application of several procedures based on 
different separation mechanisms, i.e. reverse-phase HPLC, ion exchange 
chromatography, gel filtration, isoelectronic focusing, etc. Most small peptides 
containing less than 50 amino acids can be purified by a single step reverse-phase 
HPLC. For large peptides and proteins, purification becomes much more complicated. 
Owing to the onset of relatively stable, slowly exchanging folded structures of the 
peptide chain 40, a single molecular species will give a variety of chromatographically 
distinguishable but not separable components, making separation on HPLC an 
impossible task. Either the peptide chain must be folded prior to purification into a 
single structure stable under the IHPLC conditions or conformationally independent 
separation techniques must be used to purify the target peptide in the presence of 
denaturants prior to folding. Together with the folding itself, purification of large 
peptides and proteins presents the most important current challenge for peptide 
chemists. The newly developed reagent, TbfinocCl, provides a way to tackle this 
problem. 
1.3.3 Peptide purification by Tbfmoc 
The structure of TbfrnocCl, the reagent used for peptide purification 14,11  is 
shown in Figure 1.3.1. 
Ce 
(23) TbfmocCl 
Figure 1.3.1 The structure of ThfmocCl 
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I Tbfmoc— NHCHRnCO--- NHCHR 1 CO—OH 
ACNHCHRjCO ---------OH 




[Imfmocl—NHCHRncO-- _ NHCHR1 CO_OH] 
10% piperidine/Dioxane 
H2NCHRnCO ---- NHCHR1 CO—OH 
Scheme 1.3.1 The principle of Tbfmoc purification ofpeptides 
The principle of peptide purification by Tbfmoc is shown in Scheme 1.3.1. By 
using a Tbfmoc selective adsorbent, such as charcoal, only the peptide chain which 
has a Tbfmoc group on it will be adsorbed, while the truncated peptides can be easily 
washed away. Under ideal coupling and capping conditions, only the target peptide 
has a free N-terminal amino group at the end of chain assembly which can react with 
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the TbfInocCl, making the reagent a powerful alternative tool in large peptide/protein 
purification. In practice, a small amount of deletion peptides is always present, 
especially in the case of large peptide, which will be isolated together with the target 
peptide. Although further purification is required, the crude peptide is much cleaner 
after Tbfmoc purification, which makes the subsequent purification much easier. For 
small peptide (-30 amino acid residues), a single peak can normally be obtained just 
after Tbfmoc purification. 15 It thus provides a very promising way to purify the fully 
protected peptide chain required for fragment condensation, as solvents such as 6M 
guanidine hydrochloride, 8M urea or 2-propanol can be used to dissolve the normally 
insoluble fragments. 
1.3.4 Peptide/protein folding 
To be biologically active, all large peptides and proteins must adopt specific 
folded three dimensional structures. In this biologically active, or native form, the 
peptide chain is folded into a thermodynamically preferred conformation, which is 
maintained by the accumulating relatively weak interatomic forces such as hydrogen 
bonding, hydrophobic interactions and charge interactions. 4 ' Correct folding of 
peptides/proteins is a major issue in protein science. 42 ' 43 This problem is particularly 
acute in the case of Cys containing peptides/proteins where the disulphide connections 
must be formed in one particular way to give rise to biological activity. The 
mechanism and prediction of protein folding is an important biological problem, the 
elucidation of which has been the subject of much experimental and theoretical work 
ever since the first three dimensional structure of a protein was known. 44 ' 45 ' 46 From the 
practical point of view, the preparation, purification and folding of large peptides and 
proteins is of great interest. 
There are two alternative strategies in the purification and folding of large 
peptides: folding before purification or purification before folding. Limited by the 
literature evidence currently available, it is impossible to decide between them. 
Generally, if the crude peptide contains a majority of the target sequence, folding can 
be carried out prior to purification; Otherwise pre-purification can help the folding by 
removing most of the impurities, especially when multiple disulphide bonds are 
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present. The general protocols are illustrated in Scheme 1.3.2, where GSH is 
glutathione reduced and GSSG is glutathione oxidized. 
- 
- 	CRUDE PEPTID 
Strategy 1: 	 Strategy 2: 
6M Gdm.HCI, 20%DTT 
50mM Tris pH 8.0-8.5 
50°C, 2hr 
Oxidation in buffer, pH-8.0, 
GSSG/GSH 	 if 	if 
HPLC 
8M Urea, 20%DTT 
20mM Tris pH 8.0-8.5 
50°C, 2hr 
Gel filtration/Ion exchange/ IEF 




Scheme 1.3.2 Two strategies for peptide purification/folding 
1.3.5 Protection/deprotection, reduction/oxidation of Cys --- the formation of 
disulphide bonds 
An amino acid residue which is of particular importance in peptide synthesis is 
cysteine. There are basically two different kinds of protecting groups applied in Fmoc 
SPPS. The acid labile protecting group such as Trt and acid stable protecting group 
such as Acm. Different protecting groups or different combinations of them are 
selected to suit different synthetic protocols. When acid stable protecting groups such 
as Acm are used, an additional procedure is required for the deprotection of these 
groups before generation of disulphide bonds. A number of deprotection methods 
have been developed based on the different protecting groups and protecting strategy 
used, which are summarised in Table 1.3.1 and the details can be found in the 
literature. 17,47,48 
Generation of disulphide bonds is often hampered by practical difficulties such 
as instability or insolubility of reduced peptides. A number of different methods have 
been reported. Among them, air oxidation in a dilute peptide solution is the most 
popular protocol, but the rate and yield obtained are generally low; and the 
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reproducibility is poor. 7 Oxidation systems composed of low molecular weight 
disulphides and thiols have been used extensively for peptide disulphide formation. 49 
These systems increase both rate and yield of the native conformation by facilitating 
rapid reshuffling of incorrect disulphide bonds. Mixtures of oxidised and reduced 
glutathione, cysteine, or 2-mercaptoethanol are commonly used at 1-5mM thiol and 
0.01-0.5mJ\4 disulphide reagent. 50  Optimum conditions usually involve with a 10-fold 
molar excess of reduced thiol component in a buffer, the pH of which is set up at the 
upper limit where the peptide is still able to fold. 5 ' 
A newly developed method makes use of DMSO in TFA or aqueous buffer 
solution. 52  No side-reactions were observed with amino acids such as Met, Tyr and 
Trp. 53 
Table 3. 1.1 Protecting groups and deprotection reagents for Cys 
I protecting Deprotection Reagent 
Group fFA I TFMSAI Hg(OAc)2 1 AgOTf 1'. 12 Ihiols enzyme 
Trt ± + + + - + - n 
Acm - - + + +* - n 
tBu - + + - - - n 
StBu - n n n n + 
PhAcm - - + + +* - + 
Notes: +, deprotected; -, not deprotected; +*, resulted in disulphide; n, not tested. 
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CHAPTER 2 
THE SYNTHESIS OF A NEW COUPLING REAGENT 
- AND ITS APPLICATION IN SPPS 
2.1 Introduction 
2.1.1 Development of coupling methods and coupling reagents 
The principal reaction in the synthesis of a peptide is acylation of an amino 
group of an amino acid by the carboxyl group of a second amino acid to form an 
amide bond (Section 1.2.2); the process is known as coupling. In order to convert 
carboxylic acids into acylating agents their hydroxyl group must be replaced by an 
electron withdrawing group in order to enhance the electrophilicity of the carboxyl 
group (Scheme 1.2.1). 
Numerous reagents and methods have been developed in the history of peptide 
chemistry; these were summarised in Table 1.2.1 (Section 1.2.2). Unsurprisingly the 
acid chloride was the first activated intermediate used in the early days to make very 
small peptides.' However, both the preparation and application of amino acid 
chlorides were far from unequivocal, and it was soon replaced by the more 
satisfactory acid azide method. 2 Although the Curtius rearrangement is an inherent 
shortcoming of this method, the azide process still remains a powerful and practical 
approach even today, mainly because of the negligible associated racemisation. More 
recently, the azide method has found application in peptide ligation when combined 
with a special linker. 3 
Formation of the peptide bond via acid anhydrides gained considerable 
popularity after the introduction of mixed (unsymmetrical) anhydrides in the 1950's.4' 5 
The improved version, iso-butylcarbonic acid mixed anhydride, 6 remains a valuable 
tool in peptide synthesis today. However, in the application of the mixed anhydride 
method, a small amount of the second acylation product can always be expected. This 
inherent ambiguity can be avoided if aminolysis of esters is used for peptide 
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formation. Several types of active esters were soon developed; for example, p- 
nitrophenyl, 7 N-hydroxysuccinimide, 8 pentachlorophenyl, 9 and pentafluorophenyl 
The more recently developed reagent N-hydroxybenzotriazole (HOBt), and 
its esters, are of particular interest and will be discussed further. 	- 	- - 
HOBt was first introduced into peptide synthesis as an additive to the 
carbodiimide method in 1970 by Konig et at.", to suppress the racemisation and other 
side reactions caused by the over activating effect of DCC/DIC (discussed below). 
The HOBt esters were recognised as the actual active intermediates involved in the 
formation of the peptide bond and this in situ active ester formation method soon 
gained popularity in peptide synthesis. The high reactivity of the HOBt esters can be 








R-C-NH-R' + 	- 
\/ 
(5) HOBt 
Scheme 2.1.1 The anchimeric assistance effect of the HOBI esters 
Carbodiimides, particularly N,N'-dicyclohexylcarbodiimide (DCC), were also 
introduced for peptide bond formation 13 at that time. This was regarded as a major 
event in peptide history. The novel feature of coupling reagents is that they can be 
added to a mixture of the carboxyl component of the amino acid and amine 
component of the growing peptide chain, thus no pre-activation is needed. The 
reaction between the amine component and carbodiimide does occur, but this is 
negligible as it is very slow compared to the rapid conversion of the acid to the amide. 
DCC has been replaced by diisopropylcarbodiimide (DIC)' 4"5 in SPPS due to the 
insolubility of the urea by-product of the DCC reaction, N,N'-dicyclohexylurea 
(DCCU). 
Several mechanisms have been proposed to explain the surprisingly high 
reaction rate observed in aminolysis through the carbodiimides. The powerful N=C 
group and its basic character provide the major reasons (Scheme 2.1.2). 
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Scheme 2.1.2 The mechanism of aminolysis through DCC/DJC 
However, a price has to be paid for the speedy execution of activation and 
coupling by this method. Over-activation of the reactive intermediate results in some 
loss in chiral purity when certain amino acids are involved. Furthermore, the 
nucleophilic centre of 0-acylisoureas competes with amine component for the acyl 
residue and this competition leads to the formation of unreactive by-products, N-
acylureas (Scheme 2:1.3). Both racemisation and N-acylurea formation can be 
suppressed by the addition of auxiliary nucleophilies such as HOBt. 1 ' The 
combination of DCC/DIC and HOBt soon gained its popularity and remains the most 








>  1_11_H_< 
(26) N-acylurea 
Scheme 2.1.3 The formation of N-acylurea 
The success achieved with DCC/DIC stimulated an unrelenting research for 
even better coupling reagents. Among those are carbonyldiimidazole, 1-
ethyloxycarbonyl-2-ethyloxy- 1, 2-dihydroquinoline (EEDQ) and 1 -isobutyloxy -
carbonyl-2-isobutyloxy-1, 2-dihydroquinoline (IIDQ).' 6 The latter offers some 
advantages over DCC/DIC methodology in that fewer side reactions were observed, 
but this reagent has never become as popular as DCC/DIC. 
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In the 1970s, phosphonium derivatives or BOP reagents, initially reported by 
Castro at el. 17  became increasingly popular as coupling reagents, especially for 
SPPS.' 8"9 The active ester pathway was suggested as the main route involved in the 
peptide bond formation (Scheme 2.1.4). The original reagent, BOP (10), was soon 
replaced by PyBOP (11), due to its carcinogenic by-product, 
hexamethylphosphotriamide (HTVIPA) 20 
0 RNH 
R—C" + R"3P-OBt 	R_8L_P4Rfl3 	R—C" 	 R—C 
0Bt 	 NHR 
B H' J OBt 	 (27) 
Scheme 2.1.4 The mechanism ofpeptide bond formation through BOP reagents 
Another class of reagents which are related to phosphonium reagents are the 
carbon analogues or uronium salts. 2-( 1 H-benzotriazole- 1 -yl)- 1,1,3,3 -tetramethyl-
uronium hexafluorophosphate (HBTU) (13) (Table 1.2.1), was first synthesised and 
used in solution phase peptide synthesis by Gross et al. 2 ' and further developed by 
Knorr et al. 22 for SPPS, along with other analogues (14)-(16) (Table 1.2.1).2324  A 
similar analogue, BOl (17) (Table 1.2. 1) was reported by Kiso et al. 25 These reagents 
are known as Knorr reagents. 
The mechanism of coupling through Knorr reagents is similar to that of the 
BOP reagent; both involve an active ester, as shown in Scheme 2.1.5. 
1 + PF6 
R—C" + A..'>_Y 	 / 
0 —N 	 A) 	 Y 
:B 	H 	 Aj R 
0 0 RNH2 	 II 
R—C" 	 R—C—NF-I--R' 
(28) " ' 
Scheme 2.1.5 The mechanism ofpeptide bond formation through Knorr reagents 
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One noticeable recent development in the field of coupling reagents is the 
discovery of the 7-aza analogue of HOBt, HOAt (29) and the investigation of its 
coupling efficiency relative to BOP and Knorr reagents. 26 '27 The enhanced coupling 
efficiency and lower level of racemisation reported of the HOAt esters were also 








(30) Coupling intermediate of HOAt 
Figure 2.1.1 The structures of HOAt and its active ester 
An additional benefit of this reagent is the visual indication of reaction 
completion, by the disappearance of the yellow colour of the reaction mixture. This 
feature provides a way of monitoring coupling by a specially designed instrument. 
This will be discussed further in the next section. 
More recently, tetramethyifluoroformamidinium hexafluorophosphate (TFFH, 
(19)) was reported by Carpino et al. as a rapid-acting peptide coupling reagent for 
both solution and solid phase peptide synthesis. 29 
2.1.2 Monitoring of peptide synthesis 
Stepwise SPPS has been greatly improved by the development of new 
coupling reagents and methods. Peptides with up to 50 amino acid residues can be 
synthesised regularly in most research groups and industrial laboratories. However, 
the synthesis of peptides longer than 100 residues is still a big challenge facing the 
peptide chemist. Apart from the gradually elongating peptide chain, which obviously 
accentuates the difficulties involved, smaller peptides with so called difficult 
sequences have also been reported which lead to problems in the synthesis .30,31  It is 
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well known that coupling efficiency is sequence dependent and thus unpredictable, 
despite the research effort directed at this problem. 32 Coupling percentage can drop 
dramatically at certain amino acids in the synthesis of one peptide, whilst in another 
synthesis the same amino acid can couple very easily. Whenever a serious drop occurs 
during a synthesis, coupling can normally be improved by a remedial treatment, such 
as recoupling, extending the coupling time, increasing the ratio of the incoming amino 
acid, sonication etc. It is therefore very important to follow the synthesis by an 
efficient monitoring method. 
The methods used in those early days of SPPS, i.e. amino acid analysis or the 
Schiff base reaction, were time consuming. Recent developments have led to the 
discovery of more efficient methods of monitoring; however, the majority of these 
methods require additional reactions to introduce and remove diagnostic reagents, 33 
withdrawal of resin samples 34 or construction of new instruments. 35 
The ideal approach to monitoring a coupling is to examine the solution of the 
activated amino acid during or after the coupling, without disturbing the synthetic 
process. Bodansky and Sheeham 36 first introduced this approach to Boc SPPS using 
p-nitrophenyl esters of the Naprotected  amino acids. As free p-nitrophenol absorbs at 
3 l4nm and the active esters absorb at 270nm, filtrate of a second coupling which 
absorbs only at 270nm indicates the completion of the previous coupling. A similar 
idea was introduced into Fmoc SPPS by Dryland etal. in 1986. The synthesis of a 
pentadecapeptide was carried out under continuous flow conditions, using "Fmoc-
Polyamide" chemistry. The circulating activation and deprotection mixtures were 
passed through a UV spectrophotometer, thus both acylation and deprotection 
process could be monitored. However, this method is only semi-quantitative and 
involves many errors. 
Recently, a more reliable monitoring method has been developed for Fmoc 
chemistry in this group. The efficiency of each coupling is assessed by passing the 
deprotection mixture through a UV spectrophotometer and measuring the absorbance 
at 302nm (Scheme 2 . 1 . 6) . 38 
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Scheme 2.1.6 Monitoring of Fmoc SPPS through deprotection 
However, as shown in Scheme 2.1.6, if the coupling is found to be poor at this 
stage, the coupling can not be repeated since all the amino functions of the 
penultimate amino acid have been terminated and all the amino functions of the last 
amino acid coupled have been exposed. Obviously, examination of the acylation 
process before capping and deprotection would be of great advantage. HOBt, and its 
derivatives absorb strongly at 302nm, the wave length at which the Fmoc adduct is 
examined; therefore UV monitoring of the coupling mixture is not compatible with 
Fmoc methodology. Research effort was made in order to find alternative coupling 
reagents which do not absorb at 302nm and possibly have the same, or even better, 
coupling efficiency. This led to the development of a new coupling reagent, 1-
hydroxyl-4-ethoxycarbonyl- 1,2,3 -triazole (HOCt, 31d).  39 
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2.2 Synthesis, properties and application of HOCt 
2.2.1 Development of N-hydroxy heterocyclic compounds as potential coupling 
reagents and the problems involved 
A series of N-hydroxy compounds were synthesised, and investigated as 
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Figure 2.2.1 The structure of new coupling reagents synthesised by Davison39 
Of these, HOCt (31d) showed the most promising properties as an auxiliary 
nucleophile, which did not absorb at 302nm. However, problems were encountered 
during the synthesis of this compound. 39 
The synthesis of HOCt was first reported by Bennet et al. 40 in 1991. It was 
synthesised from the diazo aldehyde using a method previously developed by 
Stojanovic, 41  but no experimental details were given. A synthetic route based on 
Stojanovic's method was followed, and adjusted by Davison, until the expected 
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Scheme 2.2.1 The process of triazole synthesis, Davison's method 
Initially the whole synthesis took one week, and only gave an overall yield of 
—5%. When the protocol was repeated, in order to obtain more material for further 
investigation, a lot of problems were encountered and the synthesis was found to be 
irreproducible. The final product was only afforded occasionally, and in a very low 
yield, but most often no product was isolated at all . 39 To overcome such difficulties, 
further investigation was obviously necessary. 
2.2.2 Further investigation of the synthesis of IELOCt --- trouble shooting 
The experiment was first carried out following Davison's procedure (Scheme 
2.2.1), except that in the last step the solvent, benzene, was replaced by dry ethanol 
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due to the toxicity of the former. The product was afforded in 42% overall yield 
without any major problem, although some steps were indeed found to need special 
attention. This will be discussed below. 
The first improvement made was to step 5, the cyclisation step. It was found 
that an NIvIR sample of the diazo ester (37) in chloroform, when left at room 
temperature for two days, changed from the yellow dia.zo solution to completely 
colourless. The sample was checked by NN'IIR again and it was found that the diazo 
compound had completely cyclised into triazole (31d). This was a very interesting 
result since the protocol developed by Davison involved refluxing the diazo 
compound in benzene in order to cyclise to the triazole, which is hazardous since 
diazo compounds are potentially explosive, especially at high temperature. Therefore 
an alternative protocol was suggested, the cyclisation being carried out in chloroform 
at room temperature. A few drops of acetic acid are added as a catalyst because it is 
present in CDC1 3 in a very small amount as an impurity. 
The whole procedure for the synthesis of HOCt was repeated and 
investigations were carried out for the other steps in the scheme. The first step was 
carried out according to Searle's method 42  and pure product could be easily obtained 
in a very high yield (95100%); therefore no further investigation was carried out on 
this step. The second step was also a known reaction which was originally reported by 
Bosshard et al.43  The same procedure was followed and the product was afforded in 
quantitative yield, after evaporation in vacuo for 1-2h. The product was hygroscopic 
but was stable enough to handle in the atmosphere. Davison's study indicated that the 
isolated product was very unstable and handling under nitrogen was recommended. In 
fact it was found that the instability was due to the presence of the reaction 
intermediate (38), resulting from incomplete reaction in step 2 (Scheme 2.2.2). Thus 
step 2 needed to be optimised in order to overcome this problem. 
As it is indicated by the mechanism (Scheme 2.2.2), the removal of the by-
product, SO2, helps to drive the reaction to completion. However, one of the starting 
materials, SOC12  is volatile, therefore it should be converted into the reaction 
intermediate before vacuum could be applied. It was found that this could be done by 
increasing the reaction time and temperature (40°C, 3hr.); The mixture was then left 
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on a rotary evaporator, in vacuo, until a white solid was afforded. The temperature of 
the water bath could be raised up to 40 °C. This protocol worked well. 
CI 	CI 
\, 
H3C 	0 - 
H3C , 
H3C' 	"H (38) 
H3Cç, SO 
r" 	i''i 	CI_ 
H (39) 
HC= N4 Me2Cr + s02 
CI 	(34) 
Scheme 2.2.2 The mechanism of reaction between DMF and SOC12 
The compound (34) is a widely used acylating reagent originally developed by 
Vilsmeier et al. and is known as the Vilsmeier reagent. 44 ' 45 
Two reactions are actually involved in step 3: the first is the required reaction 
between the diazo ester (33) and the Vilsmeier reagent (34), and the second is the side 
reaction between (33) and HC1, the by-product of the main reaction. One extra 
equivalent of diazo ester (33) is therefore required to neutralised the HC1 released 
from the reaction (Scheme 2.2.3). 
The reaction was initially carried out in freshly dried chloroform as was 
illustrated in Scheme 2.2.1 and was found to be very vigorous, producing both heat 
and gas. Therefore, the diazo ester (33) was dropped in very slowly while stirring on 
an ice bath. The reaction was complete soon after the addition of the diazo ester and 
the reaction mixture was then evaporated whereupon the product was precipitated 
from ether as soft solid which was washed with ether and dried in vacuo. This 
product was found to be very unstable and should be used immediately. A small 
amount of the by-product (36) was always trapped in the soft solid, and was very hard 
to remove due to its high boiling point. This impurity did not affect the succeeding 
reactions, but it did affect the crystallisation of the final product, thus reducing the 
overall yield. This problem has also been solved by using a different protocol in the 
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Scheme 2.2.3 The reaction mechanism of step 3 
Having pinpointed the causes of the problem in this step, it has been found 
that it is not necessary to use freshly dried chloroform; commercially available A.R. 
grade CHC13 is good enough for this reaction. This change, together with the 
replacement of super dried ethanol by H 20 as solvent in the next step, greatly reduced 
the reaction time. 
Step 4 was adapted from Stojanovic's method 41  (Scheme 2.2.4). The reaction 
was initially carried out in freshly prepared, absolutely dry ethanol, with a large excess 
of hydroxylamine (5eq.) and Na 2CO3 (3eq.). The diazo ester was isolated as yellow 
solid after the removal of the solvent and precipitation with H 20. The initial yield was 
39 around 30-40%. 
Further investigation of this reaction improved the yield to -70% under the 
same conditions. It was found that the large excess of the inorganic reagents is not 
necessary, due to their poor solubility in ethanol, nor the absolutely dry ethanol, as a 
trace of water will not affect the reaction. In fact the involvement of water in the work 
up of the diazo oxime (37) suggested that water can be used as solvent in this 
reaction, although Davison's first attempt to carry out this reaction in aqueous 
conditions failed . 39 A mixture of DCMIH 20 was therefore used as biphasic solvent 
which resulted in only slightly reduced yield (-'50%) on the first attempt. This result 
was very encouraging, and it was thus decided to carry out the reaction in water. 
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Scheme 2.2.4 Stojanovic 's method for steps 4 and 5 (Scheme 2.2. 1) 
NH20H.HC1 (leq.) was added to a little cold water (ice-salt bath) and stirred 
until it dissolved. Na2CO3 (0.5eq.) was then added as solution, followed by the 
addition of the diazo salt as solid. Bright yellow solid precipitated at once. The 
mixture was stirred on an ice-salt bath for 30 min and filtered. The yellow solid was 
washed with cold water and dissolved in chloroform. The small amount of water was 
removed in a separatory funnel and the chloroform solution dried over MgSO 4. A 
little acetic acid was added to the solution and it was left at room temperature to 
cyclise. It was found later that light also aids the cyclisation. 
The final product can be isolated in a slightly lower overall yield (3 5%) 
compared with the ethanol method, but it has the great advantage that no solvent 
needs to be removed in vacuo. As all the materials are very cheap, the yield is not the 
most important factor compared to safety. Another advantage is that any impurity 
which is carried through from the previous steps can be isolated by filtration which 
makes the final cyclisation and recrystallisation much easier. This protocol is thus 
adopted. The lower yield of this new method is partially due to the formation of 
triazole, which is very soluble in water and thus very hard to recover. 
Step 4 was further investigated by Robertson , 46 and the optimal reaction 
conditions were found to be pH 7.0-7.5, 0°C for 5 mm. This can further reduce the 
reaction time. 
After all these studies, a final procedure for the synthesis of HOCt has been 
developed as a very convenient protocol which can be carried out easily in two 
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Scheme 2.2. ]a. The modfied protocol of triazole synthesis 
2.2.3 Attempted synthesis of the HOCt Knorr reagents 
With the problems encountered in the synthesis of triazole solved, further 
investigation was carried out to study the HOCt Knorr reagents. The general 
procedure for making HBTU is shown in Scheme 2.2.5 .21,22 
The same procedure was carried out on HOCt, as shown in Scheme 2.2.6. 
Unfortunately, none of the expected solid material precipitated. Instead, a yellow oil 
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Scheme 2.2.5 The synthesis of HOBt Knorr reagent, HBTU 
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Scheme 2.2.6 Attempted synthesis of HOCt Knorr reagent, TCTU 
It was initially assumed that this was caused by the relatively strong basicity of 
the triethylamine used. Mild bases were thus tried, i.e. imidazole, 2,4-lutidine, 
piperidine and Na2CO3, but without success. The same yellow oily residue was always 
afforded, which could not be crystallised. 'H NMR spectrum of this residue showed a 
mixture of two compounds. The mixture was thus separated by flash chromatography, 
isolating only one of the products as a yellow oil. The IR spectrum showed three 
typical peaks at 2229cm'(CN group), 2135cm' (diazo group), and 1716cm' 
(carbonyl group). The 'H NMIR data showed only one ethyl group while the ' 3 C NMR 
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showed one CH3(13.66), one CH2  (62.72) and two quaternary C's (106.7 and 160.4) 
(Figure 2.2.2 (a, b, c)). 
The data indicated the presence of a diazonitrile compound (51) and a 
mechanism is thus proposed, as shown in Scheme 2 . 2 : 7 . 	 -. 
There are two possible routes leading to the same product. Route A is very 
similar to the mechanism proposed by Dulcere for the conversion of aldoxime to 
nitrile using the Vilsmeier reagent (34)•44  If this is the case, the tria.zole ring itself must 
be fairly unstable, and should exist in equilibrium with the dia.zole isomer. However, 
experiments indicate that the triazole ring is very stable under either basic or acidic 
conditions (2M NaOH or HCI for a few months). Obviously, the strongly nucleophilic 
reagent must be involved in the ring opening step. Route B, the nitrene mechanism, is 
thus proposed. The intermediate (49) is very similar to 13-styrylnitrene, an intermediate 
proposed for the deoxygenation reaction of 13-nitrostyrene. 47 ' 48 The presence of the 
strongly electrophilic carbon greatly reduces the stability of the tria.zole ring and two 
intramolecular rearrangements occur to give the more stable diazonitrile compound 
(51). This mechanism clearly indicates that the Knorr reagents of HOCt cannot be 
isolated as stable compounds. This was confirmed by the failure of another attempt to 
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Figure 2.2.2(a) JR spectrum of the diazonitrile compound 
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Figure 2.2.2(b) 'HNMR spectrum of the diazonitrile compound 
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Scheme 2.2.7 The ring open mechanism of the HOCt Knorr reagent 
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Scheme 2.2.8 Attempted synthesis of HOCt analogue of BOl 
2.2.4 Synthesis of triazole phosphate as a coupling reagent 
Another derivative of HOCt, the phosphate, was also investigated as a 
potential coupling reagent. The reaction is shown in Scheme 2.2.9. 
EtO2C 	N 
0 	 EtO2C 	N ,N 
Ph 	II 'N 	Imidazole 	H'N + 	 _ 
Ph,--,'  	 DCM 	 P O 
OH 	 /\ 
(55) Ph 	Ph 
Scheme 2.2.9 Synthesis of triazole phosphate 
The reaction went well and the product was isolated in almost 100% yield. 'H 
and 31P NMIR indicated that it was the correct material. 
2.2.5 The BOCt active esters 
Active esters have become increasingly popular as coupling reagents in 
stepwise SPPS. The active esters of HOCt were therefore investigated. FmocLeuOH 
was chosen as the standard for reaction condition studies, as its side chain structure is 
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simple and provides reasonable steric hindrance. The reaction itself is straightforward 
as shown in Scheme 2.2.10. 
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Scheme 2.2. 10 Synthesis of active ester of Fmoc Leu OH 
DCCI was used as the, dehydrating reagent because the by-product DCCU, 
was easy to remove by filtration. The reaction was carried out at various 
temperatures, monitoring by TLC, which indicated the presence of the starting 
materials, even after stirring overnight. The mixtures were thus filtered and 
evaporated to yield a white solid which was examined by NMR. A singlet which did 
not correspond to any of the starting materials was found with a chemical shift of 
"8ppm. This was found to belong to the olefinic proton of the active ester (Hb 
Scheme 2.2.10). NIVIR data also indicated that there was -20% unreacted HOCt 
present in the mixture [Ha/(Ha+Hb)]. Further investigation showed that the active 
ester is very sensitive to moisture and would hydrolyse on prolonged stirring. 
Therefore an indirect method was designed to confirm the formation of the 
active ester. FmocLeuOH and HOCt (0.5mmol each) were dissolved in dry DCM to 
which was added DCC (0.5mmol). The mixture was stirred at room temperature for 
30 mm, the white solid filtered off and the filtrate evaporated until dry. The residue 
was then dissolved in DMF/dioxane (1:1, 4m1) and the mixture was added to a 
reaction vessel, which contained 0.25mmol H 2N-Ala-resin. The mixture was vortexed 
on the synthesiser for 30 min before coupling was determined by measuring the Fmoc 
deprotection. The deprotection of Leu was 85% of that of Ala, which indicated 
approximately 85% coupling. As no other activating reagent was added, the active 
intermediate could only be the active ester. 
Reaction conditions were found to be optimal at 0 °C, in dry DCM and under 
nitrogen, therefore the active esters of all the common amino acids were prepared 
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under these conditions. The 'H N]VIIR of a few examples is illustrated in Figure 2.2.3 
(a,b,c). 
Figure 2.2.3(a) 1HNMR spectrum of FmocAlaOct, —100% ester; 
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50-9 5 
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Figure 2.2.3(b) 'H NMR spectrum of FmocLeuOCt, 70% ester; 
40 
90 	89 	B. 0 	7.97.0 	E, 5 
Figure 22.3(c) 1HNMR spectrum of FmocMetOCt, 90% ester 
As all starting materials were mixed up in exactly 1:1 ratio, and all the soluble 
materials in the reaction mixture were collected after filtering off the insoluble DCCU, 
the percentage of the free triazole in the mixture should be equal to the percentage of 
the free acid. The percentage of active ester of each amino acid was calculated and the 
results are listed in Table 2.2. 1. 
Although NMR data indicated that a high percentage of free acid was present 
in some cases, this did not necessarily mean that the reaction was not completed. As 
the active esters are highly hygroscopic, hydrolysis could occur to give the 
corresponding free acid and HOCt. Therefore the percentage of the active ester in the 
mixture may actually indicate its relative sensitivity to moisture. Some of the esters 
are too unstable to be detected by NMR. Even the most stable ones are very 
hygroscopic and were thought unsuitable for storage, therefore no further 
experiments were carried out. 
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Table 221 Chemical shift of the olefinic proton in HOCt and the active esters, 
percentage of active ester in the reaction mixtures 
of the old-inic N ott taio1e 
H in HiOCt 	It in ester 
ester 
Fmoc Ala Oct - 8.14 100 
Fmoc Arg(Pmc) OCt 7.97 - 0 
Fmoc Asp(OtBu) OCt 7.98 8.13 70 
Fmoc.Cys(Acm) OCt 8.00 8.24 30 
Fmoc-Cys(tBu) Oct 8.03 - 0 
Fmoc Glu(OtBu) OCt 7.99 8.20 70 
Fmoc Gly OCt 8.00 8.20 35 
Fmoc His(Trt) OCt - 8.15 100 
Fmoc lie OCt 8.00 8.13 80 
Fmoc Len, OCt 8.01 8.15 80 
Fmoc Lys(Boc) OCt 7.97 8.15 90 
Fmoc Met OCt 7.99 8.15 90 
Fmoc Me OCt 8.00 8.14 70 
Fmoc Phe OCt 8.01 - 0 
Fmoc Pro OCt 8.00 8.19 50 
8.03 8.20 88 
Fmoc Ser(tBu) OCt - 8.11 100 
Fmoc Thr(tBu) OCt - 8.11 100 
Fmoc Trp OCt n.s n.s n.s. 
Fmoc Tyr(OtBu) OCt 7.99 8.03 70 
Fmoc Val Oct 8.00 8.14 85 
NMR solvent: CDC13 
n.s.: insoluble, -: no corresponding peak. 
2.2.6 The reaction between HOCt and DIC, NMR study of the reaction 
mechanism 
An interesting result was observed during the study of the active esters. If the 
triazole and DIC were mixed in solution, a yellow colour gradually appeared, which 
indicated the triazole ring was opening to give a diazo compound. A mechanism for 
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the reaction is suggested, as shown in Scheme 2.2.11, which is very similar to the 
decomposition mechanism of HOCt Knorr reagent (Scheme 2.2.7). 
In order to ascertain the correct mechanism involved in the above reaction, the 
reaction mixture was monitored by acquiring real time proton NMR spectra. The 
HOCt (31.4mg, 0.2nmiol) was dissolved in CDC13 and cooled to -30'C. To the 
solution was added DIC (31 .4p.l, 0.2mmol) and a 'H NMR spectrum was acquired 
immediately. The temperature of the NTvIIR spectrometer was set at -30'C and then 
gradually increased to 25°C over a 132 minute period. The 'H NIVIIR spectra were 
acquired at different intervals as illustrated in Figure 2.2.4. 
The reaction took place immediately, as indicated by the additional signals 
appearing on the NMR spectrum (Figure 2.2.4a); these can be assigned to the reaction 
intermediate (58) as shown in Figure 2.2.4a, which presents in equilibrium with the 
starting materials; but no product formed at this stage. 
From Figure 2.2.4a it can be seen that no oxime (59) signals remain in the 
spectrum, including the extra olefinic proton signal which is expected ca. 7.3 ppm: The 
broad peak at 7.2ppm was initially thought to be the oxime proton of (59), but the 
integration of the three olefinic proton signals (8.3, 8.0 and 7.2ppm) together results 
in more than one proton, which is not possible. According to this result, route B is 
more likely to be the real mechanism for this reaction. However, if (59) present as a 
transition state rather than an intermediate, route A would also be a possible 
mechanism. 
On continuation of the experiment, no change was observed until the 
temperature was increased to -5°C in 49 mm. At this stage another methyl group 
doublet began to show up on the higher frequency side of the original ones. This 
indicates that a new kind of isopropanyl group has begun to form, together with a 
new multiplet at 3 .7ppm (Figure 2.2.4c). These signals were assigned to the final by-
product, DIV. The newly formed doublet and multiplet became stronger when the 
temperature was further increased whilst all signals belonging to the intermediate (58) 
decreased in size (Figure 2.2.4d,e). When the temperature was raised to 25°C in 123 
min all the signals belonging to the intermediate (58) disappeared (Figure 2.2.4f) as 
well as the starting materials. The small amounts of HOCt and DIC left at this stage 
are due to the precipitation of DITJ, which prevented further reaction. The reaction 
43 
was left at 25°C with monitoring, overnight, but no further reaction was observed. No 
signals of the transition states were observed because reaction was too fast in relation 
to the NIVIR time scale. 
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Scheme 2.2. 11 The mechanism of the reaction between DIC and triazole 
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Figure 2.2.4a NMR monitoring of the reaction between HOd and DIC in CD C1 3, -5°C, 38 mm 
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Figure 22.4b NMR monitoring of the reaction between HOCt and DIC in CD C13, -5°C, 43 mm 
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Figure 22. 4c NMR monitoring of the reaction between HOCt and DIC in CD C1 3, 5°C, 59 mm. 
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Figure 2.2.4d NMR monitoring of the reaction between HOCt and DIC in CD C13, 10°C, 83 min. 
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Figure 2.2.4e NMR monitoring of the reaction between HOCI and DIC in CD C13, 25°C, 92 min. 
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Figure 22.4f NMR monitoring of the reaction between HOCt and DIC in CD C13, 25 °C, 123 mm. 
These results clearly indicate that the reaction intermediate (58), which is very 
similar with the HOCt Knorr reagent in structure, can only exist at low temperature 
(<-5°C), when the temperature was increased, it soon decomposed to result in more 
stable compounds. When the experiment was repeated, the same was observed. These 
results suggest that the HOCt Knorr reagent can not be isolated at any temperature 
above 0°C. Therefore no further attempt was made in making HOCt reagents. 
The reaction between HOCt and DIC can be simplified as follows: 
stepi 




The relative concentrations of the starting materials (HOCt, DIC), reaction 
intermediate (58) and products (DILJ, 51) were calculated from the NIVIIR spectra and 
the results are shown in Figure 2.2.5. Data indicate that the reaction intermediate is 
present in equilibration with the starting materials at low temperature (-30 -5°C). 
The equilibration shifted when the temperature rose to -5°C and the product begun to 
form. Once started, this second step went on faster than the first step, therefore the 
concentrations of the starting materials and the reaction intermediate both decreased 
rapidly, until the reaction was complete. Small amounts of the starting materials were 
trapped in the mixture due to the precipitation of the product, DII]. 
Figure 2.2.5 Relative concentrations of the material involved in the reaction 
between HOCt and DIC 
51 
2.2.7 Racemisation studies of HOCt 
Racemisation remains the major side-reaction in SPPS, and any new coupling 
reagent should be well studied before use. Among the twenty native amino acids, His 
is especially prone to racemisation due to the imidazole side chain group. The 





(62) 	\'\ -NH 
Figure 2.2.6 The structure of His in a peptide chain 
The introduction of a protecting group on the ic-nitrogen has proven to be 
advantageous in overcoming this problem .49,50  However, the synthesis of the ic-
nitrogen protected histidine is very difficult and the only commercially available 
analogue, FmocHis(Bum) 51 , can only be prepared in a very poor yield and not very 
satisfactory purity. Fortunately, by introducing a very bulky electrophilic protecting 
group such as Trt on the 'c-nitrogen, and under optimised coupling condition, the 
racemisation can be greatly reduced. 
In order to study whether the new coupling reagent was likely to cause 
racemisation, a series of trimers with the general structure of Ala-X-Gly have been 
synthesised and studied. This sequence was chosen as Gly is not chiral and Ala is the 
amino acid least prone to racemisation. If the amino acid at the middle position 
racemises, the methyl group of the Ala will be presented in two slightly different 
chemical environments. The chemical shift of this methyl in the two isomers will thus 
be different. The percentage of racemisation is therefore calculated from 'H NMR. 
The first trimer studied was Ala-His-Gly and the structures of the trimers with 
D-and L-His are shown in Figure 2.2.7. 
When His(Trt) was used in the synthesis of the trimer, racemisation of His did 
occur under normal coupling conditions using HOCt to give -20% of the D-isomer 
compared with -10% using HOBt coupling. When the ic-nitrogen protected 
52 
His(Bum) was used, however, no racemisation was detected from the 'H NMR, but 
as the reagent itself was not pure, other unpredictable impurities could be involved in 
the final product. The rest of the trimers, with all commonly used Fmoc amino acids 
at the middle position, have been synthesised and investigated by Robertson. 46 The 
results indicate that His(Trt) is the only one which racemises under the standard 
coupling conditions, but the racemisation level can be reduced to a negligible level if 
the coupling is carried out at 0°C in a sonic bath. 46 
CH3 
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(63) L-Ala-L-His-GIy 
(64) L-Ala-D-His-GIy 
Figure 2.2.7 The structure of Ala-His -Gly 
Further investigation was carried out to study the effect of activation time. 
The results are listed in Table 2.2.2. Although reducing the activation time did result 
in a decrease in racemisation, it was still occuring at an unacceptable rate. However, 
an interesting result of this experiment is that pre-activation is not necessary for HOCt 
coupling, as the yield of the trimer obtained without any pre-activation is as good as 
the others according to the deprotection profile. 
Table 2.2.2 The effect of activation time 
[ttion tiiemn -- 1 
20 	
j 
20 I b U 
2.2.8 Application of HOCt --- 1. the monitoring of the coupling 
One of the objects of this study is to develop a new coupling reagent which 
does not absorb at 302nm, so that the coupling process can be monitored before 

















improvement when a bad coupling occurs. The reaction mixture is passed through a 
UV detector connected to the peptide synthesiser at the end of each coupling cycle, 
so that the unreacted Fmoc amino acid or its activated isomer are examined. To 
reduce the error caused by uneven delivery during different stages of the synthesis, an 
external standard, fluorene, was introduced. The amount of unreacted Fmoc amino 
acid is thus deduced from the peak area. A comparison is made between this real time 
monitoring and the previously developed deprotection monitoring method, and a 
typical profile is shown in Figure 2.2.8. 
0 4!! L.i 
W I I DL H CF Y V BE K DL L S S 	S C 
amino acids 
Figure 2.2.8 Coupling efficiency of peptide 1B, monitored by two different 
methods 
The two methods correspond with each other reasonably well, but errors do 
exist. This is because the solubility of some Fmoc amino acids is not good enough, 
and they therefore thus cannot be transferred to the reaction vessel completely. Even 
for the more soluble ones, reagent delivery can also vary slightly from one to the next. 
This is reasonable, as the synthesiser was not specifically designed for this monitoring 
process. The slight variation will not seriously affect the coupling process, but it does 
affect the accuracy of the coupling efficiency deduced from it. More accurate 
monitoring, therefore, will rely on improvements in the solubility of the amino acids 
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(i.e. better solvent, elevated temperature etc.), and also the delivery system of the 
synthesiser. 
2.2.9 Application of HOCt --- 2. The synthesis of endothelin analogues and 
difficult peptides 
Endothelin is a recently discovered, highly potent vasoconstrictor which has 
attracted extensive research attention from both academia and industry. The biological 
activity and SAR studies will be discussed further in Chapter 3. The synthesis of some 
analogues, however, has been found to be difficult, especially when bulky amino acids 
such as Aib are included in the sequence 52 . Triazole was thus applied in the synthesis 
of these analogues, and some typical coupling results monitored by the Fmoc 
deprotection method are shown in Figure 2.2.9 and Figure 2.2.10. In Figure 2.2.11, 
the synthesis of a BigET-1 analogue, peptide 5, using two different methods is 
illustrated. 
Figure 2.2.9 Comparison between three different coupling methods 
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Figure 2.2. 10 Comparison between HOCt double coupling and the 
HOBtisymmetrical anhydride double coupling on the synthesis of ET-1 analogue, 
peptide JC, which has four AM at positions 1,3,11 and 15 
7:H7 	11 
 14 
iv 	 I 	 _ 
HOWSynTretrical anhydride double  
0 
SR PSG I LOY PVV HE PTNVWI I DL EIC FYVC E KDM ISSC S: c 
Amino acids 
Figure 2.2.11 The coupling efficiency of triazole and HOBt on the synthesis of 
peptide 5 
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a. 	 b. 	 C. 
Figure 2.2.12 HPLC traces ofpeptide 5 
Vydac C8 column, 214nm, imi/min, A: O.1%TFA/H 20, B: O.1%TFA/CH3CN; 
Gradient:] 0%-90%B over 30mm; 
a. HOCt double coupling, crude; b. HOCt double coupling, pure, 
c. HOBt active ester and DIG symmetrical anhydride double coupling, crude. 
As illustrated in Figure 2.2.9, single coupling using HOCt/DIC is as good as 
the combination of a symmetrical anhydride coupling followed by a HOBt/DIC 
coupling. Double coupling with HOCt/DIC improved the coupling percentage by 
nearly 20%. In Figure 2.2.10, the two double coupling methods are compared in the 
synthesis of ET-1 analogues, which has the bulky amino acid, Aib at positions 1, 3 ,11 
and 15. The overall coupling yield with HOCt is nearly 30% higher. In Figure 2.2.11, 
the coupling percentages of two methods applied in the synthesis of the BigET-1 
analogue, UPS, are compared. The coupling percentages are not very different 
according to the deprotection monitoring, but the crude peptide synthesised by HOCt 
coupling is much cleaner than that synthesised by the symmetrical anhydride And 
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HOBt coupling (Figure 2.2.12). The details of each coupling protocol can be found in 
the experimental section in Chapter 3. 
HOCt has thus been adopted in this laboratory as the standard coupling 
reagent for difficult couplings. A typical example is NGF (100-114)". This small 
peptide caused a lot of problems in its synthesis, and very little pure product was 
afforded in the first few syntheses before HOCt became available. The overall 
coupling percentage was improved from <40% to >80%, and it was isolated in very 
good purity. 13 
Further evidence is provided by the synthesis of ubiquitin and its analogues 
(76mer). 54 More recently the successful syntheses of the catalytic domain of 
stromelysin (173mer) 55 and deglycosylated human erythropoietin (166mer) 46 by 
stepwise SPPS show that HOCt is a very powerful coupling reagent. 
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2.3 Experimental 
2.3.1 Synthesis of 1-hydroxyl-1H-4-ethoxycarbonyl- 1,2,3-triazole (BOCt, 38) 
Synthesis of ethyl diazoacetate (33) 
A solution of ethyl glycinate hydrochloride (210g, 1 .Smol) in water (300m1) 
was mixed with dichloromethane (500m1) in a 3-necked 3 litre flask fitted with a 
mechanical stirrer and a nitrogen inlet tube and cooled to ca. -15 °C (acetone/dry ice). 
A cold solution of sodium nitrite (124.5g, 1.8mol) in water (200m1) was added in one 
portion with stirring. The temperature was lowered to ca. -20 °C and an ice cold 
solution of 5% (w/w) H2SO4 (150m1) was added dropwise while keeping the 
temperature below -15 °C. When all the acid solution was added, the temperature was 
allowed to rise to ca. 0°C. 
The reaction mixture was transferred to an ice cold 2 litre separating funnel. 
The yellow organic layer was run into an ice cold 5% sodium carbonate solution and 
the water layer was extracted once with DCM. The combined DCM and Na 2CO3 
portions were stirred until no further gas evolved. The two layers were separated and 
the water layer was extracted once with DCM. The organic layer was dried (MgSO 4) 
and evaporated in vacuo behind a screen. The yellow liquid which was pure enough 
for next step was stored below 4°C in a well wrapped container. Yield 95%-100%. 
ö'H NIVIR(60MHz, CDC1 3): 1.3 (3H, t, CH,, J=7. 11Hz), 4.3 (214, q, CH2, J7. 13Hz), 
4.8 (1H, s, CH). 
Synthesis of the Vilsmeier reagent (34) 
N,N-dimethylformamide (DMF) (52.8g, 0.72 mol) was stirred at room 
temperature under nitrogen. Freshly distilled thionyl chloride (53m1 0.72 mol) was 
added dropwise with stirring. When all the thionyl chloride had been added, the 
mixture was warmed up to 40°C via a water bath and stirred for 2h until a very sticky 
mixture was afforded. The mixture was then evaporated in vacuo (via oil pump) for 
2h (water bath ca. 40 °C), until a white solid was afforded. Care should be taken as 
the solid is highly hygroscopic. Assumed yield 100%. 
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Synthesis of the iminium chloride (35) 
The white solid (34) was dissolved in A.R. grade chloroform (400m1) and 
cooled via ice salt bath. The liquid ethyl diazoacetate from first step was added 
dropwise under nitrogen, keeping the temperature below +5°C. When (33) had been 
added, the reaction mixture was stirred at RT for 30 mm. and then evaporated in 
vacuo to give an oily residue. Ether was added to the residue and the yellow solid 
obtained was filtered under nitrogen and washed with ether. The yellow solid was 
stored in a desiccator and used the following day in next step. Yield 130g, 88%. 
Synthesis of diazo-oxime (37) and its cyclisation to give 1-hydroxyl-1H-4-elhoxy 
carbonyl-1,2,3-triazole (HOCt) (38) 
Procedure a: NHI20H.HC1 (52.5g, 0.76mol) was suspended in commercial 
ethanol (300m1) and cooled by ice-salt bath. Sodium carbonate (40g 0.38mo1) was 
added to the suspension followed by the diazo salt (35) (130g, 0.63mo1) as a solid. 
The resulting yellow mixture was stirred mechanically for lh at 0°C. The insoluble 
impurities were filtered out and washed with ethanol (X3). The ethanol solution was 
evaporated in vacuo to give a yellow residue (oily solid). The temperature of the 
water bath should not be higher than 40 0C. Ice cold water was added to the solid 
which was filtered and washed with a little cold water to remove any inorganic 
impurities. 
ö'H NIvIR (200MHz, CDC1 3 ): 1.30 (3H, t, CH3, J=7.16Hz), 4.30 (2H, q, CH2 , 
J=7.18),7.01 (111, s, CH), >10 (1H, broad, OH). 
The yellow solid (37) was dissolved in chloroform and separated from any 
remaining water and dried (Mg50 4). After filtration of the MgSO 4, 0.5m1 of acetic 
acid added to the chloroform solution which was left at RT until the cyclisation was 
completed. (Yellow colour fades but confirm by 'H NMIR). The chloroform solution 
was evaporated in vacuo to give a white solid (38) to which was added ethyl acetate. 
The solid was filtered and washed with ethyl acetate. The filtrate was concentrated 
and stored in cold room until more crystals formed (this was repeated until no more 
crystals formed). Overall yield —35%. 
MOO 
ö'H NIvIR(200M1Hz, CDCI 3 ): 1.34 (3H, t, CH3, J=7.14), 4.38 (2H, q, CH2, J7.16), 
8.06 (1H, s, CH), —12.5 (1H, s, broad, OH). 
ö'3C NMR(200MIHz, CDC13): 13.9 (CH3), 61.7 (CH2) , 121.7 (CH), 136.5 (C), 159.2 
(C). 
Procedure b: NH20H.HC1(44g, 0.63mo1) was dissolved in a minimum of 
water and cooled via ice salt bath. Sodium carbonate (33.6g 0.32mo1) was added and 
stirred until all had dissolved. The diazo salt (35) (130g 0.63mo1) was added as the 
solid and the yellow product (37) soon precipitated. The precipitate was filtered after 
5mm, washed with a little ice cold water and taken up on to (38) as above. Overall 
yield —30%. 
ö'H NMR(200MHz, CDC1 3): 1.34 (3H, t, CH3, J=7.14), 4.38 (2H, q, CH2, J7.16), 
8.06 (1R, s, CH), —12.5 (1H, s, broad, OH). 
6 13 C NMR(200MIHz, CDC13): 13.9 (CH3), 61.7 (CH2) , 121.7 (CH), 136.5 (C), 159.2 
(C). 
2.3.2 Synthesis of the HOCt Knorr reagents 
Chioro N,N,N',N'-tetramethyluronium hexafluorophosphate(44) 
A 20% solution of phosgene in toluene (100m!) was added dropwise under 
nitrogen to a solution of tetramethylurea (11.6g, 0. imol) in toluene. After the 
evolution of carbon dioxide gas had ceased (ca. 15 mm), anhydrous ether was added 
with vigorous stirring. The solid precipitate was filtered and washed with anhydrous 
ether (3 x 50m1). The hygroscopic material (43) was immediately dissolved in 
dichioromethane (500m1) and to this solution was added a saturated solution of 
ammonium hexafluorophosphate (50m!) with stirring. The organic layer was 
separated, washed with water, dried with Mg50 4 and evaporated to yield a white 
solid which was washed with ether and dried over phosphorus pentoxide in vacuo. 
Yield 22g (82%). 
ö'H NMR(200MIHz, CDC1 3 ): 3.39 (s, 4xCH3). 
5'HNN4R(200MHz, CD 3 CN): 3.26 (s, 4xCH3). 
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HBTU, 2-(]H-Benzotriazole-1-yl)-1, 1,3,3-tetramethyluronium hexaflorophosphate 
(13) 
Chioro N,N,N' ,N' -tetramethyluronium hexafluorophosphate (2.28g, 0.01 mol) 
was dissolved in DCM (25m1) and HOBt (1.53g, 0.Olmol) was added. To the clear 
solution was added triethylamine (0.Olmol) and a white precipitate formed at once. 
The solid was filtered and washed with DCM. The solid was recrystallised from 
acetonitrile, dried and stored in the fridge. 
6 'H NT*vlIR(200MHz,  CD3CN): 3.05 (6H, s, 2xCH3), 3.41 (6H, s, 2xCH3), 6-8.2 (4H, 
m, aromatics). 
Attempted synthesis of HCTU (46) 
Chloro N,N,N' ,N' -tetramethyluronium hexafluorophosphate (2.28g, 0.01 mol) 
and HOCt (1.57g, 0.01mol) were dissolved in DCM (25m1) and cooled on an ice-salt 
bath. Triethylamine (0.Olmol) was added dropwise with stirring. The colourless 
solution soon turned yellow, and a white solid precipitated. The mixture was filtered 
and the yellow filtrate was evaporated to give a yellow oil, to which ether was added. 
None of the expected solid precipitated. The solution was evaporated again and 
checked by 'H NMR, which indicated a mixture of products. The mixture was diluted 
with DCM and washed with H20, dried with MgSO 4, filtered, and checked by NMR 
again. 
6 'HNMR(200MIHz, CDC1 3): 1.31 (-.3H, t, CH, J=7.lOHz), 2.78 (-12H, s, 2xCH 3), 
4.30 (-2H, q, CH2, J7. 12Hz). 
6 13 C NMR(200MHz, CDC1 3 ): 13.66 (CH3), 37.99 (CH3), 62.71 (CH2), 106.7 (C), 
160.4 (C), 164.6 (C). 
The NIMR data clearly indicated that two compounds were present; these were 
separated by flash chromatography (1-5% ethanollCHC1 3). Single fraction was 
collected and examined by NMR and IR. 
o 'H NMIR(200MHz, CDC13): 1.31 (3H, t, CH3, J=7.13Hz), 4.30 (2H, q, CH2 , 
J=7. 11Hz) 
6 13C NMR(200MHIz, CDC1 3):13.66 (CH3), 62.72 (CH2), 106.7 (C), 160.4 (C) 
IR (nujol): 2230cm 1 , 2135cm 1 , 1723cm 1 , 1714cm'. 
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The second compound was thus shown to be tetramethylurea by the 
subtraction of the above spectra from the NMR spectra of the mixture. 
2-Chloro-1,3-dimethyl imidazolidinonium hexafluorophosphate(53) 
A 20% solution of phosgene in toluene (lOOmI) was added dropwise, under 
nitrogen, to a solution of 1,3 -dimethyl-2-imidazolidinone (11. 4g, 0.1 mol) in toluene. 
The carbon dioxide gas ceased to evolve after ca. 15 mm. and anhydrous ether was 
added with vigorous stirring. The solid precipitate was filtered and washed with 
anhydrous ether (3 x 50m1). The hygroscopic material (52) was immediately dissolved 
in dichloromethane (500m1) and to this solution was added a saturated solution of 
ammonium hexafluorophosphate (50m1) with stirring. The organic layer was 
separated, washed with water, dried with MgSO 4, filtered, and evaporated to give a 
white solid, which was washed with ether and dried over phosphorus pentoxide in 
vacuo. Yield 22g (82%). 
5 1HNMR(200MiHz, DMSO-d6): 3.10 (6H, s, 2xCH3), 4.13 (4H, s, 2xCH2). 
Attempted synthesis of COI (54) 
2-Chloro- 1,3 -dimethylimidazolidinonium hexafluorophosphate (2.26g, 0.01 
mol) and HOCt (1.57g, 0.Olmol) were dissolved in DCM (25m1) and cooled on an 
ice-salt bath. Triethylamine (0.01mol) was added dropwise with stirring. The 
colourless solution soon turned yellow, and white solid precipitated. The mixture was 
filtered and the yellow filtrate was evaporated to give a yellow oil, to which ether was 
added. None of the expected solid precipitated. This was a similar result to that seen 
in the attempted synthesis of HCTU; thus no further experiments were carried out. 
2.3.3 Synthesis of (4-ethoxyl carboxyl- 1 ,2,3-triazofe)-yl diphenyl phosphinate 
(55) 
Diphenylphosphinic chloride (0.47g, 2mmol) was dissolved in anhydrous 
DCM (3m!). HOCt (0.314g, 2mmol) was added as a solid and the mixture was stirred 
to give a clear solution. Imidazole (0. 136g, 2mmol) in dimethyl chloride (2m!) was 
added dropwise in under nitrogen. A white solid precipitated immediately, and the 
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mixture was stirred at room temperature for 30 mm. The solid was then filtered off 
and the filtrate evaporated to give a slightly yellow oil. 
ö 'H NMR(200MHz, CDC13): 1.32 (3H, t, CH3, J7.07), 4.33 (2H, q, CH2, J7.10), 
7.31-7.73 (10H, m, aromatics). 
ö 13 C NMR(200MHz, CDC1 3 ): 14.0 (CH3), 61.2 (CH2), 120-135 (CH), 159.8 (C). 
ö 31P NMR(200MHz, CDC13): 31.7 [Ph2POCI as internal standard, 3 'P=48.32]. 
2.3.4 Synthesis of the HOCt active esters 
FmocLeuOCt, reaction condition studies 
Three reaction mixtures were prepared as follows: FmocLeu011 (177mg, 
0.5mmol) and HOCt (78.5mg, 0.5mmol) were dissolved in 5m] dry DCM. To the 
clear solution was added DCCI (103mg, 0.5mmol). These were stirred at -20° C, 0°C 
or room temperature. The mixtures were then filtered and the filtrates evaporated to 
dryness. The residues were checked by NMR. All showed a mixture of free acid and 
the active ester. 
Synthesis of active esters of the commonly used Fmoc amino acids 
Fmoc-amino acid (0.5mmol) and HOCt (0.5mmol) was dissolved in anhydrous 
DCM under nitrogen and stirred at 0°C. For some Fmoc amino acid, such as 
FmocTrpOH, which were not very soluble in DCM, DMF was added to the solution 
until dissolution was complete. DCCI (0.5mmol) in 2m1 DCM was then added, and 
the mixture stirred at 0°C for another 30n -ii. The white precipitate was filtered off 
and the filtrate evaporated. To the residue some anhydrous ether was added and the 
evaporation was repeated. The white solid was dried in vacuo over P205 . 'H NMR 
spectra were collected and results listed in Table 2.2.1. 
2.3.5 NMR study of the reaction between DIC and HOCt 
A Brucker WP-360 (360MHz) NIVIR spectrometer was set up at -20°C. HOCt 
(31.4mg, 0.2 mmol) was dissolved in —0.4 ml CDC1 3 at -20°C and DIC (31.4111, 0.2 
mmol) was added. The mixture was transferred into an NIVIR tube and 'H NMR 
spectrum acquired immediately. The temperature of the NN'IR spectrometer was 
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raised gradually up to 25°C over 1 I Omin and 'H NMR spectra were collected at 
different intervals, i.e. 0mm (-30°C), 1 1mm (-30°C), 18mm (-20 °C), 23mm (-20°C), 
28mi(-10°C), 33mm (-10°C), 38mm (-5 °C), 43mm (-5 °C), 48mm (0°C), 52mm (0°C), 
59mm (5°C), 63mm (5 °C), 71mm (10°C), 83mn (10°C), 92mm (25°C), 123mm 
(25°C), 170mm (25°C). The reaction was then left overnight under monitoring and 
more spectra were collected every 2h. 
2.3.6 Monitoring of the peptide coupling 
Exactly 0.5 mmol of Fmoc amino acid was weighed into each cartridge. The 
solvent delivery system was checked carefully and florene in DMF was used as an 
external standard (0.25mmol). After each coupling step, the un-reacted Fmoc amino 
acid, or its activated derivative in the coupling mixture, was passed through a UV 
spectrometer, followed by the standard solution in an amount corresponding to 
0.50mmol Fmoc amino acid in DMF. The amount of the unreacted Fmoc amino acid 
was thus calculated as follows: 
Coupling percentage (%) = (0.5-washing peak/standard peak) x 100/0.25 
If more than one coupling is carried out for each residue, the coupling percentages 
can be added. 
2.3.7 Synthesis of the peptides 
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CHAPTER 3 
STRUCTURE ACTIVITY RELATIONSHIP STUDIES OF 
ET-1, BIG ET-1 AND THEIR ANALOGUES 
3.1 Introduction 
3.1.1 EDRF/EDCF and cardiovascular disease, the history of endothelial studies 
The understanding of the vascular biology of cardiovascular disease and, in 
particular, of coronary artery disease is the major challenge in cardiovascular medicine 
at present. Diseases of the heart and circulation system remain the major cause of 
morbidity and mortality in Western countries. Although substantial advances have 
been made in the past two decades in surgical, interventional, and medical therapy of 
these conditions, it has become clear that only a better understanding of the cellular 
and molecular mechanisms could be the basis for rational mechanistic approaches and, 
in turn, for cause-oriented therapy for cardiovascular disease. 
Because of the special position between the circulating blood and vascular 
smooth muscle, the centre of interest has recently focused on endothelial cells, which 
were originally considered more or less inert structures covering the inner surface of 
the cardiovascular system. In the 1970s, it was discovered that endothelial cells are a 
major source of prostacyclin, a vasodilator and inhibitor of platelet function. At the 
same time, heamatologists observed that endothelial cells are a source of numerous 
substances involved in coagulation and fibrinolysis. In 1980, Furchgott et aL 
published a landmark article which described for the first time endothelium-dependent 
relaxation to acetylcholine in the rabbit aorta,' and in 1985, Moncada et al. were able 
to demonstrate that nitric oxide (NO) accounts for the biological activity of the 
putative endothelium-derived relaxing factor (EDRF) 2 . These important observations 
led to a tremendous stimulation of research in this area at the cellular level, in 
physiology and also pathophysiology. The observation that the endothelium can also 
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mediate contractile responses stimulated the research for endothelium-derived 
contracting factors (EDCF). Some of these contractile factors derived from the 
endothelium could be identified as cyclo-oxygenase products and a particularly potent 
vasoconstrictor released by endothelial cells appeared to be a peptide. In 1988, 
Yanagisawa et al. demonstrated that the latter was a 21 -amino acid peptide, which 
they called endothelin 3 . 
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Figure 3.1.1 The structures of ETs and SRTXs 
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Endothelin (ET-1), is a 21 amino acid peptide which was first isolated in 1988 
from cultured porcine aortic endothelial cells. 3 It belongs to a new class of peptides, 
and bears no similarity in its sequence to the known peptides of mammalian origin. As 
a more potent candidate for the EDCF due to its long-acting vasoconstriction, this 
peptide prompted a line of research that culminated in the identification of three 
distinct endothelin genes which encode three closely related peptides, ET-1, ET-2 and 
ET-3. The structures of the three peptides show a remarkable sequence homology 
with those which were found afterwards and are known as the sarafotoxins 
(SRTX's) 5 . Another isopeptide, vasoactive intestinal contractor (VIC), was also 
found and it was first thought to be the fourth isomer of the ET family, but recent 
report suggested that it might be a murine form of ET-2 6 . A recently discovered 
peptide, bibrotoxin, added another member to this peptide family. The structures of 
these peptides are shown in Figure 3.1.1. 
3.1.3 Biosynthesis of ETs, Endothelin-converting enzyme (ECE) 
ETs are derived from peptide precursors with -200 amino acids known as 
preproendothelins, which are cleaved after translation by an endopeptidase specific for 
the paired dibasic residues to form the proendothelins, Big endothelins (BigETs). 
BigETs are then converted to active ETs by endothelin converting enzyme (ECE) 
(Figure 3.1.2). The physiological importance of the cleavage of BigETs is indicated by 
the -400 fold more potent vasoconstrictor activity of ETs. 
The existence of a specific enzyme which converts BigET to the mature ET 
was contained in the original report of the cloning of the porcine ET-1. 3 The 
extensive efforts involved in the isolation and purification of ECE from a variety of 
sources have led to the molecular cloning and sequencing of the enzyme. 7,8,9, 10  This 
phosphoramidon-sensitive neutral metalloprotease, which has a strict substrate 
specificity, represents another plausible target for pharmacological intervention. A 
highly potent and specific inhibitor would be a useful tool in these studies. Therefore, 
the development of ECE specific inhibitors is required. 
FTI 
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Figure 3.1.2 Biosynthesis of ET-1 
3.1.4 Receptor subtypes, ETA and ETB 
Two subtypes of El receptors have been found and cloned, ET A and ET" 2 
ETA is selective for El-i and El-2, while ET B binds to all three ETs equally. 13  Both 
receptors have been cloned from human. ' 4 ' 15 A third subtype of receptor, ETc, which 
is selective to ET-3, has also been cloned from Xenopus melanophore, 16 but there 
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have been no reports of any human homologues. Evidence also pointed to the 
presence of subtypes among the various receptors. ' 7' 18 Binding studies using labeled 
ETs and the receptor selective analogues have shown a wide distribution of ET 
specific binding sites in the vascular system. ETA receptors have been found 
predominantly in the heart, blood vessels of the brain and vascular smooth muscle, 
whereas ETB receptors are widely distributed in the kidney, uterus, central nervous 
system and endothelial cells. 19,20,21 
The ligand-receptor interaction has also been a subject of extensive 
studies. 22'23 '24 The ETA receptors were suggested to recognize the tertiary structure of 
both the N-terminal and C-terminal segments, whereas the ETB receptors recognize 
predominantly the C-terminal part, explaining the differences in affinities of the two 
receptors for the isopeptides. The exact residues of the receptor involved are not 
clearly known yet, but mutational studies are in progress to identify the responsible 
residues. 
3.1.5 Physiological and pathological importance of endothelins 
ETs are widely distributed in the tissues and organs of mammals. Studies have 
found that ETs function as both circulating hormones and a endocrine factor in the 
regulation of vascular tone. The biological activity of the ET family are summarized in 
Table 3.1.1 •25  These various biological actions have implicated the ET family in a 
spectrum of cardiorenal disease states such as atherosclerosis, hypertension, 
congestive heart failure, acute coronary ischaemic syndromes, coronary vaso spasm, 
and acute and chronic renal failure. 
The biological actions of ETs clearly indicate their importance both 
physiologically and pathologically.- Two strategies are of particular importance. Active 
research and drug development progress are aimed at investigating ET inhibitors. 
Several antagonists to endothelin have been discovered (Table 3.1.2) and clinical trials 
of the use of these antagonists for many cardiorenal disease conditions are already in 
progress. 26 The receptor selective agonists, on the other hand, are also important in 
classifying the biological activity of the different receptor subtypes and understanding 
the functional activity of each of the receptor subtypes. 
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Table 3. 1.1 The biological actions of ETs 25 
Potent and long-lasting constriction of isolated vascular/nonvascular smooth muscle 
Coronary arterial vasoconstriction, increased perfusion pressure 
Vasodilation in certain tissues at low doses 
Positive inotropic and chronotropic activity 
Reduction of cardiac output 
Proarrythmogenic activity 
Mitogenic actions 
Introduction of hypertrophy of cardiomyocytes 
Inhibition of platelet aggregation in vivo (not in vitro) via release of EDRF or prostacyclin 
Chemotactic activity 
Potent contractile agonist activity in human isolated bronchus 
Inhibition of renin release 
Reduction of renal blood flow and glomenilar filtration rate 
Inhibition of arginine vasopressin release 
Stimulation of substance P release 
Stimulation of catecholamine release 
Stimulation of EDRF release 
Stimulation of ANP secretion 
Increased release of prostacyclin 
Stimulation of gastrointestinal hemorrhagic and necrotic damage in rat mucosa 
Inhibition of prolactin secretion 
Stimulation of luteinizing hormone, follicle stimulation hormone, 
and thyroid stimulation hormone release from primary monolayer cultures of rat 
anterior pituitary cells 
Stimulation of pituitary gonadotropin release 
Stimulation of glycogenolysis in rat heptocytes 
Stimulation of PDGF secretion in cultured human mesangial cells 
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Table 3.1.2 ET receptor antagonists found by random screening 
( onIpouil(1 or structure iit gomst 
T pe 
I( 	511 Ref 
ET. \ 
BQ-123 ETA 22nM 18p.M 27 
FR-139317 ETA mM 7j.tM 28 
BQ-153 ETA 21M 54)LM 29 
BQ-788 ETB 1300nM 1.2nM 30 
RE-701-1 ETB >5000nM iOnM 31 
Ro 46-2005 ETAIETB 0.22p.M 1.tM 32 
3.1.6 Development of ET receptor selective agonists/antagonists, SAR studies 
The rational design of receptor specific agonists and antagonists depends on 
the understanding of the mode of binding of ligands and the relative importance of the 
residues with respect to agonist or antagonist activities. Numerous studies have been 
carried out using synthetic analogues and fragments of ET, with each portion of the 
peptide being examined for relative importance for binding and functional activities. In 
general, the full-length analogues with bicyclic or the outer [1-15] monocyclic 
structure appears to be required for binding and agonism at the ETA receptor, while 
linear, truncated sequences have been shown to be agonists at the ETB receptor. 5358 
The C-terminal hexapeptide, especially the C-terminal amino acid, Trp, is essential for 
binding and functional activities at both receptor subtypes while the N-terminal part is 
more or less tolerant to substitutions .33,34,35  Acetylation of the N-terminus of the ET-
1 results in a remarkable loss in constrictor activity in rat pulmonary artery but not in 
the intact vascular bed, while amidation of the C-terminus causes only 16-fold loss in 
activity. 36 '37 
Systematic replacement of each amino acid of ET-1 with Ala revealed some 
interesting information in terms of the relative importance of each side chain 
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functional activity for ETA receptor binding and biological activity. 38 '39 The peptides 
were tested for their binding affinity on human vascular smooth muscle cells and for 
Table 3.1.3 Ala scan and D-amino acid scan of ET-1 39' 40 
AI* R11141111L CO*11OU D*8flJIW R!II4ITfl! CO1VC1fUil 
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Note: *Tested in Human VSM; **Tested in rabbit vena cava. 
agonism on the vena cava in vitro. Replacement of the C-terminal Trp with Ala led to 
a complete loss in binding affinity and biological activity, while replacement of Phe' 4 
and Leu'7 caused a serious decrease in biological activity but part of the binding 
affinity remained. These sites were thus suggested to be of major biological 
significance for binding in human VSM cells and agonist activity in contraction of 
rabbit vena cava. 38 Replacement of Tyr 13 with Ala caused complete loss in binding 
affinity but only slight decrease in biological activity, which is difficult to explain. On 
the other hand, changing Asp 8 to Ala8 did not effect binding affinity but greatly 
reduced constrictive activity, which indicated that this position was more important 
for biological activity than for receptor binding. The analogue ET-1[1-21, Ala 8] 
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appears to be a receptor non-selective antagonist 38 . The N-terminal residues Ser 2'4, 
Leu6, Met7, Lys9 and Glu'° were found tolerant to replacement as the corresponding 
peptides all showed some agonism. Replacement at the C-terminus was much more 
sensitive, but analogues ET-1 [Ala 16]  and ET-1 [Ala' 9] appeared to be more potent 
agonists than ET- 1 itself (Table 3.1.3). 
A mono D-amino acid scan of the ET-1 provided information on the 
orientation of the side chain and backbone conformation and their relative importance 
to functional activity. 40 It was found that inversion of configuration was generally less 
tolerated in the C-terminal region than in the N-terminal region. Inverting Asp 8 and 
Glu'° caused a considerable decrease in the biological activity, while inverting Lys 9 
was well tolerated. D-Phe' 4 and D-Leu' 7 analogues exhibited partial agonism in rabbit 
vena cava although their binding in human VSM cells decreased significantly (Table 
3.1.3). 
The two disulphide bonds were found to be important for ETA receptor 
binding and functional activity but not for the ETB receptor as the linear analogue ET-
1 [1-21, Ala' 3,11,11]  was found inactive in ETA containing tissues, while it bound to the 
ETB receptor with equal affinity as that of ET-1 41 
The full-length monocyclic analogue, ET-1 [Ala 3,1  has shown 10% 
vasoconstrictor activity of ET-1 in the isolated rat aorta, while ET-1 [Ala""] has 
shown less than 05%,4243  which indicated that the outer disulphide intact between 1 
and 15 was more important for maintaining vaso-constrictor activity in this tissue 
(ETA). Likewise, the monocyclic analogues exhibited diminished binding affinity 
relative to ET-1 in the rat cerebellum (ET B)42'43 . The Ala scan of ET-1 [Ala"", Me 7]
supported the observation of the Ala scan of ET-1 itself. 44'45 Substitution of Ser2 , 
Val '2, His16 and 1le19 with Ala produced agonists of reasonable potency, these sites 
were thus identified as tolerated sites; Substitution of Asp 8, Tyr", Ile2° and Trp2 ' 
caused a significant decrease in the binding affinity and functional activity, these 
residues were thus regarded as important sites. Substitution of Glu' ° , Phe 14 , Leu' 7 and 
Asp 18  produced analogues that showed significant binding affinity to the receptor at 
concentrations below those at which agonism was observed, these sites were thus 
suggested as candidate sites for the exploration of receptor antagonism as they played 
a more important role in receptor functional activity than in the receptor binding. 
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Further study by these authors 45 suggested that ET-1 [Pen"", N1e 7, Ala"] was a 
more potent ETA receptor selective antagonist, when penicillamine (Pen) was used at 
positions 1 and 11 to assist in the correct 1-15, 3-11 disulphide formation. 
Another independent study identified residue Asp 18  as the most important 
residue 4' and it was suggested that analogues substituted at position 18 with a 
hydrophobic amino acid, such as Val, Nva, Leu, lie y-MeLeu, or Phe, were ETA 
receptor selective antagonists. Further investigation of positions 18 and 19 showed 
that replacement of Asp 18 with Thr and of Tie 19 with a hydrophobic amino acid whose 
side-chain branches at the 'y-carbon such as Leu, cyclohexylalanine and y-MeLeu, 
resulted in analogues with significant decreased constrictor activity while still binding 
with high affinity to both receptors. 47 
Truncated monocylic ET-! analogues with different sequences between Cys' 
and Cys' 5 were also studied 48 '49 . The loop region between Cys3 and Cys" itself did not 
bind to either receptor up to 100tM. A series of analogues without the 3-11 region 
bound to both receptors with micromolar affinity and exhibited antagonist activity at 
the ETA receptor but not at the ETB receptor. It is interesting that a similar monocylic 
analogue, Cyclo- [Cys-Val-Tyr-Phe-Cys]-His-Leu-Asp-Ile-Ile-Trp, known as IRL 
1038, was reported by Urade et al. to be a potent ETB receptor antagonist. 5° In 
another independent study, it was reported that 1RL1038 was a non-selective ET 
receptor antagonist 49, with low micromolar affinity to each receptor. A later study by 
Urade et al. disclosed that subsequent preparations of IRL 1038 failed to possess the 
potency and selectivity of the original sequence. 5 ' The reason for the discrepancy is 
unknown, but it might due to the presence of ETB receptor subtypes as was reported 
recently. 18,12 
Linear analogues of ET-1 have also been studied. ET-1 [Ala' 3,11,151 showed 
5500 fold reduction in binding affinity to the ETA receptor but only 3-fold reduction 
to the ETB receptor. 53,54  A systematic truncation of the linear analogue, ET-1 
[Ala 1,3,11,15]  led to the development of several ETB selective agonists and residues 8-21 
were regarded as the minimum sequence for ETB receptor binding and agoni SM.  55'56 
N-terminal acetylation of some truncated analogues led to a compound with increased 
ET8 receptor selectivity and functional activity, and BQ-3 020, ET-1 [Ac-6-21, 
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Ala' 1,15  appeared as a potent ETB receptor selective agonist. 55 Another study 
revealed that the charged residues, Asp 8 and Glu' ° were important for ET B receptor 
binding, but Lys9 could tolerate replacements by Ala or Glu and ML 1620 ET-1 [Suc-
8-2 1, G1u9, was reported as another ETB selective agonist. 57 An even shorter 
analogue, ET-1 [Ac-10-21], was also reported to have jiM binding for the ET 
receptor 58.  Individual amino acid replacement of this analogue with Ala or D-amino 
acid revealed that the side chains of Phe' 4, Leu'7, 11e2° and Trp21 , the correct backbone 
orientation of Phe' 4 and the C-terminal hexapeptide [16-21], were all important for 
ETB selective agonism. However, when the same experiment was repeated in this 
study, some different results were observed. 
Table 3.1.4 ET receptor agonists and antagonists found by SAR study 
Compound/Structure Type IC 	- Ref. 
ETA ETB 
ET-1[1-21, Thr' 8 'y MeLeu' 91 ETAIETB antagonist 0.7nM 0.25nM 47 
ET-1[1-21, Ala' 3,11,151 ETB agonist 570nM 0.33nM 41 
BQ-3020: ET-l[Ac-6-21, Ala" 5] ETB agonist 440nM 0.2nM 55 
1RL1620 ET-1[Suc-8-21, G1u 9] ETB agonist 1900pM* 16pM* 57 
ET-1[Ac-10-21] ETB agonist llp.M 11M 55 
PD142893 ET-1[Ac-16-21, Dip ' 6] ETA/ET, antagonist 40nlvI 60nM 61 
PD145065 ET-1[Ac-16-21, D- ETA/ETa antagonist 3nM 19nM 62 
Bhg' 6 
Notes: *j  values; 
Bhg: 10,1 1-dihydro-5H-dibenzo[a,d]cycloheptene; Dip: diphenylmethene. 
In another report, 1RL1720, ET-1 [8-21, Ala" 5 ], was found to possess 
subnanomolar affinity for ETB receptor (porcine lung) and to be an antagonist of ET-
3 stimulated vasoconstriction in guinea pig trachea. 59 This result was very interesting 
with respect to that 1RL1620 and BQ-3020, two very similar analogues, being potent 
ETB agonists. This result also indicates that re-investigation of the highlighted 
analogues is of particular importance. 
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Although the C-terminal hexapeptide was found to be critical for the 
biological activity of the ETs, the hexapeptide itself showed very poor binding affinity 
for both receptor subtypes. 60 Studies of this hexapeptide showed that substitution at 
certain positions could improve its binding affinity 60 and this study led to the 
discovery of several potent antagonists with non-receptor selectivity, i.e. PD 14289361 
and PD 14506562. 
Some ET receptor selective agonists and antagonists found to data are listed 
in Table 3.1.4. 
3.1.7 Conformational studies, CD, NMR and X-ray diffraction 
In order to elucidate important structural features that might be relevant in the 
receptor binding state, the solution conformation of endothelins, sarafotoxins, and 
related analogues have been extensively studied by CD, NAM and molecular modeling 
under different conditions .63-73  CD spectra of ET-1 and its isopeptides were very 
similar, showing about 35% helical structure .63,64  NIvIIR studies suggested that a 
general helical structure exists in all ETs between Lys 9 and Cys' 5 , but varies from each 
other in detail. 11,66,67  Some groups reported that the N-terminus was averaging on 
NMR time scale68'69while others70 ' 7 ' suggested that a n-turn might be present between 
Ser5 and Asp8 . Conformation of the C-terminal hexapeptide, which is essential for 
biological activity, was surprisingly not well defined in most studies, 657 ' while a few 
studies suggested that it may be associated with the bicyclic core. 72 Aggregation of 
ET-1 in aqueous solution was detected by CD 73  and it was suggested to be the reason 
for the discrepancy in NMIR studies as organic solvents such as acetonitrile and 
DMSO had to be used. An alternative structural model of ET-1 which composed 
mainly of n-turns rather than (x-helix was thus proposed .73 
CD and NIV1R studies of monocyclic analogues, ET-1 [Ala 3,1  ET-1 [Ala 
and ET-1 [Aba" 5 ] were also reported . 63 '74 The results suggested that the structure of 
the monocyclic analogues was comparable to the natural ET-1, with increased 
structural disorder at the N-tenminus. 75 The CD spectra of the linear analogue, ET-1 
[Mal 1,15], however, showed only 52% 13-sheet structure with little helicity. 53 It was 
thus suggested that at least one disulphide bond was required to stabilize the helical 
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structure and thus no further CD or NMIR study has since been carried out for the 
linear analogues. However, our study indicated that a helical structure, very similar to 
the native one is present in most of the linear analogues studied. 76 
The three dimensional crystal structure of ET-1 by X-ray crystallography is 
different from that expected on the basis of the CD and NMIR studies. 77 It was 
reported that the structurally undefined C-terminal hexapeptide from NMR studies is 
actually helical in nature, while the N-terminal residues exist in an extended 3-strand, 
followed by an irregular helix starting at Cys 11. and extended to the C-terminus. 
3.2 SAR studies of ET-1 and its linear analogues 
Linear analogues of ET-1 were synthesized to study their binding and 
functional activity to the ET receptors. As was described previously, linear analogues 
of ET-1 are efficient at binding to the ETB receptor subtype, while are less potent at 
binding to the ETA receptor. To further study the ET 8 receptor selective ligands, SAR 
of the linear analogues was carried out. The sequences of the full length and truncated 
linear analogues synthesized are listed in Appendix I and II respectively. 
3.2.1 Replacement of the Met7 
Methionine is labile to oxidation, and it is commonly replaced by norleucine (Me) 
- without loss in biological activity. 44 ' 45 This is reasonable due to their structural similarity 
as shown in Figure 3.2.1. Leu has a slightly different structure but has also been reported 
for the replacement of Met in some studies with similar results. 78 
HO 
Met 	 Nie 	 Leu 	 Mie 	 Val 
Figure 3.2.1 The structures of Met, Me, Leu, Me and Val 
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Table 3.21 Biological activity of ET-1 analogues with different Met 7 replacements 
Ppl. 
No 










ET-1 0.0002 0.0016 0.13 0.0003 
lB [1-21, Mb3", N1e7 , X 1 " 5 1 4.5 0.0009 5,000 0.00048 
1 [1-21, Aib3", Leu7, X1,151 9.1 0.00006 151,667 0.00059 
32 [7-21, Me 7,  Aib, X' 5 ] 0.77 0.0004 1,925 0.00077 
33 [7-21, Leu7 , Aib", X' 5] 2.8 0.0009 3,111 0.0013 
6 ØØ 
53 [7-21, Leu7 , Aib" 5] 
.. 
1.8 0.0003 6,000 0.00096 
61 [7-21, Va1 7 , Mb" 5] 0,83 0.0025 332 0,0023 
62 [7-21, MeLeu7 , Aib" 5 1 0.9 0.0002 45,000 0.0015 
Notes: 
X: Cys(Acm); 
tested in rabbit renal artery vascular smooth muscle cells; 
tested in rat cerebellum; 
tested in human ETB receptor expressed in CHO cells, 
It can be seen that both Me and Leu are well tolerated at this position since 
similar results are observed in each pair with respect to receptor binding and 
functional activity. However, with Leu at position 7, the functional activity on ETB 
receptor is slightly reduced as is shown in peptides 1 and 33. It seems that the methyl 
side group on the 'y-carbon helps to reduce the functional activity towards the 
antagonist, thus a series of 7-21 analogues were synthesized with different 
substitution at position 7, including the most branched analogue, y-methyl leucine 
(Table 3.2.1, group 2). The data show that the functional activities of all the peptides 
are very similar (0.96 '-'2.3nM), which indicates that the steric effect is not critical for 
ETB receptor functional activity. The binding affinities for ET B receptor are also 
similar except that of peptide 61, which has Val at position 7, methyl group at the 13-
position of the side-chain, shows 10-20 fold lower binding affinity. The binding 
affinities of these analogues for the ETA receptor, however, are slightly different. 
Peptide 67, which has the least branched Nie at position 7, shows the lowest binding; 
while peptides 61 and 62, which are most branched at either y-  or  13- position, show 
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the highest binding. These results indicate that a branched side chain at position 7 is 
preferred by ETA receptor, while the 13-branched Val is the least tolerated by ETB 
receptor. Branching at the y- position, however, is tolerated by the ETB receptor, 
therefore in the following discussion, no distinction will be made between Leu 7 and 
Me  analogues. 
3.2.2 Replacement of Cys 1,3"5 
Five full length analogues were synthesized to study the effect of the different 
replacements of the four Cys residues at positions 1, 3, 11, and 15 (Table 3.2.2) with 
Ala and the helix promoting amino acid, a-aminoisobutyric acid (Aib). Aib was used 
to introduce some helical structure in the linear analogues, which seems to be 
important for the biological activities at the ET A receptor but was reported not to 
exist in the linear analogue, ET-1 [1-21, Ala' 3,11,15].  Aib could also help to improve 
the stability of the peptides towards proteolytic degradation and could also improve 
the solubility of the analogues which is important for the biological assay and 
CDIN]VIR studies. 
Table 3.2.2 shows the receptor binding affinities and the biological activities of 
ET-1, ET-3, the ETB selective STRX-6c and the synthetic full length analogues 
(Peptides 1C, 1, 1B, 2 and 2B). The full length analogues have a very high binding 
affinity for the ETB receptor with 10 50 's between 0.06 and 0.9 nM in CHO cells, 
which are as potent as the ET-3. The ETB receptor binding selectivities of these 
analogues are 1010 5 over the ETA receptor, showing higher selectivity than that of 
the most ETB selective peptide, STRX-6c. Their functional activities for the ETB 
receptor are also very high and comparable to that of ET-1 except peptides 1C and 
2B, which are slightly lower. These results indicate that the two disulphide bridges are 
critical for the ET A receptor binding but not for the ETB  receptor binding and 
functional activity, as has been previously reported. 11-18  Substitutions at the four Cys' 
positions are well tolerated for binding at the ETB receptor. The introduction of the 
helix inducing amino acid, Aib, does not affect the ETB receptor binding, but it does 
improve the binding affinity to the ET A receptor, since peptide 1C, ET-1 [Aib 1 ' 3" 1 ' 15 ] 
shows the highest binding affinity for the ETA receptor and peptide 2B, ET-1 [Ala 3 ' 11 ' 
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Cys(Acm)" 5 ] shows the lowest. These results indicate that positions 11 and 15 are 
more important for helical structure and therefore are more sensitive to Aib 
substitution. This is reasonable as these positions are within the helical region, [9-15 
or 16] of the ETs. Similar results are also observed in the truncated analogues, which 
will be discussed in the following sections. 
Table 3.2.2 Biological activity of ET-1, ET-3, STRX-6c and some full length ET-1 
analogues with different Cys replacements 
lkpt. 
N. 
ETs and Some Full 
I .cng(li 	\IIIIo2IIeS, 1-21 
-- lC(pJl ) 
FT, 
IC 5UtI'1) Selectivity 
FTB / ET 
ECc 1 (j.tM) 
ET I ' 
ET-1 0.0002 	- 0.0006 0.13 0.0003 
ET-3 0.0025 0.000043 58 0.00007 
STRX-6c 11 0.0035 3,143 0.00025 
1C [Aib1 ' 3 ' 11 " 51 0.77 0.0003 2,567 0.0013 
1 [Aib31 1 , Leu7 , X1,15 ] 9.1 0.00006 151,667 0.00059 
lB [Aib3 ' 11 , Me 7 ,  X1,151 4.5 0.0009 5,000 0.00048 
2 [Ala 3,  Aib", Leu7 , XLIS] 6.2 0.0001 62,000 0.00053 
2B [Ala 3 ' 11 , Len', X 1 " 5 1 16 0.0007 22,857 0.0021 
Notes :X: Cys(Acm); Mle: MeLeu; 
b: tested in rabbit renal artery vascular smooth muscle cells; 
C: tested in rat cerebellum; 
d: tested in human ET B receptor expressed in CHO cells. 
3.2.3 Effects of chain length 
Since the C-terminal part of the ET-1 has been proven to be critical for 
binding and functional activity at both receptor subtypes, truncation of the N-terminal 
part was studied. One of the full length peptide, peptide 2 was truncated to investigate 
the effect of the chain length (Table 3.2.3). From the data listed in Table 3.2.3, 
residues Cys' and Ser 2 were found not critical for the ETB receptor functional activity, 
as peptides 15-1 [2-21] and peptide 14 [3-21] are as potent as peptide 2. The binding 
affinities, however, are slightly increased for the ETA receptor but slightly decreased 
for the ETB receptor, which resulted in a 10 fold reduction in the ETB receptor 
selectivity in both peptides. The next truncation gives peptide 13 [4-21], which shows 
-.-3 fold reduction in the ET B  receptor binding affinity but a 2 fold increase in the ETB 
receptor functional activity, which indicates that residue Cys 3 has some effect on the 
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2 1-21, [Ala 3 , Leu7'Aib", X1,151 6.2 0.0001 62,000 0.00053 
15 2-21,[A1a3 , Leu7 'Aib", X1,15 1 1.7 0.0004 4,250 0.00048 
14 3-21, [Ala 3 , Leu7 'Aib", X" 5J 1.4 0.00033 4,242 0.00096 
13 4-21jLeu7'Aib",X1,1 5 1 	. 3.3 0.001 3,300 0.00042 
12 5-21,[Leu7'Aib", X 1, 15] 4.3 0.001 4,300 0.0016 
11 6-21,[Leu7'Aib11, X 1, 15] 2.8 0.0007 4,000 0.0016 
33 7-21,[Leu7'Aib", X' 15] 2.8 0.0009 3,111 0.0013 
31 8-21,[Aib", X151 7.2 0.009 800 0.0047 
30 9-21,[Aib'1, X1,151 9.9 0.15 66 0.180 
29 10-21,[Aib11 , X1,151 >2.5 1.6 - 0.370 
28 11-21,[Aib", X1,151 >2.5 >2.5 - >10 
35A Ac-12-21,[X1 ' 15] 3.9 0.58 7 6.9 
Notes: 
tested in rabbit renal artery vascular smooth muscle cells; 
tested in rat cerebellum; 
tested in human ETB receptor expressed in CHO cells. 
ETB receptor binding but has no effect on the functional activity. One more truncation 
results in peptide 12 [5-21] and the data shows that it has the same binding affinity as 
peptide 13 but has a 4 fold reduction in functional activity, which indicates that 
residue Set-4 is more important for the ETB receptor binding than for its functional 
activity. Further truncation until peptide 33 [7-21] affects neither the binding nor the 
functional activity, which suggests residues 5 and 6 are not important for ETB 
receptor binding and functional activity. In fact, peptide 33, the 7-21 analogue of 
peptide 2, is only 9 fold less potent in binding and only 2 fold less potent in functional 
activity for the ETB receptor than the full length analogue peptide 2. These results 
indicate that the N-terminal six residues are not very important for ETB receptor 
binding and functional activity, but they affect the binding affinity for the ETA 
receptor and therefore affect the receptor binding selectivity, which is 30 fold reduced 
in peptide 33. The next truncated analogue, peptide 31 [8-21], still affords reasonable 
functional activity with a further 10 fold decrease in binding affinity. Further 
truncation not only caused a serious decrease in ETB receptor binding and functional 
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activity, but also in the receptor selectivity. The shortest analogue, peptide 35A [Ac-
12-21] was found to be a poor agonist with non receptor selectivity. Therefore, the 
sequence between 8 and 21 of ET- 1 is regarded as the minimum sequence for further 
studies. 
From the above discussions, it can also be seen that as the peptide sequence is 
shortened, the receptor selectivity decreases. The major reduction occurs in peptides 
31, 30 and 29, the 8-21, 9-21 and 10-21 analogues, which indicates that the charged 
groups (Asp 8Lys9Glu'°) may play an important role in ETB receptor recognition. 
When Asp8 is replaced by Ala 8,  the receptor selectivity decreased from 6000 to only 
65 (peptides 52 and 72, Table 3.2.4C), while D-Asp 8 replacement is tolerated 
(peptides 52 and 68, Table 3.2.4B). 
3.2.4 D-Amino acid survey at selected positions 
Literature reports have shown that residues Asp 8 ' 18, Phe'4 and H15 16 are 
important in determining the agonist/antagonist property of the ET-1 analogues. D-
amino acids were introduced into these positions in the full length and truncated 
analogues to study the importance of stereochemistry at these positions (Table 
3.2.4A, 4B, and 4C). 
When Asp 8 in peptide 26 is replaced with D-Asp, the binding affinity for the 
ETB receptor was found to decreased by 20, but the functional activity for the ETB 
receptor remains more or less the same. This indicates that the backbone 
conformation at position 8 is more important for ETB receptor binding than for the 
functional activity. It was decided to replace J516 with D-Phe in peptide 24 since this 
substitution turned an agonist into a potent antagonist in a previous study of the C-
terminal hexapeptide. 33 This substitution caused serious decrease in binding affinity, 
as well as the functional activity at the ETB receptor subtype as was shown in the 
Table, but no antagonism was observed. This result indicates that Phe is not tolerated 
at position 16 in the full length analogue. Since Asp" has been suggested to be an 
important residue, D-Asp was introduced into this position in peptide 22. It is found 
that the binding affinities of this peptide for both receptors are reduced as well as the 
functional activity through ETB receptor. These results indicate that the back bone 
conformation of Asp" is critical for binding to both receptors and is also important 
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for ETB receptor functional activity. The replacement of Phe' 4 with D-Phe also causes 
serious reduction of binding affinity and functional activity as shown in peptide 21. 
Combination of two D-amino acid replacements normally comprises the effect of both 
substitutions as shown in peptides 23 and 25. 
Table 3.2.4A Biological activity ofpeptide 2 and its full length [1-21] analogues 
with D-amino acid replacements 
Pept 
No 




IC 	iM Selectt%1 
ET, [ET,  
EC(iM) 
2 [Ala 3 , Leu7 Aib, X1,15 1 6.2 0.0001 62,000 0.00053 
26 [Ma3 , Leu7'Aib' 1 , X" 5 , dAsp8 ] 16 0.002 8,000 0.00032 
21 [Ala3 , Leu7'Aib", X" 5 , dPhe'] 13 0.25 52 >10 
22 [Ala 3 , Leu7'Aib", XI, 15, dAsp 8] >25 5.8 - >10 
24 [Ala 3 , Len" Aib", X 1, 15 , dPhe 6J 17 0.56 31 0.48 
23 [Ala 3 , Leu7 'Aib11 , X15 , dPhe' 6 , 20 11 2 >10 
dAsp' 8] 
25 [Ala 3 , Leu7 'Aib", X1,15 , dAsp8 , 13 1.8 7 0.54 
dPhe' 6] 
Notes: 
tested in rabbit renal artery vascular smooth muscle cells; 
tested in rat cerebellum; 
tested in human ETB receptor expressed in CHO cells. 
Previous studies suggested that residues between 8 and 16, known as the 
helical region, might be of significance with respect to receptor agonism. D-amino 
acids were thus introduced into each of these positions in some truncated analogues in 
order to study the effect of the backbone conformation (Table 3.2.4B). Results show 
that inversion of residues between Lys 9 and Tyr 13  causes a 20-50 fold reduction in 
ETB receptor binding affinity, but does not affect the functional activity through ETB 
receptor, which again indicates that these groups are important for receptor 
recognition but not for functional activity. Replacement of Asp 8 with D-Asp does not 
affect the binding affinity for ETB receptor whereas the functional activity is improved, 
indicating that the back-bone conformation at this position is not critical. This result 
contrasts to that observed in the full length analogues, where D-Asp 8 replacement 
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caused a 20 fold decrease in the ETB receptor binding affinity (peptides 2 and 26, 
Table 3.2.4A). Residues Phe' 4 and His16, however, are very sensitive to conformation 
change in the truncated analogues, since peptides 70 and 71 show very poor binding 
and functional activity at the ETB receptor. These results are consistent with those 
observed for the full length analogues. It is very interesting to notice that the binding 
affinity of all these analogues at ETA receptor remains more or less unchanged, and 
the selectivity of these analogues is thus reduced except for peptide 68. 
Table 3.2.4B Biological activity of truncated peptide 52 (8-21) and its analogues 










52 [Aib1151 0.27 0.001 270 0.025 
68 [Aib' 1 " 5 , dAsp8] 4.4 0.001 4,400 0.0074 
69 [Aib1115 , d1,ys9] 5.5 0.02 275 0.015 
59 [Aib 5 , dGlu' °] 2.9 0.05 58 0.037 
58 [Aib" 5 , dVal' 2] 4.1 0.03 137 0.037 
57 [Aib' 1 " 5 , dTyr' 3 ] 5.8 0.02 290 0.018 
70 [Aib11 " 5 , dPhe141 7.4 1.4 5 >10 
71 [Aib'" 5 , dHis16] 6 0.1 60 0.15 
4fTAIbrl:r5 A1alr xrs ] .4 o:uio 
39 [Aib" 5, dAla", X' 5 14 






tested in rabbit renal artery vascular smooth muscle cells; 
tested in rat cerebellum; 
tested in human ETB receptor expressed in CHO cells. 
As Asp8 shows some special activity, further investigation of this residue was 
carried out (Table 3.2.4C). Asp 8 was replaced with D-Asp in three pairs of [7-21] 
analogues. The analogues with D-Asp8 all show -P10 fold reduction in functional 
activity at ETB receptor comparing with their L-Asp 8 isomers, while the binding 
affinity for this receptor changed in a different way. In one pair (peptides 33 and 34, 
Leu7), the binding affinity of the D-Asp 8 analogue was 3 fold increased, while in the 
other two pairs (peptides 62, 64, Me  and peptides 61, 63, Val), the binding affinities 
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of the D-Asp8 analogues were decreased. The increase or decrease was minor in 
groups 1 and 3, indicating that the backbone conformation of Asp 8 is not critical in 
these peptides. However, D-Asp 8 replacement in group 2 caused 200 fold decrease in 
ETB receptor binding affinity. This result, and also those observed in Table 3.2.4A and 
6C, indicates that the same substitution can result in totally different effects in 
different sequences. In group four, the effect of Ala' substitution was investigated. 
The data indicates that replacement of Asp 8 with Ala8 results in a 67 fold decrease in 
the ETB receptor binding affinity and 104  fold decrease in functional activity. This 
result clearly indicates that Asp 8 is more important for the ETB receptor functional 
activity than for its binding. This replacement, however, does not affect the ETA 
receptor binding and the selectivity of this peptide at the ETB receptor is therefore 
reduced (from 6000 to 65). 













33 [Leu7 , Mpg, Aib"X' 5] 2.8 0.0009 3,111 0.0013 
34 [Leu, dAsp8 , AIb"X' 5] 26 0.0003 86,667 0.018 
62 09 45,000 
64 [M1e7 , dAsp8 , Aib" 5] 1.3 
0.000..
0.02 65 0.019 
61 .IVâl 7 , Asp 8 , ........ . i18.. .O02.. 32 0.002. 
63 
[MlelAsprAibir.is1 .................. 






53 [Leu7 , Asp8 , Aib" 5] 1.8 0.0003 6,000 0.00096 
. 
72 [Leu7 , Ala8 , Aib" 5] 1.3 0.02 65 >10 
Notes: 
X: Cys(Acm); 
b: tested in rabbit renal artery vascular smooth muscle cells; 
C: tested in rat cerebellum; 
d: tested in human ETB receptor expressed in CHO cells. 
3.2.5 N-Acetylation of ET-1 analogues 
Although the N-terminal acetylation of ET-1 itself is not tolerated, the N-
terminal acetylation of some truncated analogues has been found to improve the 
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binding affinity at the ETB receptor. 556 ' The same study was carried out on some 6-
21, 7-21 and 8-21 analogues (Table 3.2.5). However, the data indicate that N-
terminal acetylation does not affect the binding affinities of these analogues to the ETB 
receptor, while the functional activity is increased by 1.6-9 fold. These results suggest 
that N-terminal acetylation of these analogues is tolerated but not necessary for the 
functional activity. 





IC c ,(pJ%l 
F T 
IC , 0 (4m) 
FT,' 
S& I& 	Ii'. 'h 
FT1, / ET 
FCco(I.LM) 
[TB" 
33 (7-21,Leu7 ,Aib",X151 2.8 0.0009 3,111 0.0013 
33a [Ac-7-21, Leu7 , Aib, X' 5 ] 16 0.0064 2,500 0.00081 
[1 i7 Aib 151 0.0023 




63a [Ac-7-21, Val', dAsp 8 , Aib"' 5] 
.8.. 
4.4 






41 [8-21, Ala", X15] 6.4 0.05 128 0.110 
41a [Ac-8-21, Ala", X' 5] 3.5 0.042 83 0.036 
Notes: 
X: Cys(Acm); 
b: tested in rabbit renal artery vascular smooth muscle cells; 
C: tested in rat cerebellum; 
d: tested in human ET B receptor expressed in CHO cells. 
3.2.6 SAR study of the truncated analogues, 8-21 of ET-1 
Since the minimum sequence which affords nM ETB receptor binding is 33, 
the 8-21 analogue of ET-1, further study was carried out with the 8-21 analogues. 
Several such analogues with different substitutions at certain positions were 
synthesized and studied (Table 3.2.6). 
In the first group, the effect of Cys" 5 substitution was investigated to 
compare with the results obtained for the full length analogues. As discussed above in 
the full length analogues, substitution at these positions is generally tolerated. The 
analogue with Aib at positions 11 and 15 (peptide 52) showed the highest binding 
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affinity at both receptor subtypes, while that with Ala at position 11 and Cys(Acm) at 
15 (peptide 41) was the most potent agonist at ETB receptor. The 30 fold increase in 
the ETA receptor binding affinity of peptide 52, compared to peptide 31, indicates the 
importance of Aib at position 15 for the ETA receptor binding. In the second group, 
analogues with different substitution at some highlighted positions were investigated. 
Lys9 has been reported as a position of interest. When it was replaced with G1u 9, the 
analogue proved to be a highly selective and very potent ETB receptor antagonist, 
IRL 1620, ET-1[Suc-8-21, G1u9]. 57 The same change was made to the 8-21 analogue 
but the data indicates that this substitution is not tolerated as peptide 55 showed very 
poor binding affinity at both receptors and very poor agonism at the ETB receptor. 
The reason for this discrepancy is unknown, but is probably due to the presence of 
different ETB receptor subtypes. 
Table 3.2.6 Biological activity of truncated ET-1 analogues 
analogues of 8-21 







FT, I ETA 
t( 	,(t1j1  
ET 'd 
52 [Aib 11,15 ] 0.27 0.001 270 0.025 
31 [Aib' 1 , X' 5 ] 7.2 0.009 800 0.0047 
41 [Ala", X' 5] 6.4 0.05 128 0.110 
41a Ac-[Ala", X' 5] 3.5 0.042 83 0.036 
39 [dAla", X' 5] 14 0.037 378 0.058 
55 [G1u9 , Aib" 151 >2.5 >2.5 - >10 
46 [Aib"' 5 , Thr18] 1.3 0.003 433 0.300 
50 [Aib"" 5,Leu' 8 ] 0.16 >2.5 <1 >10 
66 [Aib"" 5 , Mle' 9] 4.7 4.6 1 >10 
37 [Aib"" 5 , Thr18Mle191 8.3 1.0 8 >10 
37a Ac-[Aib"" 5 , Thr' 8M1e191 11 0.55 20 >10 
36 [G1u9 Aib" 5 , Thr' 8Mle' 91 24 2.9 8 >10 
36a Ac-[G1u9 Aib" 5 , Thr18M1& 91 26 1.7 15 >10 
Notes: 
tested in rabbit renal artery vascular smooth muscle cells; 
tested in rat cerebellum; 
tested in human ETB receptor expressed in CHO cells. 
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3.2.7 Comparison among the truncated 6-21, 7-21 and 8-21 analogues 
As discussed in Section 3.2.3, the 6-21 and 7-21 analogues are -10 fold more 
potent for the ET8 receptor than the 8-21 analogues, thus further research was carried 
out to study the effect of residues 6 and 7 under different substitution patterns (Table 
3.2.7). 
Table 3.2.7 Biological activity of truncated ET-1 analogues 
analogues of 6-21, 7-21 and 8-21 
Pept. 
No. 
Truncated 6-21, 7-21 








Leu7, Aib 15 
54 [6-21] 2.0 0.0002 10,000 0.00072 
53 [7-21] 1.8 0.0003 6,000 0.00096 
52 [8-21] 0.27 0.001 270 0.025 
Leu7, Ala", X'5 
40 [Ala", X' 5] 2.8 0.003 933 0.0053 
65 [7-21] 9.6 0.005 1,920 0.0044 
41 [8-21] 6.4 0.05 128 0.110 
47 [6-21] 1.4 0.0005 2,800 0.290 
46 [8-21] 1.3 0.003 433 0.300 
Aib1t"5, Leu 18 
51 [6-21] 0.085 0.074 1 >10 
50 [8-21] 0.16 
ti'8....................... . 
>2.5 <0.06 >10 
38 [6-21] 
Glu...4.ThT1 'T5 	fji9 ......
3.0 0.18 17 >10 
36 [8-21] 24 2.9 8 >10 
G1u9, Mb"3"5 Thr'8MIe' 9 
56 [1-21] 2.6 0.03 87 >10 
Notes 
b: tested in rabbit renal artery vascular smooth muscle cells; 
C: tested in rat cerebellum; 
d: tested in human ET8 receptor expressed in CHO cells. 
In the first group, three peptides with Aib 11" 5 are studied. The data shows that 
the 6-21 and 7-21 analogues have very similar binding affinity and functional activity, 
91 
while the 8-21 analogue showed increased binding affinity for the ETA receptor but 
decreased binding affinity and functional activity for the ETB receptor. The binding 
affinity of the 8-21 analogue is 20--30 fold less potent than the 6-21 and 7-21 
analogues for the ET 8 receptor, which indicates that residues 6 and 7 are important 
for the ETB  receptor binding under this substitution. The slightly increased affinity 
within the 8-21 analogues for the ET A receptor binding is unexpected, but it clearly 
indicates that residues 6 and 7 are not critical for the ETA receptor recognition. 
In the second group, peptides with Ala"Cys(Acm)' 5 were investigated. The 
data indicate that the 6-21 and 7-21 analogues are very similar in binding and 
functional activity while the 8-21 analogue is much less potent. The binding affinity of 
all three peptides for the ETA receptor, however, are very similar. 
Asp 18  is another interesting residue as well as Asp 8 . In the SAR study of 
bicyclic ET-1 analogues, Kikuchi et al. found that replacement of Asp 18  with a 
hydrophobic amino acid afforded potent ETA receptor antagonists while analogue ET-
1 [1-21, Thr 18Mle'9] was an antagonist with no receptor selectivity. 46 In another 
independent study of the monocyclic analogues, Hunt et al. reported that analogue 
ET-1[1-21, Ala"", N1e7, showed antagonism at the ETA receptor .45  It is 
known that the disulphide bond(s) play an important role in ETA receptor binding but 
not in the ETB receptor, it would be very interesting to introduce the same 
substitution into the ET 8 selective linear analogues. Therefore peptides with different 
substitutions at position 18 were studied (groups 3 and 4). In group three, peptides 
with Aib"5Thr' 8 were studied. The binding affinities of both peptides to the ETA 
receptor were very similar, but those for the ET B receptor was 6 fold decreased in the 
8-21 analogues, indicating that residues 6 and 7 were important for the ET B receptor 
binding but not for the ET A receptor. The binding affinities for both receptor subtypes 
are comparable to those of the corresponding peptides in group one, which indicates 
that Thr' 8 is tolerated. However, the functional activities of both peptides with Thr' 8 
were greatly decreased, especially that of the 6-21 analogue, which indicates that 
Asp 18  is essential for the ETB receptor functional activity as discussed above. In group 
four, peptides with Aib" 15Leu' 8 were studied. Compared with the peptides in groups 
one and three, the binding affinities of both peptides for the ET A receptor were 
increased, especially the 6-21 analogue (peptide 51). This result indicates that Asp 18  is 
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not necessary for ETA receptor binding and a hydrophobic residue, such as Leu, is 
preferable. The binding affinity for the ET B receptor, however, seriously decreased, as 
did the functional activities through the ETB receptor, which indicates that Asp" is 
very important for ETB receptor binding and functional activity. Compared to the 
corresponding peptide in group three, the ETB receptor functional activities of these 
peptides were further decreased which indicates that hydrophilicity is significant at 
this position. The data also indicate that residues 6 and 7 are important for both 
receptors with this substitution. In group five, peptides with Thr' 8Mle'9 were 
investigated for antagonism. However, this replacement was not tolerated by the ETB 
receptor as indicated by the significant decrease both in binding and functional 
activity. Residues 6 and 7 are important for both receptors as is shown by the 
increased binding affinity of peptide 38. In order to further increase the binding 
affinity for the ETB receptor, this peptide was lengthened, without the substitution at 
position 9, to give a full length analogue, peptide 56. As shown by the data in Table 
3.2.7, the ETB receptor binding and selectivity are both improved, but the analogue is 
a poor agonist rather than an antagonist. 
3.2.8 Synthesis and folding of ET-1 
Apart from its numerous biological actions and potent physiological 
importance, ET and its precursor peptide, BigET, have set new tasks for the peptide 
chemist. The correct formation of the two disulphide bonds is the most difficult part 
of the synthesis. Random oxidation of the fully reduced peptides normally affords a 
mixture of two different isomers in a ratio of 3:1 •79,80  Orthogonal thiol-protecting 
groups have therefore been developed , 81 ' 82' 83 but the yields in such procedures has 
never been reported. In this study, BigET-1 was synthesized according to a method 
developed in this laboratory by Stewart 84, and new method was developed for the 
synthesis of ET-1 which is described in the following. 
The peptide chain of ET-1 was assembled by double triazole coupling 
methodology (Section 3.3.1) and all four cysteines were protected with Trt group. 
The crude peptide was afforded in good purity according to the HPLC (Figure 
3.2.2a), thus it was decided to carry out the oxidation without pre-purification. 
However, the crude peptide was not soluble in the oxidation mixture (0.1M Tris 
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buffer, pH 8.0, (37 0C)) in IM Guanidine.HCI, the same mixture in 6M Gunindine.HCI 
had to be used in order to dissolve the crude peptide. 
According to the CD studies that the helical structure in ET- 1 analogues was 
very strongly conserved, therefore it was decided to carry out the oxidation in 6M 
gunindine.HCI and 0. 1M Tris buffer. Reduced and oxidized glutathione were added to 
make a final concentration of 5mM and 0.5mM respectively. The mixture was stirred 
at 0-10°C overnight and monitored by HPLC, which showed one major peak with the 
same retention time as commercial ET-1 in 30mm (Figure 3.2.2b). The situation did 
not change in the next 8 hrs, so the peptide was isolated and purified twice by 
preparative HPLC on a P&P C18 column and lyophilized to give 15mg final product 
(overall yield 19.4%). A co-injection of the purified peptide with commercial ET-1 
resulted in a very' sharp single peak (Figure 3.2.3.a). The peptide was analyzed under 
different HPLC conditions (Figure 3.2.3b,c). MS of the synthetic peptide gave the 
required mass. The 2D N1VIR of this peptide is shown in section 3.2.9, which also 





I 	 ' -1-----  30 	 20 30 20 (mm) 
Figure 3.2.2 HPLC monitoring ofpeptide 60 oxidation and folding 
in 6m guanidine. HC1, 0. IM Tris buffer (pH 8.5); 
a. 30mm; b. 8k; c. after purification. 
214nm, lml/min; Hichrom C18 column (size B). 
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(mm) 	 (mm) 	 (mm) 
Figure 3.2.3 HPLC analysis of peptide 60 
214nm, lml/min; a. RP C18 (size A); b. Vydac C18 (size B), 
c. co-injection with native ET-1, Hichrom C18 column(size B); 
3.2.9 Conformational studies of ET-1 and its linear analogues 
Information on the secondary and tertiary structure of the peptide is important 
for the study of structure-activity relationships. The conformation of peptides in the 
ET family have been extensively analyzed due to their biological importance . 6468 
However, no research effort has ever been made into the conformational study of 
linear analogues except the early report of ET-1 [Ala 1,3,11,11],13  probably due to the 
absence of helical structure in this early report. 53 However, when the CD experiment 
was carried out in this study, a surprisingly high percentage of helical structure was 
observed in most of the analogues upon addition of trifluoro ethanol (TFE). Further 
study was carried out using CD as well as 2D NMR to examine the effect of different 
substitutions and chain length to the helical structure. 
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Two typical CD spectra are illustrated in Figure 3.2.3 and the secondary 
structure contents are calculated using the CONTIN procedure. 85 The results are 
listed in Table 3.4.8 and Table 3.4.9. From the data in Table 3.2.8 it can be seen that 
all full length analogues without D-amino acid replacement have a high percentage of 
helical structure apart from peptide 2B, which has Ala at position 11 while all the 
others have the helix promoting Aib at this position. This result indicates that Aib is 
important for the helical structure especially at position 11. A similar result was 
observed in a truncated analogue, peptide 40 (Table 3.2.9). Replacement with Ala at 
positions 1 and 3 did not affect the helix structure, as shown in peptides 1, 2 and lB. 
However, peptide 1C, the analogue with Aib at positions 1,3,11,15, showed the 
highest helix extent, which indicates that position 15 also plays a role in promoting the 
helical structure. As shown in Table 3.2.1, peptide 2B is as potent as the other full 
length analogues in terms of the ETB receptor binding and functional activity, which 
indicates that helical structure is not important for the ETB receptor functional 
activity. The binding affinity of 2B to the ETA receptor, however, was slightly 
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Figure 3.2.3 Typical CD spectra, a. in buffer 1; b. in buffer 2 
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Table 3.2.8 Circular dichroisin data of the full length ET-1 Analogues 
Pephde a-helix % J-sheet % remarnder% 
Bufferl Buffer2 Rtjtkrl lIuffer2 Bufkrl Buffer'_ 
3±081 2212 48±16 
2 6±0 65 2±1 2 56±0 75 7±J 241 39±1.2 21±2.2 
0±000 69±075 46±1H) 1±0 75 2U 
IC 6±065 26±411 42±076 5I±fl92 47±13 
21 0±0 00 1 2 	II 	'l 9±() 73 ±J 81 41±0 7 ±1 4 
22 ±io 19±13 62±11 72±4 9±24 
2±0 55 10±1 41 O±0 8 ±1 2 49-0.97 37± 0 
.25 2±0 81 11±1 46±1 2 	 2 52±1.4 33±.3.- 
26 3±0 68 9±O 7 8±() 78 4±1 1 22±1 
Notes: 
Buffer 1: 50mM boric acid/H20 1: 1 (vlv) (J)H7.0). 
Buffer 2: buffer 1/trifluoroethanol 1:1 (v/v). 
It is interesting that all the linear analogues show much lower binding affinity 
for the ETA receptor, compared to ET- I itself, despite the presence of helix. One 
explanation could be the increased flexibility of the helical structure in the linear 
analogues, but other effects may also be involved. 
When the sequence was truncated from the N-terminus, the percentage of 
helix and 13-sheet increased which indicates that the N-terminal part of the structure is 
random, while the C-terminal may exist as the 13-sheet in the solution studied. 
D-amino acid substitution changes the backbone conformation and therefore 
can affect the helical conformation if the replacement takes place in the helical region, 
as shown in peptides 21, 23-25 (Table 3.2.8). However, in peptides 22 and 26, the 
percentage of helix is almost unchanged because the positions of the replacement are 
not within the helical region. However, in the truncated pair, peptides 33 and 34, a 
great effect was observed on the helical structure in the D-Asp 8 analogue. Peptide 34 
was dramatically disrupted showing only half of the helicity of the L-Asp 8 analogue in 
buffer 2. 
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Table,?. 2. 9 circular dichroism data of come truncated ET-1 analogues 
I'tptuics (i-helix % -hi.t 	', remainder% 
Bufferl Buffcr2 Buffer  Buffer2.: Bufferl Buffer2 
2±1 1 34±1 3 8-1 	- 58+i. 30±2 1 - 8±24 
13 5±092 2±L9 56±1.1 53±2 	. 39±18 2l33 
3±0.71 29±1.3 14  3±() 60±1 4 44±1 4 10±2 3
0±0 00 29±1 3 7- 3±1 3 27±1 8±2 3 
13 4±0 88 u±i 6 6±1 o 6,±1 31±1 i ..3± 	9 
0±0 92 16±1 100±0 05 6±1 6 0+0,00 
16 fl S 29±41 78 S 7j 	78 fl S ft±4 	111 
18 fl S 7 fl S 74 fl S 
0±0 00 26±1 3 1(.)o—+ () 06 41±1 0±0 00 33±13 
0±() 00 21±1 S I 00Th) &)) 59±1 0±() (H) 20±3 3 
-0) ii S 7 	j 74± 3 ii S 19±2.2 
Notes. 
n.s.: insoluble in buffer 1,. 
Buffer 1: 50mM boric acidJ1-120 1: 1(v/v) (pH7.0), 
Buffer 2: buffer 1 /trifluoroethanol 1:1 (v/v). 
Replacement with L-amino acid(s) at the C-terminal region does not affect the 
helical structure, neither does replacement of Lys 9 with Glu, as shown in peptides 36 
and 38 (Table 3.2.9). Both peptides showed a high percentage of helical structure but 
very poor ETB receptor binding affinity and functional activity (Table 3.2.9). This 
results indicate that the helical structure is not necessary for ETB receptor binding but 
the charge groups are important. 
Since CD studies indicate a high percentage of helical and 13-sheet structure 
exists in most of the linear analogues, 2D 'H NMR was carried out to study the 
structures in detail. 
D20/CD30D (1:1) was chosen as the solvent as it is similar to that used in the 
CD studies. The 1D 'H NMR of peptide 1 was very well defined, especially in range 
6.5-9.0 ppm, where the NT-I signals appear, which indicates the presence of a well 
folded conformation (Figure 3.2.4). A systematic study would obviously be significant 
and the research was continued by Hewage. 86 A helical region similar to those 
98 
reported (9 to 15) was observed in most of the analogues studied. 86  In one particular 
analogue, peptide 1, the helical structure was found to start at the very beginning of 
the N-terminus (Figure 3.2.5). This is probably due to the presence of Aib at position 
3. In another analogue, peptide 26, however, the helical structure was observed at 
residues [9-16] (Figure 3.2.6). The reasons for this could be the presence of a D-Asp 
at position 8 and also Ala at position 386 
The structure of ET-1 in the same solvent was also studied and the resulting 
structure is shown in Figure 3.2.7. 
Figures 3.2.5, 3.2.6 and 3.2.7 show that the structure of the linear analogue is 
very similar to that of the native ET-1 in the same solution. This result indicates that 
the disulphide bonds are not critical for the helical structure as suggested in the early 
reports . 5 ' The structure of a truncated analogue, peptide 33 [7-21], was also studied 
and the data indicates that the truncation of the N-terminus six amino acids (Cys'- 
Leu6) does not affect the helical structure. Replacement of Asp 8 and Asp 18 with D-
Asp does not appear to affect the helical structure either as shown in peptide 26. 86 All 
these results are consistent with the CD studies. 
Figure 3.2.4 'HNMR spectrum ofpeptide 2 
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Figure 3.2.5 3D \MR structure ofpeptide 
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?CP2 
Figure 3.2.7 3D NMR structure ofsvnthetic human ET-1 
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3.3 SAR study of B1gET-1 analogues, ECE inhibitors 
3.3.1 Introduction 
The purification of ECE by several groups in 1993 rapidly led to the molecular 
cloning and sequencing of the enzyme from different sources .87,11,89  All forms of ECE 
show >95% homology in amino acid sequence in their putative extra cellular domains, 
but studies have revealed that ECE from various lines and tissues show some 
distinctive features of specificity. Most data supported the occurrence of isozymes of 
ECE. 
Some key features of ECE specificity have been emerged as a result of 
detailed studies on the purified enzymes. Wong et al. 90 reported that a neutral ECE 
did not cleave a decapeptide substrate containing five amino acids on both sides of the 
cleavage site. This suggested that portions of the substrate sequence far from the 
cleavage site may be essential for enzyme recognition. Okada et al.91 found that 
residues 27-34 of BigET-1 were important for conversion by a neutral ECE from 
bovine endothelial cells. In a later report by these authors, BigET-1 [19-34] was 
proposed as the minimum sequence for ECE recognition .92  The N-terminal disulphide 
loop, BigET-1 [1-15], appears to hinder conversion since truncated forms have 
substantially higher specific activity. One shorter analogue, BigET-1 [16-37] showed 
3-fold greater activity while another analogue, BigET-1 [18-34, Phe 22], exhibits 12-
fold higher specific activity than BigET-I itself 9 
There are limited reports on requirements for efficient inhibition of ECE. 
Phosphormidon was found showing some inhibitory activity at the very early stage of 
the ECE studies, but it is not specific for ECE.26'93 Narhamnopyranosyloxyhydroxy 
phosphinyl-Leu-Trp (PR) was reported to inhibit ECE, but it was several orders 
magnititude less potent on ECE than on the ECE-like enzyme, E-24,1 1. 10 A more 
potent, dual inhibitor, CGS 26303 was reported recently which displays an IC 50 of 0.1 
nM for E-24,1 I and 1.1 p.M for ECE. 94 Features that are important for selectivity of 
ECE over E-24,11 induced the discovery of a prototype compound, 3- 
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(1-naphthyl)-1-phosphonopropyl-Leu-Trp, which presents one of the most potent 
ECE inhibitor to date (10 50=0.26p.M) and shows 400-fold greater ECEIE-24,1 1 
selectivity than PR. 95 
Inhibition of ECE by synthetic peptides has also been studied. Morita et. al.96 
reported that ECE did not cleave truncated BigET- 1 analogues with D-amino acid at 
position 20, 21, 22 or 23. One of the analogues, BigET-1 [16-38, D-Va1 22] was found 
to be an ECE inhibitor with a Ki value of 2.5x10 5M. 96 
A systemic SAR study has been carried out in this laboratory using cloned 
human ECE- 1 in order to evaluate each of these important residues towards ECE 
inhibition. The structures of the BigET-1 analogues have been synthesized are listed in 
Appendix III, and their ECE inhibitory activities are discussed in detail below and the 
research is being continued by Swenson. 97 
3.3.2 Effects of chain length and important residues 
A series of BigET- 1 analogues with differing chain lengths were studied in 
order to study the effect of chain length and important residues for ECE recognition 
(Table 3.3.1). 
Table 3.3.1 Effects of chain length for ECE 
Pepilde Structure 1IthibItUn (%) 1C o 
BET[1 38, ('vc(Acni 1 	' I 




BET 16-321 0 140 
6# BETII7-341 0 57H 
16 BET19-391 
BETI22-38 Lui 7M 
27 BETf19-341 
BET[19-34 	I LII I) 
I* BET[19-34 Lui 
8 BETt27-34 	1-L1III * 	1M 
- 	- - - 	- 	- - r 	-- - --- ------97 
NULSe. WSWU Ill 	IL1WI1LIL.C1 cells; 	iata IIUILL .WClLM)l1. 
104 
Peptide 5 is a full length linear analogue with an extra Leu at 33'. Data show 
that this peptide is a poor ECE inhibitor (67.4% at 200p.M). Residues 27-34 were 
reported as important for ECE recognition, but the segment itself is not long enough 
to show any activity (peptide 8). Peptides 9 [19-34, Leu 34] and 10 [19-34, Leu 32 ' 34] 
are more active than peptide 16 [19-38] which indicates that residues 35-38 are not 
important for ECE recognition and substitution of G1y 32 ' 34 with Leu32' 34 is also 
tolerated. Data also show that peptide 83 [16-38] is the most active inhibitor, while 
peptide 84 [16-34] is only -P2 fold less active. These results indicate that residues 16-
34 are most important for ECE recognition. Further truncation from both ends results 
in peptides 85 [16-32] and 86 [17-34]. The IC 50 values indicate that residue His 16 is 
more important than residues Leu 33 and G1y34, and BigET-1 [16-32] can be regarded 
as the minimum sequence for ECE recognition. 
3.3.3 Synthesis of the reduced isostere, FmocTrp(CH 2NH)Va1 011 
Modification of the peptide bond (CONH) is one of the most direct 
approaches to alter peptide conformation. Numerous structural mimics of the CONH 
bond have been proposed and used. The peptides afforded were resistant to enzyme 
hydrolysis and have therefore been widely used in the investigation of enzyme 
inhibitors and receptor antagonists. 
The simplest isostere is the reduced peptide bond w(CH 2NH) group. The 
preferred method for the introduction of the reduced peptide bond is the reductive 
alkylation of an cc-amino group by the reaction of a protected amino acid aldehyde in 
the presence of sodium cyanoborohydride (NaCNBH 3) in solution98 or on solid 
phase. 99"00 The solid phase methodology has the advantage of convenience but is 
prone to racemisation unless strict reaction conditions are applied.' 00 Ho et al. 
suggested two potential steps where racemisation could occur in the preparation of 
Boc protected reduced isostere, the amino aldehyde (60) and the intermediate imine 
(61) (Scheme 3.3.1).00 
There appeared to be few problems of the 4J(CH 2NH) group reaction with 
other Boc amino acids under normal coupling conditions. The exception to this was 
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Gly, which would react with the secondary imine, but this could be avoided by 
coupling through its p-nitrophenyl ester.' °° 
ECE cleaves BigET-1 between Trp 21 and Va122 . The reduced dipeptide 
isostere, Trp (CH2NH) Vat was thus introduced into some BigET-1 analogues to 
produce inhibitory activity. 
BOCN) 	 BOC N OH 	
BoC N) o 
(65) 	 (66) 	 (67) 
- 	BOCN c_® 
H 	H H R2 (68) 	 H 	H H R2 (69) 
R H 
BOCN)( NYLO_® 
H 	H H R2 (70) 
Scheme 3.3.1 Racemisation during the synthesis of the reduced isostere 
a. the aldehyde, b. the reduced isostere 
There has been no literature report on the synthesis of the Fmoc protected 
reduced isostere to date, which is probably due to the base lability of the Fmoc group. 
Therefore it was decided to make the Z-protected isostere instead which could be 
deprotected and converted to the Fmoc protected isostere as shown in Scheme 3.3.2. 
The procedure worked well and the methyl ester of the isostere (77) 
was obtained in good yield and purity. Nevertheless, hydrolysis of the methyl group to 
make the free acid caused a lot of problems. The methyl group, which normally can be 
removed very easily under mild conditions such as LiOH in acetone/H 20, remained on 
under quite harsh conditions such as 2M NaOH 40-50 °C. This is due to the presence 
of the bulky Boc group in the neighboring position. But this protection is necessary 





















the coupling of this isostere to the growing peptide very difficult. This method was 
therefore abandoned. 
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Fmoc—NHCHCi-tNHCHC4 A OH 
Oz) (84) 
H 
Scheme 3.3.3 Attempted synthesis of Fmocrrp çv(CH 2NH) Val by solid phase 
synthesis, method 2 
Fmoc was chosen as the protecting group since Z and Boc are incompatible 
with the above reaction conditions. A similar procedure was followed and 
FmocTrpCHO was afforded in good yield and purity. A solid phase reductive 
alkylation was then followed as shown in Scheme 3.3.3. The reaction was carried out 
under the optimized conditions proposed by Ho et al.'°° to suppress racemisation. As 
Trp was present, a suitable cleavage condition had to be found. 5% H20/TFA, RT, 
lhr was applied to a small scale of resin bound isostere, however, a very dark colour 
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appeared when TFA was added which indicated this condition was too harsh for this 
isostere. Mild cleavage conditions were therefore tried. However, even when the resin 
was cleaved with 50% TFA/DCM, at 0 °C, the solution still became coloured. Further 
reduction of the TFA caused ineffective cleavage and was not suitable. Addition of 
scavengers, such as EDT and thioanisole could overcome the side reactions but 
further purification was required. This procedure was left for future investigation. 
Since FmocTrpCHO could be made in very good yield and purity in solution, 
the more reliable solution phase reductive alkylation was chosen. With the advantage 
of the Fmoc group already present, there was no need to protect the secondary amine, 
























CH30H 	z 01 ~N  (84) 
H 
Scheme 3.3.4 Synthesis of FmocTrp yi(CH2NH) Val OH through the benzyl ester, 
After purification by dry flash chromatography, the benzyl ester was afforded 
in good yield and purity. The benzyl group was then easily removed by hydrogenation 
to give the final product, FmocTrpji(CH 2NH)Val OH, which was not soluble in many 
common solvents which caused problems in filtration from Pd/C. It was found later 
that it was soluble in DMF. The final pure product was afforded as a slightly coloured 
foam. It is worthwhile to point out that the solubility of the final product in DMF 
suggested that the hydrogenation could be better carried out in DIMF, but no further 
investigation was made. 
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3.3.4 The inhibitory activity of the BigET-1 analogues with the reduced isostere 
BigET-1 analogues with the reduced isostere Trp.i(CH 2NH)Val at the 
cleavage site have been synthesized and their ECE inhibition activity evaluated. The 
results are shown in Table 3.3.2. 
Table 3.3.2 The Inhibitory activity of BigET-1 analogues with the reduced isostere 
Note: * tested in CHO/humanECE-1 cells 
The data indicate that the longer analogues [1-38, 12-38] show tM inhibition 
while the shorter one [19-38] does not inhibit at 100p.M. This result indicates that 
residues between 12 and 19 are important for enzyme recognition. It is interesting to 
notice that the IC 50 of the oxidized BigET-1 analogue, BigET-1 [1-38, Trp(CH 2NH) 
Va12122] is 32.2 p.M, i.e. three time less potent than the linear analogue. This result 
indicates that the introduction of this reduced isostere greatly affects the structure of 
the native BigET, at least near the enzyme recognition site. As the most important 
residue His 16 is not included in these analogues, further studies of these analogues will 
be carried out by Swenson. 
3.3.5 Substitutions at position 22, the sulphur containing amino acids, Cys and 
Pen 
Studies of the mutants of preproET-1 showed that some substitutions at 
positions 21 and 22 were tolerated, which indicated the absence of strict sequence 
specificity of ECE. Therefore, substitutions at these sites were studied in order to find 
some inhibitory activity. The sulphur containing amino acids are normally of interest 
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in enzyme inhibitory studies, thus both Acm protected and unprotected Cys and Pen 
were introduced into position 22 to study their effect on ECE inhibition. 
Table 3.3.3 The Inhibitory activity of BigET-1 analogues with different  
substitution at position 22 
Strtictti re  
16 BETII9-31 39 	.00pM 12 
, BETI 19 	Pcn(ALIu) 12 %2OOM 
1311'I 	1 I•'c•i I 	(I 
BET[l9-34 
BET[ 19-34, 	\ALm 
BET[ 19-34, 	 I I7 
l3FT 19 	4 	Pcjit \Lflfl 
BET[ l9-4 Pen 	I 
$4 BETII6-341 0 O 'S 
BEfl Io-34 C(Acrn) 	I ().33 
BET]16-34 C 22]  001 
$1 }3FTI 16-4 	Pcn(ALIn 	I 
22 BFTII6 	4 Pen 	I 1(1 
Note: tested in CHO/humanECE-1 cells 
Three groups of analogues have been studied: [19-38], [19-34] and [16-34] 
analogues (Table 3.3.3). The low inhibitory activity of the 19-38 and 19-34 groups, 
compared to the [16-34] group, indicates that residues between 16 and 18 are 
important (discussed above). In the most potent group 3, the analogue with Cys at 
position 22 shows the highest inhibitory activity. When the SH is protected with Acm, 
the activity decreased dramatically, which indicates either the free SH or the size of 
the side residue is important. Pen is thus introduced into this position (peptides 81 and 
82). The inhibitory activity of both peptides are very similar but much less potent 
compared to their Cys 22 analogues. These results indicate that the size of the residue, 





All Fmoc amino acids were purchased from either Bachem, Novabiochem, or 
were synthesized as described in the text, and are of the L-configuration unless 
otherwise stated. Peptide synthesis grade dimethylformamide (DMF) and 1,4-dioxane, 
and HPLC grade acetonitrile, were obtained from Rathburn Chemicals. Automated 
peptide synthesis was carried out on an adapted ABI 430A peptide synthesiser. UV 
spectra were recorded on a Varian Cary 210 double beam spectrophotometer. 
Sonication was carried out in a Decon FS300b sonic bath. Infrared spectra were 
recorded on a BIO-RAD SPC3200 instrument. Optical rotations were measured using 
an AA1000 polarimeter. Melting points were recorded in open capillaries on a Buchi 
510 oil immersion melting point apparatus, and uncorrected. Nuclear magnetic 
resonance (NMR) spectra were recorded on either a Jeol FX-60 (60M14z), a Brucker 
WP-80 (80MHz), a Brucker WP-200 (200IVIFIz), a Brucker AC-250 (250MHz), a 
Brucher WH-360 (360MHz) or a Varian VXR 600S (600MHz) spectrometer. 
The HPLC was carried out using either an ABI system with 1406A solvent 
delivery systems, a 1480 injector/mixer and a 1783A detector/controller; or a Gilson 
system with 306 solvent delivery systems, a 81 1C dynamic mixer, a 805 manometric 
module, a 119 UV/VIS detector and a Gilson 715 software-driven gradient controller. 
FAB mass spectra were measured on a Kratos MS50TC instrument, using either 
thioglycerol, 3-nitrobenzyl alcohol or glycerol as matrix. Laser desorption mass 
spectra were measured on a PerSeptive Biosystems LaserTec Benchtop II system. 
Amino acid analysis was performed on a LKB 4150 alpha amino acid analyser on the 
hydrolysate obtained after heating samples at 110°C for 18-36 hours in a sealed 
Caritus tube, followed by evaporation to dryness. 
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3.4.1.2 Loading of the first amino acid on the Wang resin or CI-Trt resin 
Wang resin: Fmoc amino acid (6 eq. with respect to the resin) was dissolved 
in DMF (lOmi per gram of resin), to which was added DIC (3 eq. with respect to the 
resin) and the mixture was sonicated for 10 mm. The Wang resin was pre-swollen in a 
little DIMF. DM" (30mg) was added to the preswollen resin followed by addition of 
the amino acid mixture. The resin mixture was sonicated at RT for 2h, filtered, 
washed with DMF, dioxane, DCM and dried. 
CI-Trt resin: Fmoc-amino acid (6 equivalent relative to the resin) was 
suspended in dry DCM (1 Omi per gram of resin), to which was added a small amount 
of dry D1VIF to dissolve the Fmoc-amino acid. The mixture was added to the resin 
followed by 1/3 of the total DIEA. The mixture was stirred for 5mm, then added the 
remainder of DIEA in DCM (1:1 v/v). The mixture was stirred for a further 60 mm. 
then HPLC grade methanol (0.8m1 per gram of resin) was added and the mixture 
stirred for 5 mm. to cap the remaining trityl group. The resin was washed with DCM, 
DMF, isopropanol, methanol then ether, and dried over KOH in vacuo. 
3.4.1.3 Fmoc and Tbfmoc loading tests 
The loading of the resin was checked by deprotection of a few mg of the Fmoc 
amino acid bound resin and the UV absorption at 302nm. measured. The loading was 
then calculated by the following formula: 
C=cA 
where c is the mole absorbance constant which is 9,000 in 20% piperidine/DMF. 
Loading (mmoL'g) 10A302/9Wt 
where A300 is the absorption at 302nm; Wt is the weight of resin bound amino acid 
(mg) in lOmi 20% piperidinefDMF solution. 
The loading of resin bound peptide can be calculated the same way, and the 
coupling percentage is then calculated by the following formula: 
Coupling percentage (%) = final loading(mmol/g) x final resin weight (g) 
x100/(original loading (mmoLfg) x initial resin weight (g) 
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The Tbfmoc protected, resin bound peptide (-10mg), accurately weighed, was 
sonicated in 20% piperidine/dioxane (lOmi) for 10 mm. The UV absorption at 364nm 
was measured and the loading was then calculated by the following formula:' ° ' 
Loading (mmol/g) = 6.613 x A364/ resin bounded peptide weight (mg) 
3.4.1.4 Solid phase synthesis of peptides 
All peptides mentioned in this text were synthesized on the adapted ABI 430A 
Peptide Synthesizer using Fmoc chemistry. The Wang resin was used for peptide 
acids except where Cys, Pro or His is the C-terminal amino acid and the 
dibenzosulberenyl resin for peptide amides. When Cys, Pro or His is the C-terminal 
amino acid, the trityl chloride (Cl-Trt) resin was used to avoid racemisation. The 
Amino acid side chain protections are: OtBu (Asp, Glu), tBu (Ser,Tyr), Boc (Lys), 
Trt (His, Cys), Acm (Cys), Pmc (Arg). The Fmoc group was deprotected with 20% 
piperidine in DMF; acetylation is carried out in a solution of 0.5M acetic anhydride, 
0. 125M DIEA (diisopropylethylamine) and 0.2% HOBt in DMF. The deprotection of 
Fmoc was monitored by an on line UV monitoring system. For triazole coupling, the 
acylation was also monitored by passing the washings through the UV detector and 
examining the unreacted Fmoc amino acid or the active intermediate. 
Routinely, most residues were incorporated using double couple cycles, in 
which the first coupling cycle used a preformed symmetrical anhydride, following by 
the second coupling using a preformed HOBt active ester. The exceptions to this were 
Asn, Gin and His, which were coupled twice via their HOBt esters and Gly, which 
was coupled singly as a symmetrical anhydride. This method is refereed to as double 
coupling method 1 in this text. 
When difficult sequences or large peptides were involved, the residues were 
incorporated using the active ester of the newly developed coupling reagent, HOCt, 
single or double as indicated. The only exception was His which was coupled through 
its HOBt ester due to increased racemisation with HOCt. This is refereed as double 
coupling method 2 in the text. 
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In the symmetrical anhydride cycle, two cartridges each containing 0.5mmol 
Fmoc amino acid were used, and the symmetrical anhydride was formed via the 
addition of 0.5mmol DIC. In the active ester cycle, either HOBt or HOCt, one 
cartridge containing 0.5mmol Fmoc amino acid was used and the active ester was 
formed via the addition of 0.5mmol DIC. 
3.4.1.5 Cleavage, purification and analysis of the peptides 
The completed peptide was cleaved from the resin with TFA plus scavengers. 
The three mixtures used for cleavage of different peptide sequences are listed below 
as A, B or C. 
Cleavage mixture A: 
EDT (1.0 ml), H20 (0.25 ml), TFA (10 ml); 
Cleavage mixture B: 
EDT (1.0 ml), H20 (0.25 ml), TIS (0.2 ml), TFA (10 ml); 
Cleavage mixture C: 
EDT (1.0 ml), phenol (0.75g), thioanisole (0.5m1), TIS (0.2 ml), H20 (0.2 ml), 
TFA (10 ml) 
Crude peptide was precipitated from ether after removing the TFA in vacuo. 
The crude peptide was then purified by HPLC under one of the conditions described 
in the next section. Pure peptide was dried by lyophilization and analyzed by analytical 
HPLC, FAB/laser desorption mass spectroscopy and amino acid analysis. 
3.4.1.6 IIPLC conditions 
Three types of HPLC columns were referred to in this text. Type I is made 
from ABI aquapore RP300 reverse phase silica (300A pore size, 7p.m spherical silica), 
Type II is from Vydac reverse phase silica (300A pore size, 5p.m spherical silica) and 
Type III is from Hichrom RPB reverse phase silica (1 1OA pore size, 5 p.m spherical 




RP C18: 220 x 4.6mm (size A) 
	
RP C18: 250 x 10mm (size C) 
RP C8: 220 x 4.6mm (size A) 
	
RP C8: 250 x 10mm (size C) 
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Vydac C18: 250 x 4.6mm (size B) 
	
Vydac C18: 250 x 22mm (size D) 
Hichrom C18: 250 x 4.6mm (size B) 
RP C4: 100 x 4.6mm (size E) 
The solvents used were: 
Solvent A: 	0.1%TFA/H20 
Solvent B: 	0.1%TFA/CH3CN 
The peptides were eluted by an increasing concentration of solvent B in 
solvent A. The gradient used for analytical HPLC was identical unless otherwise 
stated, which is 
10%-10% (2mm), 10%-90% (30mm), 90%-10% (2mm), which is simplified as 
10-10(2), 10-90(30), 90-10(2). 
For preparative HPLC the gradient used was dependent on the nature and 
quantity of impurities present. The conditions used are summarized in Appendix IV 
and V. 
3.4.1.7 Elimans' test 
The purified peptide (0.2-0.3mg) was dissolved in 10 ml 0.1M phosphate 
buffer (pH7.3) containing 1mM EDTA, with or without 6M guanidine. A 2.5m] 
sample of the solution was placed in a T.JV cell and another 2.5 ml of the buffer was 
used as the reference. To each cell was added 50 ml 3mM DTNB, and it was tested at 
412nm for absorbance. 
3.4.2 Synthesis of the linear ET-1 analogues 
The ET-1 analogues were synthesized either via standard double coupling or 
triazole coupling as is mentioned above. The sequences of these analogues are listed 
in Appendix I and II. The coupling and cleavage methods used and the molecular 
weight of each peptide are summarized in Table 3.4.1. The HPLC conditions and the 
amino acid analysis data are listed in Appendix IV. 
116 










M+1/iv1}1 average 	Found 
60 0.553 HOCt double B 2491.1/2493.0 2489.3 
1 0.575 HOCt double B 2583.3/2585.0 2579.0 
lB 0.583 HOCt double B 2583.3/2585.0 2583.9 
1C 0.604 HOCt double B 2405.3/2406.8 2408.1 
2 0.575 HOCt double B 2569.2/2571.0 2565.9 
2B 0.583 HOCt double B 2555.2/2557.0 2557.4 
21 0.567 HOCt double B 2569.2/2571.0 2571.6 
22 0.567 HOCt double B 2569.2/2571.0 2569.6 
23 0.567 HOCI double A 2579.3/2581.0 2580.0 
24 0.567 HOCt double A 2579.3/2581.0 2578.8 
25 0.567 HOCt double A 2579.3/2581.0 2581.0 
26 0.567 HOCt double B 2569.2/2571.0 2569.3 
56 0.636 HOBtJDIC B 2405.3/2406.8 2402.7 
15A 0.509 HOBtJDIC B 2498.2/2499.9 2498.6 
15-1 0.581 HOCt double B 2395.2/2396.8 2398.8 
14 0.567 HOCt double B 2308.2/2309.7 2308.1 
13 0.567 HOCt double B 2237.1/2238.6 2237.7 
12 0.567 HOCt double B 2150.1/2151.5 2151.6 
11 0.567 HOCt double B 2063.1/2064.5 2064.1 
40 0.581 HOBt/DIC B 2049.1/2050.4 2049.3 
54 0.579 HOBtJDIC B 1974.1/1975.3 1974.1 
47 0.506 HOBtJDIC B 1960.1/1961.4 1969.8 
51 0.597 HOBtJDIC B 1972.1/1973.4 1971.6 
38 0.547 HOBtJDIC B 1975.1/1976.3 1971.9 
33 0.561 HOCt double B 1950.0/1951.2 1953.7 
33a 0.561 HOCt double B 1992.0/1993.3 1995.8 
72 0.521 HOBtJDIC B 1817.0/1818.2 1817.6 
53 0.579 HOBI/DIC B 1861.0/1862.2 1865.6 
62 0.521 HOBtJDIC B 1875.0/1876.2 1873.5 
64 0.521 HOBtJDIC B 1875.0/1876.2 1877.4 
(to be continued) 
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Table 3.4.1 Synthesis and cleavage method for ET-1 analogues(continued) 





\1+1IMH a erage 	Found 
67 0.521 HOBtJDIC B 1861.0/1862.2 1862.3 
61 0.521 HOBtJDIC B 1847.0/1848.2 1850.8 
61A 0.521 HOBtIDIC B 1887.9/1889.2 1893.0 
63 0.521 HOBtJDIC B 1847.0/1848.2 1845.4 
63A 0.521 HOBtJDIC B 1887.9/1889.2 1886.1 
32 0.561 HOCt double B 1950.0/1951.2 1951.3 
43 0.550 HOBtJDIC B 1966.0/1967.3 1964.6 
34 0.561 HOBtiDIC B 1950.0/1951.2 1952.0 
65 0.536 HOBtIDIC B 1936.0/1937.3 1932.6 
52 0.579 HOBtJDIC B 1747.9/1749.0 1748.8 
39 0.550 HOBtIDIC B 1822.9/1824.1 1823.4 
31 0.561 HOCt double B 1836.9/1838.1 1837.5 
41 0.550 HOBIJDIC B 1822.9/1824.1 1822.7 
41A 0.550 HOBtJDIC B 1863.9/1865.1 1866.7 
50 0.597 HOBtJDIC B 1746.0/1747.1 1744.5 
46 0.506 HOBtJDIC B 1733.9/1735.0 1738.3 
66 0.536 HOBtJDIC B 1761.9/1763.1 1783.1* 
55 0.579 HOBtJDIC B 1748.9/1750.0 1750.3 
37 0.522 HOBtIDIC B 1747.9/1749.0 1749.5 
37A 0.547 HOBtJDIC B 1788.9/1790.0 1789.1 
36 0.547 HOB1J'DIC B 1748.9/1750.0 1748.8 
36A 0.547 HOBtIDIC B 1789.9/1791.0 1791.0 
68 0.536 HOBtJDIC B 1747.9/1749.0 1748.5 
69 0.536 HOBtIDIC B 1747.9/1749.0 1772.1* 
59 0.507 HOB1IDIC B 1747.9/1749.0 1745.9 
58 0.507 HOBtJDIC B 1747.9/1749.0 1749.9 
57 0.507 HOBtIDIC B 1747.9/1749.0 1745.9 
70 0.536 HOBtJDIC B 1747.9/1749.0 1749.4 
71 0.536 HOBtJDIC B 1747.9/1749.0 1747.5 
30 0.561 HOCt double B 1721.9/1723.0 1722.0 
29 0.561 HOCt double B 1592.8/1593.9 1592.1 
28 0.561 HOCt double B 1464.7/1465.8 1464.7 
35A 0.550 HOBtJDIC B 1420.7/1421.7 1421.3 
* Sodium salt sequestered from the matrix 
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3.4.3 Synthesis of ET-1 (peptide 60) 
The synthesis of this 21 amino acid peptide was carried out by standard double 
coupling via HOCt and the protecting group for the four Cys was Trt. The peptide 
resin was cleaved with solution B, and the crude, fully reduced peptide (80mg) was 
dissolved in 6M guanidine.HC1 (200m1), which contained 0. 1M Tris buffer (pH 8), 
GSSG (0.5mM) and GSH (5mM). The mixture was stirred at RT overnight. 
Analytical HPLC showed a major single peak. This was purified using a C18 
preparative column, eluting with a linear gradient of 0.1% TFAIH20 with increasing 
concentration of 0.1% TFAICH3CN at 5mllmin. The correct fraction was dried by 
lyophilization to give 15.5mg ET-1 (yield 19.4%). This was analyzed by different 
analytical HPLC (RP C18, Vydac C18 and Hichrom C18 columns), MS mlz 2489.3 
(C 10911159N25032S 5 requires 2492.0) and a co-injection with commercial human ET-1 
(Peptide Institute INC., Japan), confirmed that they are the same peptide. 
3.4.4 Attempted synthesis of Fmoc-Trp(CIL2NH)Va1OB (84) through Z-
Trpxji(CH2N(Boc))Va1OB (78), method 1102 
Synthesis of Z-Trp-N, 0-dimethylamide (74) 
To a suspension of N,O-dimethylhydroxylamine hydrochloride (5.2g, 52mmol) 
in DCM (30m1) was added N-methyl piperidine (6.5m1, 52mmol) while stirring at 0°C. 
In another flask, Z-Trp (17.66g, 52mmol) was suspended in DCM (250m1) and the 
suspension was stirred at 0°C under N 2 and N-methyl piperidine (6.5m1, 52mmol) was 
added. To the clear solution of Z-Trp was added ethyl chlorofomate (5.78g, 52mmol) 
dropwise, keeping the temperature below 0 °C. After 3 minutes, N,O-
dimethylhydroxylamine solution from the other flask was transferred into the solution 
of mixed anhydride at 0°C under nitrogen. The reaction mixture was stirred at 0°C for 
1 hr and allowed to warm up gradually to RT and stirred overnight. A slightly yellow 
solution was afforded which was evaporated. The residue was dissolved in EtOAc 
(150m1) and the insoluble impurities removed by filtration. The filtrate was washed 
with citric acid (20%), H 20, aqueous NaHCO3 and saturated NaCl and dried over 
MgSO4. The solution was evaporated to give a white foam, 18.5g (92.9%). 
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5 1HNMR(CDC13, 60MHz): 3.2 (5H, m, NCH3, CH2), 3.7 (3H, s, OCH3), 4.1 (1H, m, 
CH), 5.1 (2H, m, CH2), 5.6(1H, m, NH), 7.07.5 (10H, m, aromatics), 8.5 (1H, br. 
NH). 
Synthesis of Z-Tryptophal (75) 
A solution of N,O-dimethyl amide of Z-Trp (9.5g, 24.9mmol) in dry THF 
(150m1) was stirred under nitrogen and cooled to -10 °C. To the solution was added 
LiAIH4 (LAH, 1.27g, 33.57mmol) in small portions. The mixture was allowed to 
warm up to RT when all the LAH had been added, the mixture was stirred for another 
30 mm., then quenched with 10% KHSO4 solution (125m1 H 20). The pH of the 
suspension was adjusted to 3.0 with IN HCl (-30mi). The solution was diluted with 
EtOAc (SOOml) and layers separated. The aqueous layer was further extracted with 
EtOAc twice and the organic layers were combined and washed with citric acid 
(20%), H20, aqueous NaHCO3 and saturated NaCl and dried over MgSO 4 . The 
solution was evaporated to give a colourless solid (8.0g. 100%). The product gave 
satisfactory NN'IR and thus was used without further purification. 
6'HNMR(CDC13, 60 MHz): 3.1 (2H, m, CH 2), 4.2-4.7 (3H, m, CH, CH2), 5.5 (1H, 
d, NH), 7.17.6 (10H, m, aromatics), 8.3 (1H, s, NH), 9.6 (1H, s,CHO). 
Synthesis of Z- T,p(CH2NH) Va1OCH 3 (76) 
L-valine methyl ester hydrochloride (5.0g) was suspended in DCM (50ml) to 
which was added saturated NaHCO 3 (50ml). The mixture was stirred for 10 min and 
the layers were separated. The H 20 layer was extracted with DCM and the DCM 
layers combined, dried with MgSO 4 and evaporated to give a nearly colourless liquid 
(3.2g, 24.42 mmol), which was dissolved in isopropanol (5ml) and used at once in 
next step. 
Z-TrpCHO (8.2g, 24.9nimol) was dissolved in isopropanol (150m1) to which 
was added the above solution followed by 4A molecular sieves (3.6g). The mixture 
was stirred under nitrogen for 1 hi, then a solution of NaCNBH 3 (2. lOg) in 
isopropanol (6mi) was added dropwise while stirring. The mixture was stirred under 
nitrogen overnight (RT). The mixture was filtered, and the filtrate evaporated. The 
residue was dissolved in EtOAc and washed with saturated NaHCO 3, NaCl and dried 
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over MgSO4 and evaporated again. The residue was purified by flash chromatography 
(1'-5 % EtOHICHC13 ). The portion with pure product was evaporated and dried to 
give a white solid (6.0g, 56.5%). 
ö'H NMR(CDC13, 80 MHz): 0.95 (6H, dd, 2xCH3), 1.90 (1H, m, CH), 
2.43-.2.71(2H, 2 seperated multiplets, CH 2), 3.03 (3H, m, CH, CH2), 3.65( 3H, d, 
OCH3), 4.0 (1H, m, CH), 5.12-.5.20 (3H, m, NH,CH 2), 6.93-7.35 (9H, m, 
aromatics), 7.63 (1H, m, aromatic CH), 8.39 (1H, s, NH). 
Synthesis of Z- Trp(CH 2N(BOC)) Va1OCH 3 (77) 
Z-Trp(CH2NH)Va1OCH3 (4.29g, 9.86mmol) was dissolved in dry THF 
(lOOml) and DMAP(0. 1 19g, 0.99mmol) was added followed by (Boc) 20 (2.35g 10.8 
mmol). The reaction mixture was stirred at RT and monitored by TLC (EtOAc/Ether 
= 1:9). TLC indicated that the reaction was complete in 30 mm. The mixture was then 
evaporated and the oily residue was partitioned between ether (400mi) and 1M 
KHSO4 (200m1) and the layers separated. The organic layer was washed with 1M 
KHSO4, sat. NaHCO3 , NaCl and dried over MgSO4. The solution was evaporated to 
give a slightly coloured foam (3.53g, 67%). 
6'H NMR(CDC13 , 80 MIHz):0.93(6H, dd, 2xCH3), 1.20(9H, s, 3xCH3), 1.98(1H, m, 
CH), 2.5-2.7(2H, 2 separated multiplets, CH 2), 3.00(3H, CH, CH2), 3.65(311, d, 
OCH3), 4.1(1H, broad, CH), 5.15(2H, d, CH 2), 5.3(1H, NH), 7.1-7.7(10H, m, 
aromatics), 8. 1(1H, d, NH). 
Attempted synthesis of Z- Trp(CH 2N(BOC)) Va1OH(78) 
The Boc protected dipeptide methyl ester (3.53g) was dissolved in methanol 
(lOmi) and IN NaOH (lOmi) was added. The clear methanol solution became cloudy 
when NaOH was added and heat was given off. The mixture soon become very sticky 
and hard to stir. TLC (EtOAc/ether 1:9) showed that the starting material disappeared 
in c.a. Shrs. The mixture was evaporated and sat. KHSO4 was added to the residue. A 
very sticky oil precipitated which was extracted with EtOAc, washed with sat. NaCl 
and dried over MgSO4 to give some slightly coloured foam (3.53g, 103%). However, 
111 NTVIIR showed that the methyl group was still intact. No further effort was made. 
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ö'H NMR(CDC13, 80 MHz):0.93(6H, d), 1.20(9H, s), 2.0(1H, m), 2.5-3.0(5H, m), 
3.65(3H. d, OCH), 4.1(1H, broad), 5.35(1H, d), 7.17.5(10H, m), 7.7(1H, m), 
8.1(1H, d). 
3.4.5 Synthesis of FmocTrp(CH2NH)Va1OH(84), methods 2 and 3 
Synthesis of Fmoc- Tip-N, O-dimethylamide(81) 
To a suspension of N,O-dimethylhydroxylamine hydrochloride (1.09g, 
ilnimol) in DCM (30m1) was added N-methylpiperidine (1.35m1, limmol) while 
stirring at 0°C. In another flask, Fmoc-L-Trp (4.265g, lOmmol) was suspended in 
DCM (50m1). The suspension was stirred at 0°C under N 2 and N-methylpiperidine 
(1.25m1, lOmmol) was added. To the clear solution of Fmoc-Trp was added ethyl 
chioroformate (0.96m1, lOmmol) dropwise, keeping the temperature below 0°C. After 
3 minutes, N,O-dimethylhydroxylamine solution from the other flask was transferred 
into the solution of mixed anhydride at 0°C under nitrogen. The reaction mixture was 
stirred at 0°C for 1 hr and allowed to gradually rise to RT overnight. A slightly yellow 
solution was afforded which was evaporated. The residue was dissolved in EtOAc 
(150m1) and the insoluble impurities removed by filtration. The filtrate was washed 
with citric acid (20%), H20 and saturated NaCl and dried over MgSO 4. The solution 
was evaporated to give a white foam, 4.4g (94%). m.p. 98-100°C, FAB MS mlz 470 
(C28H27N304 requires 469.54), Rf =0.30 (DCMJEtOAc 4:1), [aID 2°  -42.1 (in DMF). 
ö'H NMR(CDC13 , 200 MHz): 3.16--3.32(5H, m, NCH3 , CH2), 3.64(3H, s, OCH3), 
4.17-4.35(4H, m, 2xCH, CH2), 5.67(1H, d, NH), 7.0-7.8(13H, m, aromatics), 
8.33(1H, s, broad, NH). 
Synthesis of FmocTipCHO(82) 
Fmoc-Trp-N,O-dimethylamide (4.4g, 9.4mmol) was dissolved in dry THF 
(80m1) and cooled by dry ice/acetone bath (-20°C). LAH (0.475g, 12.5mmol) was 
added in small portions under N 2 . The mixture was stirred at -20°C for 10 min and the 
cold bath was removed to allow the temperature rise to RT and the mixture was 
stirred for another 30 mm. The reaction was quenched with 0.6M KHSO4 solution 
(50mi) and the pH of the solution adjusted to 3.0 with IN HCl(-30nl). The solution 
122 
was diluted with EtOAc and layers separated. The aq. layer was extracted twice with 
EtOAc and the combined EtOAc layers were washed with 20% citric acid, aq. 
NaHCO3, and brine, dried over MgSO4 and evaporated to give a white foam (3.8g, 
100%). It was pure by TLC and NIvIIR and used without any further purification. m.p 
158-160°C, FAB MS m/z 410 (C 26H22N203, requires 410.47), Rf =0.52 
(hexanelEtOAc=1 :2), [aID 2° -45.5 (in DMF). 
ö'H NMR(CDC13, 200 MHz): 3.30(2H, m, CH 2), 4.154.22(2H, m, CR2) 
4.34-.'4.62(3H, m, CH, CH2), 6.95-7.75(13H, m, aromatics), 8.14(1H, s, NH), 
9.65(1H, s, CHO). 
Attempted synthesis of Fmoc-Trp(CH 2JVH) Va1OH(84) by solid phase approach, 
method 2 
FmocValOH was loaded on the Wang resin (loading 0.644mmollg without the 
Fmoc) and the Fmoc group was removed with 20% piperidine. The NI-1 2-Val-resin 
(1.93g, 1.24mmol) was suspended in 1% HOAcIDMF under nitrogen and 4A 
molecular sieves (3.0g) added. FmocTrpCHO (1.62g 3.95mmol) in THF was added 
followed by NaCNBH3 . The mixture was stirred under nitrogen for 2hrs at RT and 
sonicated overnight. The Kaiser test showed a dark brown colour which indicated the 
formation of secondary amide. The mixture was then filtered, first with a Buchner 
funnel to remove the molecular sieves then with a sinter funnel to remove the resir 
which was washed with DMF, DCM, methanol and DCM and dried for lhr under 
vacuum. 
The resin was cleaved as follows: 
(1). 0.5% H20/TFA, lhr at RT 
(2).50%-80% TFAIDCM lhr at 0°C 
but a pink to purple colour was inherent which indicates the oxidation of Trp. This 
procedure was therefore abandoned. 
Solution phase synthesis of Fmoc-Trp(CH21%JH)  Va1OH(84) ---method 3 
FmocTrpCHO (I. 68g, 4. immol) was dissolved in a mixture of dry MeOH and 
THF (1:1) and the mixture was stirred under nitrogen. 4A molecular sieves (5g) was 
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added followed by HCl.NHValOBn (1.0g, 4. immol) and NaBHCN (0.3 50g, 
5.1mmol) as solids. The clear solution afforded was stirred under nitrogen overnight 
at RT to give a cloudy mixture (molecular sieves crashed). The mixture was filtered 
and the filtrate concentrated. The residue was dissolved in EtOAc (lOOm!) and 
washed with sat. NaHCO 3, NaCl and dried over MgSO 4. The EtOAc solution was 
evaporated to give a slightly coloured foam. TLC showed two compounds which 
were separated by dry flash chromatography (DCM!EtOAc=4: 1) to give 2.2g (89.5%) 
pure product (85). m.p. 130-133°C, FAB MS m/z 603 (C38H39N304 requires 602.75), 
Rf 0.63 (DCMIEtOAc=4: 1), [aID2° -28.3 (in DMIF). 
ö'H NMR(CDC1 3 , 200 MHz): 0.95 (6H, d, 2xCH3), 1.94 (1H, m, CH), 2.46-2.76 
(2H, 2 separated multipltes, CH 2), 3.03(3H, CH, CH2), 3.95-4.50 (4H, m, 2xCH, 
CH2), 5.15 (3H, m, CH2, NH), 6.92-7.78 (18H, m, aromatics), 8.25 (1H, s, NH). 
Fmoc-Trpi(CHNH)ValOBn (85, 2.2g, 3.6mmol) was dissolved in lOOml 
MeOH and the solution was bathed in nitrogen for lhr and 10% Pd/C (0.4g) was 
added. The mixture was hydrogenated. A white solid precipitated soon afterwards and 
TLC (CH30HJCH3C1 1:9) showed that the reaction had gone to completion in c.a. 30 
mm. The mixture was dissolved with difficulty in THF and filtered through ceilite. 
Other solvents were tried but THF was the most suitable. (It was found later that it 
was soluble in DMF). Solvent was removed to give a slightly coloured solid (1.3g. 
84%). m.p. 134-135°C, FAB MS m/z 512 (C 31H33N304 requires 511.62), [aID2° -37.1 
(in DMF). 
ö'H NIMR(DMSO-d6, 200IVIHz): 0.92 (6H, d, 2xCH3), 1.94 (1H, m,CH), 2.50-3.10 
(5H, m, 3xCH, CH2), 3.88--4.29 (4H, m, 2xCH, CH 2), 5.76 (1H, s, NH), 6.93-7.69 
(12H, m, aromatics), 7.87 (2H, d, NH), >10.5 (1H, COOH). 
3.4.6 Deprotection and oxidation of Cys(Acm), conversion of peptide 45 to 
peptide 045, the BigET-1 84 
Peptide 45 (BigET-1[1-38, Cys(Acm)" 3" 1 ' 15 ], 50mg, pure) was dissolved in 
TFA (3m!) and cooled on ice-salt bath. Anisole (48ul, 40 eq) was added and the 
mixture was saturated with nitrogen. Silver trifluromethanesulphonate, AgOTf 
(114mg, 40eq.) was added and stirred at 0°C for 3 hrs. and at RT for 2 hrs. The 
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Sephadex column eluting with 15% acetic acid. The peptide fractions collected were 
added to 1M guanidine HC1 (iliter), and the pH adjusted to 8 with concentrated 
ammonia. L-glutathione reduced, GSH (237mg) and L-glutathione oxidized, GSSG 
(50mg) were added to the mixture and this was stirred overnight. The solution was 
loaded to a RP 1 8C 18 column through A pump and washed with water until all the 
guanidine had passed through. A shallow gradient (0-70% acetonitrile in 60 mm) was 
applied. 
a. 
	 b. 	 C. 
10 	 20 	10 	 20 	10 	 20 (mm) 	 (mm) 	 (mm) 
Figure 3.4.1 HPLC traces ofpure peptide 045 (BigET-1) 
214nm, imi/min; a. Vydac C18 (size B); b. RP C8 (size B); 
c. Co-injection with native BigET-1, Vydac 08 (size B). 
The corresponding fraction collected and it was pure on analytical HPLC and 
MS was as expected (mlz found 4294.5, C 189H282N48056 S 5 requires 4283.0). Ellmam's 
test was negative and co-injection with the natural BIgET-1 confirmed that it was the 
correct product (Figure 3.4.1). 
The same procedure was applied to Peptide 18 to give peptide 018. mlz 
found 4290.0, C 189H290N48055 S 5 requires 4275.0. 
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test was negative and co-injection with the natural BigET-1 confirmed that it was the 
correct product (Figure 3.4.1). 
The same procedure was applied to Peptide 18 to give peptide 018. mlz 
found 4290.0, C 189H290N48055S5 requires 4275.0. 
3.4.7 Synthesis of FmocPen(Acm) 103 
L-Penicillamine (1.64g, 1 immol) and N-Hydroxymethylacatamide (1.17g, 
13.2mmol) were dissolved in 10% TFAIH20 (5m1). The mixture was cooled on an 
ice-bath and trifluoromethanesuiphonic acid/TFA (1:19, 30m1) added while stirring. 
After 90 minites stirring under argon, TLC (n-butanollacetic acid/H 20, 10:2:3) 
indicated that all the L-penicillamine had reacted. The solvent was removed in vacuo 
leaving an oil which was dissolving in 10% aqueous sodium carbonate (50m1) and the 
pH was adjusted to 10 by the continued addition of further aqueous sodium 
carbonate. The mixture was then cooled in an ice-bath and Fmoc-OSu (3.71g, 
lOmmol) dissolved in dioxane (SOml) added dropwise over Mr. The reaction was 
allowed to warm slowly to RT and maintained and stirred for 2 days. The pH of the 
reaction was monitored and maintained at 10 throughout. The mixture was then 
poured into H20 (200ml) washed with ether (3x50m1), acidified with 6M HCI to pH 2 
and extracted with ethyl acetate (3x5Oml). The combined ethyl acetate extracts were 
washed with 0. 1M HC1 (2xlOOml), water (2Xl00ml), and brine (2xlOOml), dried over 
MgSO4 and after filtration, solvent was evaporated in vacuo. The product was 
recrystallised from warm ethyl acetate and allowed to stand at cold room (4°C) 
overnight giving a white solid. Yield 3.Og (62%). 
5 1H NMR(CDC1 3 , 200MEIz): 1.35 (3H, s), 1.45 (3H, s), 1.95 (3H, s), 4.1-4.6 (6H, 
m), 5.85 (NH, d), 7.2-7.8 (8H, m). 
3.4.8 Deprotection of Pen(Acm) 
Pure peptide 17 (18mg, 7.74p.mol) was dissolved in 50% acetic acid (lml), 
Hg(OAc)2 (24.6mg, lOeq.) was added and stirred at RT overnight. 2-Mercapto- 
ethanol (33.7j.tl, 50eq) was added and stirred for 3hrs at RT. The mixture was 
centrifuged and the supernatant applied to HPLC which showed two peaks. The two 
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The mixture was dissolved in 6M guanidine HCl containing 1mM EDTA 
(lOmi) and 2-mercaptoethanol (20tl) was added. The mixture was stirred at RT for 
2hrs and HPLC showed that the dimer peak disappeared to give a sigle peak 
corresponding to the monomer (Figure 3.4.2). The mixture was applied to the G25 
Sephadex column and eluted with 15% acetic acid. The fraction of peptide was 
purified with HPLC (conditions in Appendix IV) to give the pure product (Figure 
3.4.2). Quantitative Ellmans' test assay gave a value of 0.92 (1.00) SH group. 
Peptide SI 7 
peptide I7 
I 	
• 	 -r 10 .2010 	
10 	 10 	
(min) 
(mm) 	
(mm) 	 (mm) 	 )	
10 
	




Figure 3.4.2 HPLC monitoring of the deprotection of the Acm from peptide 17 
214nm, imi/min, Vydac C18 (size B),a. 5mm; b. 30mm; c. 120mm; 
L after purification; e. co-injection ofpeptides 17 and Si 7. 
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3.4.9 Synthesis of BigET-1 analogues 
The sequences of the BigET- 1 analogues are listed in Appendix ifi and the 
methods used to synthesize these analogue are summarized in Table 3.4.2. The HPLC 
conditions and amino acid analysis data are listed in Appendix V. 
Table 3.4.2 Synthesis and purjfication methods for BigET-1 analogues 
Peptide 







M+lIIH average 	Fotiiid 
45 0.505 HOCt double 4569.1/4572.3 4566.1 
045 4281.0/4284.0 4294.5 
5 0.550 Triazole Double C 4682.2/4685.4 4687.0 
0.550 HOBtJDIC C 4686.5 
18 0.532 HOBtIDIC C 4556. 1/4559.3 4555.6 
018 0.532 HOBtJDIC C 4272.0/4275.0 4290.0 
7 0.489 HOCt double C 3156.6/3158.7 3155.6 
6 0.489 HOCt double C 2208.2/2209.6 2207.7 
16 0.482 HOBtIDIC C 2221.2/2222.6 2222.2 
17 0.482 HOBtJDIC C 2324.2/2325.7 2324.8 
S17 0.482 	. HOBtJDIC C 2253.1/2254.6 2253.6 
3 0.514 HOBIJDIC B 1922.0/1923.2 1922.9 
83 0.504 HOBtJDIC C 2586.2/2587.9 2588.8 
84 0.533 HOBIJDIC C 2159.1/2160.5 2157.5 
79 0.504 HOBtIDIC C 2234.1/2235.6 2235.3 
80 0.504 HOBtJDIC C 2163.1/2164.5 2165.1 
81 0.504 HOBtIDIC C 2262.1/2263.6 2264.0 
82 0.504 HOBtIDIC C 2191.2/2192.5 2191.9 
27 0.633 HOBtIDIC C 1794.0/1795.1 1794.3 
76 0.547 HOBtIDIC C 1868.9/1870.2 1870.2 
75 0.547 HOBIJDIC C 1797.9/1799.1 1800.0 
77 0.547 HOBtJDIC C 1897.0/1898.2 1899.0 
78 0.547 HOBIIDIC C 1825.9/1827.0 1826.8 
9 0.612 HOBtJDIC C 1850.0/1851.2 1851.4 
10 0.612 HOBIJDIC C 1906.1/1907.3 1907.0 
8 0.612 HOBtiDIC B 897.5/898.1 898.0 
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3.4.10 Biologcal Assays 
The biological assays of the ET-1 and BigET-1 analogues were carried out by 
the biologists at Parke Davis Pharmaceutical Research at Michigan. These are 
described below. 
3.4.10.1 Endothelin binding assays 62 
Membranes were prepared from cultured rabbit renal artery vascular smooth 
muscle (ETA) or crude cerebellar tissue from adult male blue Laurie rats (ETB). 
Incubations were performed in 12 x 75 mm polypropylene tubes containing 20 mM 
Tris, 2 mM EDTA, 100 p.M PMSF, 100 jiM bacitracin, 30pM [ 1251]ET-1 
(2000CiImmol) and 5 p.g rabbit renal artery vascular smooth muscle or 5 p.g rat 
cerebellar membranes (total volume of 250 p.L) (pH 7.4, 37°C). The order of 
additions (0°C) was as follows: test compound, [ 1251]ET-1, and membrane. Test 
compounds were diluted in a buffer (20 mM Tris, 2mM EDTA, lmg/mL BSA) to five 
times the final incubation concentration. [ 1251]ET-1 was diluted in the same buffer. 
Membranes were diluted in buffer containing 100 p.M PMSF and 100 p.M bacitracin, 
without BSA. Following the last addition, the tubes were manually agitated and 
incubated at 37 0C for 2 h. Incubations were terminated by filtration through 
Whatman GF/B filters which were presoaked with 50 mM Tris containing 0.2% BSA 
and 100 p.M bacitracin (pH 7.3, 5 °C). Nonspecific binding was defined as binding in 
the presence of 100 nM ET-1 and specific binding was defined as total binding minus 
nonspecific binding. IC 50 values were calculated by weighted nonlinear regression 
curve fitting to mass action equation. 
3.4.10.2 Aráchidonic acid release (AARB) 62 
Confluent monolayers of cultured rat cerebellum cells were incubated in 0.5 ml 
of the Loading Media (LM: Ham's Nutrient Mixture F12 and Dulbecco's Eagle 
Medium (1:1) with 0.5% fetal calf serum, and 0.25 p.Ci of [3H]-arachidonic acid 
(Amersham) per ml of media) for 18 h at 37°C in a 5% CO2/95% air atmosphere. The 
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LM was aspirated and the cells were washed once with the assay buffer (Hank's 
balanced salt solution + 10 Mm HEPES + fatty acid-free BSA(lmgIml)), and 
incubated for 5 min with 1 ml of the prewarmed assay buffer. This solution was 
aspirated, followed by an additional 1 ml of prewarmed assay buffer and further 
incubated for another 5 mm. A final 5 min incubation was carried out in a similar 
manner. The same procedure was repeated with the inclusion of 10.tl of the test 
compound (mM to 10 p.M), 10.tl of ET-1 (0.3nM) and the incubation was extended 
to 30 mm. This solution was collected, 10 ml of scintillation cocktail was added and 
the amount of [3H]-arachidonic acid was determined in a liquid scintillation counter. 
3.4.10.3 ECE inhibiting 104,105 
A reaction mixture containing 0.1 p.M BigET-1, 100mM Hepes-KOH (pH 
7.0), 50mM NaCl, 50p.M pepstatin A, 100p.M leupeptin, 200p.M 
phenylmethylsuiphonyl fluoride, indicated concentration of BigET- 1 analogue (as the 
inhibitor, DMSO for control), and the membrane fraction of CHO/human ECE-1 
cells. The final concentration of DMSO was 1.5%. After incubation for 1 hr at 37°C, 
the reaction was stopped by adding EDTA to give a final concentration of 10mM. 
This final mixture was then directly analyzed for mature ET-1 by enzyme-linked 
immumosorbant assay. 
3.4.11 CD Spectroscopy 
CD spectra of the ET analogues were recorded over the range 260 to 1 9Onm 
using a JASCO J600 spectropolarimeter. The concentrations of peptides were in the 
range of 0.06-0.27 mg/mi, and the path length was 1 mm. Samples were dissolved in 
25mM boric acid, pH 7.0 (buffer 1) or 50mM boric acid (pH 7.0) /trifluoroethanol 
(TFE) 1:1 (v/v). The secondary-structure contents were determined using the 
CONTIN procedure 8 ' and the peptide concentrations were calculated using 67210 
for peptides 1, 2, 1B, 1C, 2B, 21, 22, 24, 25, 26; 6=7090 for peptides 12-15, 
33,34,39, 40; s=6970 for peptides 36,38,5 1; and c8370 for peptide 43106 
130 
3.4.12 NMR studies 
All NMR experiments for the peptides were performed using 5mm proton 
(inverse) probe on a Varian VXR 600S (600MHz)spectrometer operating at 599.945 
MHz. The peptide samples were dissolved in a mixture of CD 30D/H20fD20 
(50:45:5) in 5mm diameter Wilmad 528PP NMR tubes. The NUR experiments were 
performed on the sample at pH 3.6 and 298K and the 1H NMIR signal of CD 30H was 
used as internal reference and defined as 3.3ppm 
The 2D phase-sensitive DQF COSY, TOCSY and NOESY NTVIIR experiments 
were performed as descibed by Hewage. 86 
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CHAPTER 4 
THE CHEMICAL SYNTHESIS OF 0)-AGATOXIN lIlA 
4.1 Introduction 
The level of intracellular Ca2 regulates many cellular processes, including neuro-
transmitter and hormone secretion, the activity of ion channels and enzymes, cytoskeletal 
function, cell proliferation, and gene expression. 1,2  Voltage-sensitive Ca2 channels are 
among the most heterogeneous of ion channels. Peptide toxins are valuable tools for the 
characterisation of ion channels.' Vertebrate voltage-sensitive Ca 2 channels have been 
classified according to biophysical and pharmacological properties, and divided into two 
broad categories: the low voltage activated type (or T-type) and the high voltage 
activated type. The latter is further classified into three subtypes (L-, N-,P-, Q-, R-type) . 3 
Numerous studies suggested that N-type Ca 2+  channels at presynaptic nerve terminals 
mediated a substantial proton of the Ca2tdependent  transmitter release in the brain. 4 
co-Agatoxins are a group of peptides isolated from the venom of the funnel-web 
spider Agelenopsis aperta. Their sequences are listed in Table 4.1.1.15  The co-agatoxins, 
as well as the somewhat smaller 0)-conotoxins, have been valuable tools in defining 
various classes of Ca2  channels. 5 '6 '7'8'9 Among these, co-agatoxin lilA (co-AgalilA) was 
of particular interest as it was the only known agent that blocked the L- and N-type Ca 2 
channels equally well. 5,10,11 
Due to the limited natural sources, an enormous effort had been made in the 
purification and isolation of the a)—agatoxins. Chemical synthesis was an alternative 
solution to this problem. At present, only the structure and biological activity of the type 
IV co-agatoxins has been well studied, 12,13,14, 15 and their disulphide patterns identified 
(Table 4.1.1). 16,17  Little is known about the six disulphide bonds which are present in the 
type ifi co-agatoxins. Synthesis of the type III co-agatoxins has never been reported. In 
fact, co-agatoxin IVA is the only co-agatoxin which has been successfully synthesised 
chemically. 16  An attempt was made in this study to synthesise co—agatoxin lilA 
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chemically. Although the product obtained was not homogenous due to uncontrolled 
disulphide bond formation, it did show some of the biological activity of native w-
agatoxin lilA. 
Table 4.1.1 The structures of w-agatoxins 
U)- .gatoxin Sequence 
a)-Aga-IA AKALP PGSVCDGNESDCKCYGKNHKCRCPWKWHFTGEGPCTCE KGMKHTC I 
TKLHCPNKAEWGIDW 
o)-Aga-11A GCIEIGGDCDGYQEKSYCQCCRNNGFCS - 
o)-Aga-111A SC IDIGGDCDGEKDDCQCCRRNGYCSCYSLFGYLKSGCKCVVGTSAEFQGI 
CRRKARQCYNSDPDKCESHNKPKRR- NH2 
The 12 Cys of 
-c ------ C ------ C-CC ----- C-C ------ ----- C-C ----------- 
co-Aga-IIIA 
co-Aga-IVA KKKC IAKDYGRCKWGGTPCCRGRGC ICS IMGTNCECKPRLIMEGLGLA 
co-Aga-I\TB EDNC IAEDYGKCTWGGTKCCRGRPCRCSMIGTNCECTPRLIMEGLSFA 
Disulphide pattern 
I'l l 
 -------  -cCc-  ------ -C ------------ 
of IVA/IVB 
4.2 The synthesis of co-agatoxin lilA 
4.2.1 Introduction 
As shown in Table 4.1.1, co-agatoxin lilA is a 76 amino acid peptide, containing 
12 cysteines that form 6 disulphide bridges. There are 10395 possible combinations for 
their formation, which means only one out of 10395 different cysteine combinations 
represents the native pairing. Thus the correct formation of these disulphide bonds is 
fundamentally the most difficult and challenging part of the chemical synthesis. 
Solid phase peptide synthesis has been discussed in previous chapters and the 
same methodologies are applied here. As mentioned in Chapter 1, folding and disulphide 
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bond formation are concomitant processes, assuming the disulphide exchange is rapid 
and reversible. Since the biologically active (native) form is the thermodynamically 
preferred conformation, hopefully, it would emerge as the major product under ideal 
folding conditions. On the other hand, even a mixture of different disulphide patterns 
would also be useful if they possessed some of the required selectivity and biological 
activity of co-agatoxin lilA. 
4.2.2 The first synthesis of co-agatoxin lilA utilising DICIHOBt coupling method 
The peptide was first synthesised utilising the DIC symmetrical anhydride and 
HOBt active ester double coupling protocol. Trt was used as the protecting group for all 
the twelve cysteines. The coupling percentage dropped dramatically at residues 
Lys39Cys40Va141Val42-----resin, and the absorption for Fmoc-piperidine adduct became too 
small after Arg20 (Figure 4.2.1). The overall yield was 4.5% according to the 
deprotection of the last amino acid which was checked manually using the formula given 
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Figure 4.2.1 The coupling of w-agatoxin 11L4 by DIC symmetrical anhydride and 
HOBt active ester methodology 
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The completed peptide resin was reacted with TbfmocCl and the Tbfrnoc-peptide 
cleaved from the resin with TFA and scavengers. The HPLC of the crude Tbfmoc 
peptide is shown in Figure 4.2.2. 
The Tbfinoc-peptide was purified by HPLC and portions which absorbed at both 
214nm and 364nm were collected. The Tbfmoc group was removed by dissolving the 
peptide in 6M guanidine.HCI containing 0. 1M Tris buffer (pH 8.5 at 37°C) and 0.2M 
DTT. The mixture was incubated at 37°C and the reaction was monitored by dual 
wavelength HPLC, which indicated that the reaction was complete in -3 h (Figure 
4.2.3). 
The mixture was chromatographed using a G50 Sephadex column and the 
peptide portions were dried by lyophilization to give the fully reduced peptide. The 
peptide was folded in 0.1 M Tris buffer in the presence of GSSG and GSH and the 
folding was monitored by HPLC (Figure 4.2.4). The fully oxidised peptide was isolated 
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Figure 4.2.2 HPLC traces of crude Thfmoc o-agatoxin 11L4, the 1st synthesis 
	
RP C8 (size A), (- 214nm, 	364nm), imlimin. 
140 
I 	 I 
10 20 
(mm) 
I 	 T- 
10 20 
(mm) 
Figure 4.2.3 HPLC monitoring of the deprotection of Thfmoc, 1st synthesis 
RP C8 (size A), (-. 214nm, .....364nm), lml/min. 
a. 10mm; b. 120mm; c.180min; it after gel filtration 
a. 
I 	 I 	 I 	• 	 I 10 20 (mm) 	 10 20 (mm) 
Figure 4.2.4 HPLC monitoring of the folding process 
RP C8 (size A), 214nm, 1 mI/mimi. 
a. 30mm; b. 2 days; c. 3 days. it after purification 
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4.2.3 The second synthesis of w-agatoxin lilA utilising HOCt coupling method 
In order to improve the yield of this peptide, a second synthesis was attempted 
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Figure 4.2.5 The coupling percentage using HOCt; 
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Figure 4.2.6 The crude Thfmoc peptide of the 2nd synthesis 
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The coupling yield dropped again at the same residues which indicated that these 
are the difficult sequences. However, an overall yield of 30% was afforded which is 25% 
better than the first synthesis where the amino acid was coupled by HOBt active ester 
and DIC symmetrical anhydride methodology. The peptide was reacted with Tbfmoc and 
the Tbfmoc-peptide cleaved as before. Comparison of the HPLC traces of the crude 
peptides from HOCt and HOBt synthesis showed that HOCt synthesis was much better 
(Figures 4.2.1 and 4.2.6). 
The crude peptide was fully denatured in 6M guanidine.HCI containing 0.2M 
DTT. The mixture was incubated at 37°C for lh and purified by G50 Sephadex gel 
filtration. The corresponding portions were collected and lyophilised. The Tbfmoc group 
was removed by incubation of the peptide in 6M guanidine.HC1 (0. 1M Tris pH 8.5, 1 m 
EDTA, 0.2M DTT) and the reaction was monitored by dual wavelength HPLC (Figure 
4.2.7). 
Figure 4.2.7 HPLC monitoring of the deprotection of Thfmoc, 2nd synthesis 
RP C8 (size A), 
(- 
214nm, 	364nm), imi/min.. 
a. 10mm; b. 60mm; c.120min; tL180min; e. after gelfiltration 
The mixture was eluted from a G50 Sephadex column and the corresponding 
portions were collected and folded in 0. 1M Tris buffer in the presence of GSSG and 
GSH. The folding process was monitored by HPLC (Figure 4.2.8) which indicated that 
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the reaction was complete in 3 days. The mixture was purified by HPLC and the peptide 
was lyophilised to give 15mg product. 
10 	 20 (mm)  10 	
20 (mm) 
Figure 4.2.8 HPLC monitoring of the oxidation and folding process 
RP C8 (size A), 214nm, imi/min.. 
a. 30mm; b. 2 days; c. 3 days. iL after purification 
4.3 Studies of the disulphide patterns 
4.3.1 Introduction 
The unambiguous assignment of the co—agatoxin disulphide bonds is critical for 
understanding the molecular basis of the biological activity. Unfortunately, no general 
method exists for elucidating disulphide connections. Sequential enzymatic and chemical 
cleavage with subsequent analysis of the disulphide bond containing fragments have been 
employed most often for localisation of disulphide connections in peptides. Success in 
utilising this methodology alone is problematic, particularly with highly folded cysteine 
rich peptides such as the o—agatoxins. This has been shown clearly in the assignment of 
the four disulphide bonds in the co—agatoxin I\TB and IVC. 16 Since twelve cysteines are 
present in the co—agatoxin lilA, the assignment of the six disulphide bonds would be even 
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more difficult. However, with the disulphide pattern of IV type co—agatoxins already 
known, efforts have been made to predict the disulphide pattern in the c0-agatoxins.' 8 As 
shown in Table 4.1.1, among the twelve cysteines in co-agatoxin lilA, eight are present in 
a very similar pattern as shown in co-agatoxin IVA (Cys 2 ' 9"8' 19' 25 ' 27' 38' 40), despite the 
dissimilarity in the sequences. Supposing the same disulphide pattern in the Type IV co-
agatoxins also applied to the co-agatoxin lilA, this still leaves 4 cysteines with three 
possible disulphide patterns, which are: 
2-19, 9-25, 18-40, 27-38, 16-67 and 52-59. 
2-19, 9-25, 18-40, 27-38, 16-52 and 59-67; 
2-19, 9-25, 18-40, 27-38, 16-59 and 52-67; 
According to a calculation based on the known data, (a) is regarded as the most 
likely pattern and (b) is the second, while (c) is the least possible.' 8 
4.3.2 Trypsin digestion of the synthetic co-agatoxin lilA 
An attempt was made to study the disulphide patterns in the synthetic peptide. 
Trypsin was chosen for the digestion of co-agatoxin lilA as it cleaves basic amino acids 
(Arg, Lys). The possible fragments with the predicted disulphide patterns are shown in 
Figure 4.3.1. 
I 	 iI.Jit 	£ 	 6 	(a) 2 9 16 18 19 	25 27 




1 	 13 14 	 20 22 	35 36 	3940 	53 5455 5758 	6667 	 747576 
I 	II' 	ii 	 I 	 I 	 I 	I 	 (c) 
2 9 	16 18 19 25 27 38 0 	52 59 67 
13 14 	 2022 	35 36 	39 40 	535455 57 58 	6667 	 747576 
Figure 4.3.1 Possible fragments by trypsin digestion with the predicted disulphide 
patterns 
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As seen in Figure 4.3.1, all fragments are connected with each other due to the 
presence of multiple disulphide connections except one in pattern (b). This means that 
two fragments can be isolated if pattern (b) is the correct pattern; and only one fragment 
can be isolated if (a) or (c) is the correct pattern. The HPLC of the enzyme digestion 
showed three major peaks and the MS of the mixture is shown in Table 4.3.1. The 
fragments were separated on HPLC, but the fractions collected failed to show any useful 
information on the MS. 
Since no MS signal corresponding to the most simple fragment connected by 
Cys59 and Cys67 , pattern (b) is unlikely to be present in the synthetic o)-Aga lilA. 
However, the most sensitive signals obtained on MS were at 1472 and 1492, which 
indicated the presence of a fragment and its sodium salt. According to the MS of the 
tryptic fragments, this signal is likely to be fragment [40-53], thus a connection between 
Cys40 and Cys52  is likely to be present, which does not corresponding to any of the 
predicted pattern. Obviously, an extensive investigation is required in order to further 
define the disulphide pattern in w—AgaIIIA. 
Table 4.3.1 The MS of enzyme digestion fragments and the possible sequences 
Possible sequences and the corresponding M 
1472.8/1492.4 40-53 (1469.7, Na 1490.7); 36-39 + 58-66 (14616) 
2141.8 1-20 (2134.8) 
2168,2189 
2299.2 1-13 + 14-21 (2309.9) or 1-21(2290.9) 
2578.7 22-3 5 + 67-74 (2560.2) 
3179.5/3189.0 36-53 + 56-66 (3141.4) 
3214/3220/3226 
4882.7 1-13 + 14-21 +22-35 + 67-74 (4870.0) 
However, it was found later that the synthetic peptide was a mixture of numerous 
conformations (Figure 4.3.3), therefore further investigations into folding and oxidation 
conditions should be carried out before a proper assignment can be made. 
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ine -> 10.00 	15.00 	20.00 	25.00 	30.00 	35.00 
Figure 4.3.3 Comparison of the synthetic and native a)-agatox:n JIM on HPL 8 
a. native o.-AgaIIIA; b. synthetic w-AgalIL4 
A: 0.1%TFA15%CH 3CN in H20, B: 0.1% TFA15% H20/CH3CN, 
Gradient (t,B%): (0,5), (30,35), (35,80). 
4.4 Biological activity of the synthetic v-agatoxin lilA 
The synthetic w-agatoxin lilA was tested in cell lines expressing recombinant R- 
2+ type Ca channels using whole-cell voltage-clamp techniques (Figure 4.4.1). The IC 50 of 
the synthetic peptide was - I .tM, while that of the native co—agatoxin lilA was 20nM. 
The binding and functional activities of the synthetic co-AgalliA for the N-type of Ca 21  
channels are 8.9nM and l70nM respectively, 47 and 27 fold less potent than that of the 
native co-AgalliA (Table 4.4.1). These results were very interesting, considering that the 
synthetic peptide was a mixture. Although the activity of the synthetic peptide was 50 
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fold less potent than the native w—agatoxin lilA, it was still potent enough, and 
potentially very useful in the biological studies. However, when this work was under the 
way, a synthetic peptide, SNX- 111, corresponding to the structure of the o-conopeptide 
MVIIA from Conus magus, was found to be highly effective neuroprotective agent in 
animal models of transient global ischemia.' 9 Therefore, this work was not carried any 
further. 
lOpMCd 2 ' 
0. 
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Figure 4.4.1 Comparison of native ai-AgaIIJA and synthetic w-AgaIIL4 (RAga) 
on R-type Cd channel currents 
Table 4.4.1 The binding and functional activity of synthetic and native w-AgaIllA 
peptide Binding Functionality 
1€ 	(ni1) IIC5o(nf1) 
Native co-AgaillA 0.19 6.2 




All general experiments were the same as described in Section 3.4.1 unless 
otherwise stated. 
4.5.2 The first synthesis of o-agatoxin lilA 
4.5.2.1 Synthesis of o-agatoxin lilA utilising IIOBtIDIC coupling method 
The loading of the commercial dibenzosuberenyl resin (0.65mmol/g) is too high 
for the synthesis of large peptides such as w-agatoxin lilA. The first amino acid was 
therefore coupled manually to reduce the initial loading. Arg(Pmc)OH (1 .Ommol) was 
dissolved in DMF and DIC (0.50mmol) was added. The mixture was sonicated at RT for 
10 mm. then added to the Fmoc deprotected dibenzosuberenyl resin (1.Og). The resulting 
mixture was sonicated for lh at RT. The loading of FmocArg(Pmc) was tested as 
described in Section 3.4.1 and it was found to be 0.223mmoIIg. 
The synthesis was carried out at 0.11 mmol  scale and the subsequent amino acids 
were coupled once as the DIC symmetrical anhydride and then as the HOBt active ester. 
The coupling efficiency was monitored by the absorption of the Fmoc-piperidine adduct 
(302nm). The Fmoc of the last amino acid was left intact in order to check the loading 
manually. 
The completed peptide resin (52.1mg) was deprotected with 20% 
piperidinefDMF (lOml) and the UV absorption at 302nm was observed (A302=0. 11). The 
loading of the last amino acid was 2.4 xlO 3mmolJg according to the formula given in 
Section 3.4.1. 
Loading =10xA302/9WtlOxO.11/9x52.12.4x10 3 mmol/g 
The theoretical loading of the peptide is 0.053mmoIIg. The overall yield is 
therefore calculated as follows: 
2.4x10 3 I 0.053 = 0.042 = 4.5% 
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4.5.2.2 Purification and folding of o-agatoxin lilA 
TbfmocCl (45.8mg, 0. immol) and DIEA (15m1, 0.09mmol) were dissolved in dry 
DCM (-.'50m1) and the peptide on resin (1.5g) was added. The mixture was sonicated at 
RT for 2h in the absence of light. The mixture was then filtered and washed with DCM, 
dioxane, and DCM again. The resin was dried and the Tbfmoc loading was tested by 
sonicating 13.8mg of the Tbfmoc resin in 20% piperidine/dioxane (1 OmI) for 1 5mm. The 
absorbance at 3 64n was 0.100 and the loading of Tbfmoc was calculated as follows: 
Loading(mmol/g) = 0.613xA364/13.8 = 0.6130.100/13.8 = 4.4x10 3 mmollg 
The resin bonded peptide was then cleaved with TFA: EDT: thioanisole: H 20 
(10:1:0.5:0.5) and 0.75g of phenol at RT for 5h. The resin was filtered off and the filtrate 
was reduced in vacuo to remove TFA. The residue was precipitated with ether, filtered 
and washed with ether. The crude peptide was purified by RP HPLC using dual wave 
length, 214nm1364nm, (RP C8, size D; Gradient (t, CH 3 CN%): (2,10), (10,30), (35,50)). 
The portions which absorbed at both wave lengths (214nnV364nm) were collected and 
lyophilised. The peptide obtained (10mg) was incubated at 37 °C in 6M guanidine.HC1,. 
containing 0. 1M Tris buffer (pH 8.5, 37°C), 1mM EDTA and DTT(50mg) to remove the 
Tbfmoc group. The reaction was monitored by dual wave length HPLC (RP C8, size B) 
and it was complete in about 3h. The mixture was chromatographed on G50 Sephadex 
column, eluting with 30% acetic acid. The peptide portions were lyophilised to give the 
fully reduced peptide (c.a. 5mg). The reduced peptide was dissolved in 6M 
guanidine.HC1 (0. 1M Tris pH8.0, 1mM EDTA, 0.5m1) and diluted rapidly into 50m1 1M 
guanidine.HC1 (0.1M Tris pH8.0, 1mM EDTA, 0.5mM GSSG / 5mM GSH). This 
solution was stirred gently at RT for 3 days until a sharp peak appeared on HPLC. The 
mixture was adjusted to pH 4.0 with acetic acid and loaded onto a RP C8 HPLC column 
through the A pump and washed with 2% CH3 CN until all the salt had eluted. A shallow 
gradient (2%-60% CH 3CN over 60 mm) was then applied. The peptide portion was 
collected and lyophilised to give the final peptide (3mg). Ellmans' test was negative. 
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4.5.3. The second synthesis of co-agatoxin IEEA 
4.5.3.1 Synthesis of co-agatoxin lILA using HOCt coupling method 
A second synthesis was carried out using HOCt double coupling methodology. 
The same FmocArg(Pmc) resin (0.5g, loading 0.223mmo1/g) was used and an overall 
coupling yield of -30% was afforded according to the Fmoc deprotection file. The 
coupling of the last amino acid was tested by sonicating the peptide resin (34.6mg) in 
20% piperidine/DMIF (lOml) for 10 mm. The UV absorption at 302nm was 0.516 and the 
loading was calculated in the same way as described in section 4.5.2 to give a final 
loading of 0.018mmol/g and an overall yield of 34%. 
4.5.3.2 Purification and folding of co-agatoxin lilA 
TbfmocCl (68.7mg, 0.15mmol) and DIEA (20pi, 0.11mmol) were dissolved in 
dry DCM (-50nil) and the peptide resin (1.6g) was added. The mixture was sonicated at 
RT for 2h in the absence of light. The mixture was then filtered and washed with DCM, 
dioxane, and DCM again. The resin was dried and the Tbfmoc loading was checked by 
sonicating 10.5mg of the resin in 20% piperidine/dioxane (lOmi) for 10mm. The 
absorbance at 364nm was 0.274. The Tbfmoc loading was calculated the same way as 
described in Section 4.5.2 to give a loading of 0.019 mmollg. 
The resin bound peptide was then cleaved with TEA: EDT: thioanisole: H 20 
(10:1:0.5:0.5) and 0.75g of phenol at RT for 5h. The resin was filtered off and TFA was 
removed in vacuo. The residue was precipitated with ether, filtered and washed with 
ether. The crude peptide was dissolved in 20m1 6M guanidine.HC1 plus DTT (200mg) 
and incubated at 37°C for lh and the mixture was chromatographed on G50 Sephadex 
column, which was eluted with 30% acetic acid. The portions which absorbed at 
wavelengths 226nm and 364nm were collected and lyophilised to give the Tbfmoc-
peptide (90mg). 
The Tbfmoc-peptide (90mg) was dissolved in 6M guanidine.HC1 (0. 1M Tris pH 
8.5, 1mM EDTA, 500mg DTT, 50mi) and incubated at 37°C to remove the Tbfmoc 
group. The reaction was monitored by dual wave length HPLC (RP C8, size B). The 
absorbance at 364nm disappeared and the peak sharpened gradually. The reaction was 
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complete in 3h and the mixture was chromatographed on a G50 Sephadex column 
eluting with 30% acetic acid. The peptide portions were collected and lyophilised to give 
50 mg crude peptide. 
The crude peptide was dissolved in 6M guanidine.HC1 (0.1M Tris pH8.0, 1mM 
EDTA, 200m1) and the milky solution was diluted rapidly into a mixture of 1M 
guanidine.HC1 (0.1M Tris pH8.0, 1mMEDTA, 0.5mM GSSG/ 5mM GSH, 500m1) with 
lOOml pure water to give a final concentration of 1M guanidine.HC1. The mixture was 
stirred gently at RT and monitored by ITPLC. Aggregation was observed after 20h, and 
further 400m1 of the same 1M guanidine.HCI solution was added. The mixture was 
stirred for another 2 days until .a sharper peak was observed on HPLC. The mixture was 
purified by HPLC under the same conditions as described in Section 4.5.2 to give 15mg 
(11%) final product. 
MS mis: found 8516.9, requires C 347H1130114S 12 : 8517.7. 
Amino acid analysis (6M HCl, 110°C, 48h): Asp/Asn 10(9.12), Thr 1(0.89), Ser 7(4.89), 
Glu/Gln 6(7.11), Pro 2(-), Gly 8(8.00), Ala 2(2.18), Cys 12(9.07), Val 2(2.13), Ile 
3(2.63), Leu 2(2.41), Tyr 4(2.39), Phe 2(2.27), His 1(1.01), Lys 7(6.66), Arg 7(6.25). 
HPLC Rt 15mm (RP C8, size A,(t,B%): (2,10), (32,90); 
HPLC Rt 15mm (Vydac C8 size B,(t,B%):(2,10), (32,90)). 
4.5.4 Enzyme digestion 
The peptide (0.5mg) was dissolved in 0.5 ml 0.1M NH 40AC (pH7.0) which 
containing 0.1mg trypsin. The mixture was incubated at 37 °C and monitored by HPLC. 
A sample of the solution (200ml) was taken after 2h and the reaction was terminated by 
addition of lOp.l 6M HC1. The remaining digest was terminated after 7h. Both samples 
were identical on HPLC and were analysed by MS. The mixture was then separated on 
analytical IHPLC (Hichrom C18, size B, 10-70% over 60 mm). The fractions were 
lyophilised but they failed to give any signal on MS. 
4.5.5 Biological assay 17 
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Appendix I Sequences of ET-1, ET-3, and full length ET-1 analogues 
fept. Structure 
1 	 5 	 10 	 15 21 
ET-3 




I 	 I 
CysSerCysSerSerLeuMetAspLysGluCysValTyrPheCysHisLeuAspl lel leTrp 
1C AibSerAibSerSerLeuNleAspLysGluAibValTyrPheAibHisLeuAspllelleTrp 
1 X SerAibSerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
lB X SerAibSerSerLeuNleAspLysGluAibValTyrPhe X HisLeuAspIleIleTrp 
2 X SerAlaSerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
2B X SerAlaSerSerLeuLeuAspLysGluAlaValTyrPhe X HisLeuAspIleIleTrp 
26 X SerAlaSerSerLeuLeuaspLysGluAibValTyrPhe X HisLeuAspI1eI1eTrp 
21 X SerAlaSerSerLeuLeuAspLysGluAibValTyrphe X HisLeuAspllelleTrp 
24 X SerAlaSerSerLeuLeuAspLysGluAibValTyrPhe X pheLeuAspllelleTrp 
22 X SerAlaSerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuaspllelleTrp 
23 X SerAlaSerSerLeuLeu.AspLysGluAibvalTyrPhe X pheLeuaspllelleTrp 
25 X SerAlaSerSerLeuLeuaspLysGluAibValTyrPhe X pheLeuAspllelleTrp 
56 AibSerAibSerSerLeuLeuAspLysGluAibvalTyrPheAibHisLeuThrMlel leTrp 
Notes: 




Amino acids in lower case italic are the D-isomers, and those in bold are replacement 
positions. 
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Appendix II Sequence of ET-1 and its truncated analogues 
Pept. 	 Structure 
1 	 5 	 10 	 15 	 21 
ET-1 CysSerCysSerSerLeuMetAspLysGlucysValTyrPheCySHiSLeUASPl lel leTrp 
	
15A 	Ser X SerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuAspIleIleTrP 
15-1 	SerAlaSerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuAspIleIleTrp 
14 	 AlaSerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
13 	 SerSerLeuLeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
12 	 SerLeuLeW½spLysGluAibValTyrPhe X HisLeuAspIleIleTrp 
11 	 LeuLeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
40 	 LeuLeu.AspLysGluAlaValTyrPhe X HisLeuAspllelleTrp 
54 	 LeuLeuAspLysGluAibValTyrPheAibHisLeuAspl lel leTrp 
47 	 LeuLeuAspLysGluAibValTyrPheAibHisLeuThrI leIleTrp 
51 	 LeuLeuAspLysGluAibValTyrPheAibHisLeuLeuI lel leTrp 
38 	 LeuLeuAspGluGluAibValTyrPheAibHisLeuThrMlel leTrp 
33 	 LeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
33A 	 AcLeuAspLysGluAibValTyrPhe X HisLeuAspllelleTrp 
72 	 LeuAlaLysGluAibValTyrPheAibHisLeuAspllelleTrP 
53 	 Le.thspLysG1uAibVa1TyrPheAibHisLeuAspI1eI leTrp 
62 	 MleAspLysGluAibValTyrPheAibHisLeuAspllel leTrp 
64 	 MleaspLysGluAibValTyrPheAibHisLeuAspIleI leTrp 
67 	 NleAspLysGluAibValTyrPheAibHisLeuAspIleIleTrP 
61 	 ValAspLysGluAibValTyrPheAibHisLeuAspI lel leTrp 
61A 	 AcValAspLysGluAibValTyrPheAibHi sLeuAspl lel leTrp 
63 	 ValaspLysGluAibValTyrPheAibHisLeuASpI lel leTrp 
63A 	 AcValaspLysGluAibValTyrPheAibHisLeuAsPIleIleTrP 
32 	 NleAspLysGluAibValTyrPhe X HisLeuAspIleIleTrp 
43 	 LeuAspLysGluAibValTyrTyr X HisLeuAspIleIleTrp 
34 	 LeuaspLysGluAibValTyrPhe X HisLeuAspIleIleTrp 
65 	 LeuAspLysGluAlaValTyrphe X HisLeuAspIleIleTrp 
(to be continued) 
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Appendix II Sequence of ET-1 and its truncated analogues 
(continued) 
Pept. Structure 
1 	 5 	 10 	 15 	 21 
52 AspLysGluAibValTyrPheAibHiSLeuASPIleIleTrP 
31 AspLysGluAibValTyrPhe X HisLeuAspIleIleTrP 
41 AspLysOluAlaValTyrPhe X HisLeuAspIleIleTrp 
41a AcAspLysGluAlaValTyrPhe X HisLeuAspIleIleTrP 
39 AspLysGlualaValTyrPhe X HisLeuAspIleIleTrp 
55 AspGluGluAibValTyrPheAibHiSLeUASPIleI leTrp 
46 AspLysGluAibValTyrPheAibHisLeuThrIleI leTrp 
50 AspLysGiuAibValTyrPheAibHiSLeULeUIleIleTrP 
66 AspLysGluAibValTyrPheAibHiSLeUMleI lel leTrp 
37 AspLysGluAibValTyrPheAibH± sLeuThrMlel leTrp 
37A AcAspLysGluAibValTyrPheAibHiSLeUThrMlel leTrp 
36 AspGluGluAibValTyrPheAibHi sLeuThrMlel leTrp 
36A AcAspGluGluAibValTyrPheAibHisLeuThrMleI leTrp 
68 aspLysGluAibValTyrPheAibHiSLeUASPIleI leTrp 
69 AsplysGluAibValTyrPheAibHisLeuASpIleIleTrP 
59 AspLysgluAibValTyrPheAibHiSLeUASPIleI leTrp 
58 AspLysGluAibvalTyrPheAibHiSLeuASPIleI leTrp 
57 AspLysGluAibVal tyrPheAibHisLeuASpIleIleTrP 
70 AspLysGluAibValTyppheAibHiSLeUASPI leIleTrp 
71 AspLysGluAibValTyrPheAibhiSLeUASPIleIleTrP 
30 LysGluAibValTyrPhe X HisLeuAspIleIleTrp 
29 GluAibValTyrPhe X HisLeuAspllelleTrp 
28 AibValTyrPhe X HisLeuAspIleIleTrp 
35A AcValTyrPhe X HisLeuAspIleIleTrP 
Notes: 




Amino acid in lower case italic are the D-isomers, and those in bold are 
replacement positions. 
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Appendix III Sequences of BigET analogues 
structure 
1 	 5 	 10 	 15 	 20 	 25 	 30 	 35 	38 	39 
BigET(45) ysSerCysSerSerLeuMetASpLysGluCysValTyrPheCy sHisLeuAspIleIleTrpValAsnThrProGluHisValValProTyrGlyLeuGlySerProArgSer 
5 
X Ser X SerSerLeUMetASPLYSG1U X ValTyrPhe X HisLeuAspIleIleTrpValAsnThrProGluHiSValValPrOTyrGlyLeULeUGlYSerPrOArgSer 
18 X Ser X SerSerLeuMetAspLySGlU X ValTyrPhe X HisLeuAspllelle W--V AsnThrProGluHisValValProTyrGlyLeuGlySerProArgSer 
S18 
cysSercsSerSerLeuMetAspLYSG1UCYSVa1TYrPheCYSHiSLP11e11e w- -v AsnThrProGluHisValValProTyrGlyLeuGlySerPrOArgSer 
7 ValTyrPhe X HisLeuAspllelle w- -v 
AsnThrProGluHisValValProTyrGlyLeuGlySerPrOArgSer 
6 









(to be continued) 
Appendix III Sequences of BigET analogues 
(continued) 
peptide structure 
1 	 5 	 10 	 15 	 20 	 25 	 30 	 35 	38 	39 
83 HisLeuAspl lel ieTrpValAsnThrProGluHisvalvalProryrGiyLeuGiyserproArgser 
84 HisLeuAspl lel ieTrpVa1AsnThrProGiuHisva1va1pro'rrGiyLeuGiy 
79 }IisLeuAspllelleTrp X AsrlThrProGluHisVaiVaiproTyrGiyLeuGiy 
80 HisLeuAspl lel leTrpCysAsnThrProGluHisvalvalproTyrGlyLeuGiy 
81 HisLeuAspllelleTrp X'AsnThrProGluHisVaiVaiproTyrGlyLeuGly 
82 HisLeuAsplie I ieTrpPenAsnThrProGluHisvaivalProTyrGlyLeuGly 
27 lie I leTrpValAsnThrProGluHisvalvalproTyrGiyLeuGiy 
76 IieIieTrp X AsnThrProGiuHisVaiVaiproTyrGlyLeuGly 
75 I lel ieTrpCysAsnThrProGiuHisVaivalproTyrGlyLeuGly 
77 IieIieTrp X' AsnThrProGiuHisVaiVaiproTyrGiyLeuGiy 
78 I lel leTrpPensnThrProG1uHisvaiva1ProTyrG1yLeuGiy 
9 I lel leTrpVaiAsnThrProGiuHisvaivalproryrGiyLeuLeu 
10 IieIleTrpVaiAsnThrProGiuHisvaivalProTyrLeuGlyLeu 
8 GluHisVaiValProTyrLeuGiyLeu 
Notes: X: Cys(Acm); X: Pen(Acm), W-V: Trp(CH 2NH)Val; Amino acids in bold are replacement positons. 
Appendix IV 
HPLC conditions and amino acid analysis data for the ET-1 analogues 
Pept. IIPLC HIPLC Amino acid analysis 
No. Analyticala Preparative" 6M HCl, 110 °C 
60 RP C18(A) RPC18(C) Asp 2(2.05), Ser 3(2.81), Glu 1(1.16), Cys 4(3.22), 
(ET-1) 18mm (60,2), (120,50). Val 1(1.03), Met 1( 0.92), lie 2(1.67), Leu 2(1.98), 
VydacClS(B) Repurified: Tyr 1(0.87), Phe 1(0.98), His 1(1.00), Lys 1(0.99). 
21min RP C18 24hrs. 
Hichrom C18 (2,10), (6,25), 
(B) 	22mm (30, 40). 
1 RP C18(A) RPC18(C) Asp 2(2.45), Ser 3(2.21), Glu 1(1.16), Cys 2(1.60), 
18mm (2,10), (10,35), Val 1(1.05), lie 2(1.65), Leu 3(2.98), Tyr 1(0.30), 
VydacCl8(B) (25,50). Phe 1(0.93), His 1(0.97), Lys 1(0.98). 40hrs: 
21mm 
lB RP C8(A) RPC18(C) Asp 2(2.01), Ser 3(2.38), Glu 1(1.17), Cys 2(1.33), 
22mm (2,10), (10,30), Val 1(0.99), lie 2(1.62), Leu 2(1.94), Nie 1(1.02), 
(25.42). Tyr 1(0.49), Phe 1(0.93), His 1(0.98), Lys 1(0.96). 
36hrs. 
1C Vydac C18(13) RPC18(C) Asp 2(1.82), Ser 3(2.70), Glu 1(1.25), Val 1(1.27), 
23mm (2,10), (10,30), lie 2(1.45), Leu 2(1.84), Tyr 1(1.00), Phe 1(0.99), 
(26,45). His 1(1.00), Lys 1(1.04), NIe 1(0.98). 36hrs 
2 Vydac C18(B) RPC18(C) Asp 2(2.07), Ser 3(2.10), Glu 1(1.04), Ala 1(0.91), 
21mm (2,10), (10,35), Cys 2(1.19), Val 1(0.96), lie 2(1.65), Leu 3(2.84), 
(22, 45). Tyr 1(0.53), Phe 1(0.90), His 1(0.98), Lys 1(0.84). 
40hrs. 
2B RP C18(A) RPCI8(C) Asp 2(2.06), Ser 3(2.15), Giu 1(1.13), Ala 2(1.88), 
22mm (2,10), (10,30), Cys 2(1.41), Val 1(1.18), lie 2(1.83), Let' 3(3.00), 
(25,40). Tyr 1(0.28), Phe 1(1.00), His 1(1.04), Lys 1(1.04). 
40hrs. 
21 RP C8(A) RPC18(C) Asp 2(2.01), Ser 3(2.59), Giu 1(1.13), Ala 1(0.99), 
18mm (2,10), (10,30), Cys 2(1.51), Val 1(1.01), lie 2(1.19), Let' 3(2.97), 
(24,38). Tyr 1(0.61), Phe 1(0.97), His 1(1.01), Lys 1(1.01). 
______  30hrs.
22 Vydac C18(B) RPC18(C) Asp 2(2.03), Ser 3(2.40), Glu 1(1.16), Ala 1(0.99), 
18mm (2,10), (10,30), Cys 2(1.14), Val 1(0.94), lie 2(1.36), Leu 3(2.76), 
(24,38). Tyr 1(0.65), Phe 1(0.98), His 1(0.91), Lys 1(0.92). 
30hrs. 
23 RP C18(A) RPC18(C) Asp 2(2.10), Ser 3(2.44), Glu 1(1.19), Ala 1(0.98), 
20mm (2,10), (10,30), Cys 2(1.53), Val 1(1.07), lie 2(1.20), Leu 3(2.94), 
(26,45). Tyr 1(0.61), Phe 2(2.08), Lys 1(1.04). 30hrs. 
24 RP C18(A) Vydac C18(D) Asp 2(2.03), Ser 3(2.60), Glu 1(1.02), Ala 1(1.11), 
20mm (2,10), (12,40), Cys 2(1.34), Val 1(1.07), lie 2(1.59), Leu 3(2.92), 
(22,58). Tyr 1(0.41), Phe 2(1.89), Lys 1(1.01). 30hrs. 
25 RP C18(A) Vydac C18(D) Asp 2(2.02), Ser 3(2.24), Glu 1(1.12), Ala 1(1.05), 
18mm (2,10), (10,50), Cys 2(1.24), Val 1(1.04), lie 2(1.47), Leu 3(2.88), 
(18,57). Tyr 1(0.53), Phe 2(1.95), Lys 1(1.02). 30hrs. 
26 RP C18(A) RPC18(C) Asp 2(2.09), Ser 3(2.32), Glu 1(1.15), Ala 1(1.02), 
18mm (2,10), (10,35), Cys 2(1.30), Val 1(0.99), Ile 2(1.54), Leu 3(2.83), 
(25,45). Tyr 1(0.57), Phe 1(0.92), His 1(1.01), Lys 1(1.01). 
30hrs. 
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56 Hichrom C18 RPC18(C) Asp 1(0.91), Ser 3(2.70), Glu 1(1.25), Val 1(1.27), 
(B) 	20mm (2,10), (10,30), lie 1(0.97), Leu/lvlle 4(3.64), Tyr 1(1.00), Phe 
(32,50) 1(0.99), His 1(1.00), Lys 1(1.04), Me 1(0.98). 
36hrs 
iSA PP C18(A) RPC18 Asp 2(2.05), Ser 3(2.40), Glu 1(1.16), Cys 2(1.18), 
18nun (2,10), (10,30), Val 1(0.98), lie 2(1.42), Leu 3(2.86), Tyr 1(0.65), 
(26,42) Phe 1(1.01), His 1(0.99), Lys 1(0.98). 48hrs. 
15-1 RP C18(A) RPC18(C) Asp 2(2.01), Ser 3(2.47), Glu 1(0.85), Ala 1(0.93), 
18mm (2,10), (10,30), Cys 1(0.48), Val 1(1.33), lie 2(1.60), Leu 3(3.00), 
(8),(27,43). Tyr 1(0.87), Phe 1(1.01), His 1(1.04), Lys 1(0.98). 
48hrs. 
14 PP C18(A) RPC18(C) Asp 2(2.03), Ser 2(1.61), Glu 1(0.94), Ala 1(1.08), 
18mm (2,10), (10,30), Cys 1(0.82), Val 1(1.23), lie 2(1.82), Leu 3(3.09), 
(24,50). 	. Tyr 1(0.83), Phe 1(0.97), His 1(1.03), Lys 1(0.96). 
24hrs. 
13 PP C18(A) RPC18(C) Asp 2(2.00), Ser 2(1.52), Giu 1(0.86), Cys 1(0.57), 
18mm (2,10), (10,30), Val 1(1.27), lie 2(1.65), Leu 3(2.99), Tyr 1(0.82), 
(24,50). Phe 1(0.94), His 1(1.03), Lys 1(0.96). 24hrs. 
12 PP C18(A) RPC18(C) Asp 2(2.07), Ser 1(0.78), Giu 1(1.02), Cys 1(0.27), 
18mm (2,10), (10,30), Val 1(1.17), lie 2(1.75), Leu 3(2.86), Tyr 1(0.88), 
(24,50). Phe 1(1.03), His 1(1.04), Lys 1(0.99). 24hrs. 
11 PP C18(A) RPC18(C) Asp 2(2.08), Glu 1(0.83), Cys 1(0.74), Val 1(1.29), 
18mm (2,10), (10,30), lie 2(1.61), Leu 3(3.01), Tyr 1(0.72), Phe 1(1.04), 
(24,50). His 1(1.07), Lys 1(1.08). 24hrs. 
40 PP C18(A) RPC18(C) Asp 2(1.99), Glu 1(1.36), Ala 1(1.00), Cys 1(0.77), 
16mm (2,10), (10,28), Val 1(1.01), lie 2(1.56), Leu 3(2.88), Tyr 1(0.63), 
(26,43). Phe 1(1.03), His 1(0.89), Lys 1(1.10). 26hrs. 
54 PP C18(A) RPC18(C) Asp 2(1.98), Giu 1(1.19), Val 1(0.99), lie 2(1.16), 
19mm (2,10), (10,30), Leu 3(3.02), Tyr 1(0.99), Phe 1(0.99), His 1(1.05), 
(28,38). Lys 1(1.01). 24hrs. 
47 RP C18(A) RPC18(C) Asp 1(0.98), Thr 1(1.03), Glu 1(1.21), Val 1(1.01), 
20mm (2,10), (8,26), lie 2(1.24), Leu 3(3.04), Tyr 1(0.99), Phe 1(1.00), 
(30,40). His 1(1.05), Lys 1(1.01). 24hrs. 
51 PP C18(A) RPC18(C) Asp 1(0.96), Giu 1(1.16), Val 1(0.99), lie 2(1.32), 
19mm (2,10), (10,32), Leu 4(3.92), Tyr 1(0.89), Phe 1(0.99), His 1(1.03), 
(26,43). Lys 1(1.00). 24hrs. 
38 PP C18(A) RPC18(C) Asp 1(1.04), Thr 1(1.02), Glu 2(2.31), Val 1(0.98), 
19mm (2,10), (10,32), lie 1(0.91), LeuIMle 4(3.50), Tyr 1(1.00), Phe 
(28,44). 1(1.01), His 1(1.00). 20hrs. 
33 PP C18(A) RPC18(C) Asp 2(2.21), Giu 1(1.23), Cys 1(0.60), Val 1(1.09), 
16mm (2,10), (10,25), lie 2(1.47), Leu 2(1.94), Tyr 1(0.94), Phe 1(1.04), 
(22,35). His 1(1.01), Lys 1(1.01). 20hrs. 
33A RP C18(A) RPC18(C) Asp 2(1.96), Glu 1(1.20), Cys 1(0.83), Val 1(1.03), 
20mm (2,10), (10,28), lie 2(1.34), Leu 2(1.94), Tyr 1(0.84), Phe 1(1.03), 
(24,38). His 1(1.00), Lys 1(1.01). 20hrs. 
72 PP C18(A) RPC18(C) Asp 1(1.08), Glu 1(1.21), Ma 1(1.03), Val 1(1.02), 
24n-tin (2,10), (10,28), lie 2(1.38), Leu 2(1.97), Tyr 1(0.91), Phe 1(1.01), 
(24,38). His 1(0.99), Lys 1(1.03). 20hrs. 
53 Vydac C18(B) RPC18 Asp 2(2.18), Glu 1(1.21), Val 1(1.04), lie 2(1.49), 
20mm (2,10), (10,28), Leu 2(1.96), Tyr 1(0.93), Phe 1(1.03), His 1(0.99), 
(30,40). Lys 1(1.02). 20hrs. 
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62 RP C18(A) RPC18(C) Asp 2(2.13), Glu 1(1.17), Val 1(0.99), He 2(1.52), 
16mm (2,10), (10,30), LeuJMle 2(1.92), Tyr 1(0.91), Phe 1(1.00), His 
Hichrom C18 (26,40). 1(1.00), Lys 1(0.99). 20hrs. 
(B) 	20mm 
64 RP C18(A) RPC18(C) Asp 2(2.09), Glu 1(1.21), Val 1(0.99), lie 2(1.43), 
17mm (2,10), (10,30), Leu/Ivlle 2(1.89), Tyr 1(0.88), Phe 1(1.00), His 
Hichrom C18 (26,40). 1(1.02), Lys 1(1.01). 20hrs. 
20mm 
67 Hichrom C18 RPC18(C) Asp 2(2.21), Glu 1(1.16), Val 1(1.00), lie 2(1.44), 
(B) 	20mm (2,10), (10,28), Leu 1(0.98), Me 1(0.96), Tyr 1(0.89), Phe 1(1.01), 
(26,40). His 1(0.99), Lys 1(0.98). 20hrs. 
61 RI' C18(A) RPC18(C) Asp 2(2.20), Giu 1(1.21), Val 2(2.03), lie 2(1.42), 
18mm (2,10), (10,28), Leu 1(0.98), Tyr 1(0.90), Phe 1(0.98), His 1(1.0 1), 
(28,40). Lys 1(0.98). 24hrs. 
61A RP C18(A) RPC18(C) Asp 2(2.18), Giu 1(1.12), Val 2(2.04), lie 2(1.39), 
20mm (2,10), (10,30), Leu 1(0.99), Tyr 1(0.88), Phe 1(1.01), His 1(1.02), 
(28,42). Lys 1(0.99). 24hrs. 
63 Hichrom C18 RPC18(C) Asp 2(2.13), Giu 1(1.18), Val 2(1.98), Ile 2(1.41), 
(B) 	17mm (2,10), (10,32), Leu 1(0.99), Tyr 1(0.92), Phe 1(0.98), His 1(1.00), 
(28,43). Lys 1(0.99). 24hrs. 
32 RP C18(A) RPC18(C) Asp 2(1.97), Glu 1(1.13), Cys 1(0.81), Val 1(0.99), 
17mm (2,10), (8,25), lie 2(1.37), Leu 1(0.93), Me 1(0.97), Tyr 1(0.86), 
(26,38). Phe 1(0.96), His 1(0.96), Lys 1(0.99). 20hrs. 
43 Vydac C18(13) RPC18 Asp 2(2.03), Glu 1(1.23), Cys 1(0.84), Val 1(0.99), 
16mm (2,10), (10,28), lie 2(1.42), Leu 2(1.98), Tyr 2(1.68), His 1(0.97), 
(26,35). Lys 1(1.00). 20hrs. 
34 Vydac C18(B) RPC18(C) Asp 2(2.05), Glu 1(1.20), Cys 1(0.82), Val 1(1.03), 
17mm (2,10), (10,28), lie 2(1.37), Leu 2(1.99), Tyr 1(0.82), Phe 1(1.03), 
(26,36). His 1(1.0 1), Lys 1(1.02). 2Ohrs. 
65 Hichrom C18 RPCI8(C) Asp 2(1.96), Glu 1(1.16), Cys 1(0.76), Val 1(1.02), 
(B) 	20mm (2,10), (10,30), lie 2(1.46), Leu 2(1.98), Tyr 1(0.79), Phe 1(0.99), 
(27,48). His 1(1.01), Lys 1(1.02). 20hrs. 
52 RI' C18(A) RPC18 Asp 2(2.18), Glu 1(1.21), Val 1(1.04), lie 2(1.49), 
16mm (2,10), (10,28), Leu 1(0.99), Tyr 1(0.93), Phe 1(1.03), His 1(0.99), 
(24,38). Lys 1(1.02). 20hrs. 
39 Vydac C18(B) RPC18(C) Asp 2(1.22), Glu 1(1.14), Ala 1(1.13), Cys 1(0.81), 
19mm (2,10), (10,28), Val 1(1.08), lie 2(1.48), Leu 1(1.10), Tyr 1(0.67), 
(30,40). Phe 1(1.04), His 1(1.02), Lys 1(1.01). 30hrs. 
31 HP C18(A) RPC18(C) Asp 2(1.91), Glu 1(1.15), Cys 1(0.95), Val 1(1.01), 
18mm (2,10), (8,25), lie 2(1.29), Leu 1(0.99), Tyr 1(0.84), Phe 1(0.97),  
(22,33) His 1(0.97), Lys 1(0.99). 20hrs. 
41 RP C18(A) RPC18(C) Asp 2(2.01), Glu 1(0.80), Ma 1(1.20), Cys 1(0.72), 
18mm (2,10), (10,30), Val 1(1.00), lie 2(1.43), Leu 1(1.00), Tyr 1(0.60), 
Hichrom C18 (25,42) Phe 1(0.93), His 1(0.91), Lys 1(0.90). 36hrs. 
(B) 	19mm 
41A HP C18(A) RPC18(C) Asp 2(1.94), Glu 1(1.13), Ma 1(0.94), Cys 1(0.88), 
20mm (2,10), (10,30), Val 1(1.0 1), lie 2(1.24), Leu 1(1.02), Tyr 1(0.76), 
(28,45) Phe 1(0.98), His 1(1.02), Lys 1(1.00). 30hrs. 
50 HP C18(A) RPC18(C) Asp 1(1.06), G!u 1(1.16), Val 1(0.94), lie 2(1.22), 
18mm (2,10), (10,32), Leu 2(1.90), Tyr 1(0.95), Phe 1(0.98), His 1(1.02), 
(24,43) Lys 1(0.97). 20hrs. 
46 HP C18(A) RPC18 Asp 1(1.08), Thr 1(1.05), Glu 1(1.18), Val 1(1.00), 
19imn (2,10), (8,26), lie 2(1.42), Leu 1(0.98), Tyr 1(0.93), Phe 1(1.01), 
(30,40) His 1(0.99), Lys 1(1.02). 20hrs. 
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66 RI' C18(A) RPC18(C) Asp 1(1.03), Glu 1(1.20), Val 1(1.00), lie 2(1.54), 
20mm (2,10), (10,34), LeuIMie 2(1.89), Tyr 1(0.91), Phe 1(1.00), His 
Hichrom C18 (30,45) 1(0.99), Lys 1(1.04). 20hrs. 
(B) 	18mm 
55 Vydac C18(3) RPC18(C) Asp 2(1.90), Glu 2(2.29), Val 1(0.99), lie 2(1.19), 
17mm (2,10), (10,28), Leu 1(1.03), Tyr 1(0.99), Phe 1(0.97), His 1(1.04). 
(25,38) 20hrs. 
37 Vydac C18(B) RPC18(C) Asp 1(1.00), Thr 1(1.07), Glu 1(1.20), Val 1(1.00), 
17mm (2,10), (10,30), lie 1(0.94), LeulMie 2(1.89), Tyr 1(1.00), Phe 
(25,40) 1(1.00), His 1(0.99), Lys 1(1.05). 20hrs. 
37A Vydac C18(3) RPC18(C) Asp 1(1.16), Thr 1(1.18), Giu 1(1.22), Val 1(1.00), 
21mm (2,10), (10,32), lie 1(0.98), LeuIMle 2(1.92), Tyr 1(1.01), Phe 
(26,42) 1(0.99), His 1(0.97), Lys 1(1.00). 20hrs. 
36 Vydac C18(B) RPC18(C) Asp 1(0.98), Thr 1(1.02), Glu 2(2.34), Vat 1(1.01), 
18mm (2,10), (10,32), lie 1(0.95), LeulMie 2(1.89), Tyr 1(0.93), Phe 
(22,42) 1(0.99), His 1(1.00). 20hrs. 
36A Vydac C18(B) RPC18(C) Asp 1(0.96), Thr 1(1.04), Giu 2(2.30), Vat 1(0.93), 
20mm (2,10), (10,32), lie 1(0.98), Leu/Mle 2(1.92), Tyr 1(0.91), Phe 
(26,46) 1(0.98), His 1(1.00). 20hrs. 
68 RI' C18(A) RPC18 Asp 2(2.08), Giu 1(1.21), Vat 1(1.04), lie 2(1.45), 
23mm (2,10), (10,30), Leu 1(0.97), Tyr 1(0.87), Phe 1(1.02), His 1(0.99), 
(25,40) Lys 1(1.01). 20hrs. 
69 RI' C18(A) RPC18 Asp 2(2.02), Giu 1(1.18), Vat 1(1.02), lie 2(1.48), 
19n-d (2,10), (10,30), Leu 1(0.98), Tyr 1(0.85), Phe 1(1.01), His 1(1.00), 
(25,40) Lys 1(1.01). 20hrs. 
59 Hichrom C18 RI'C18 Asp 2(1.98), Giu 1(1.22), Vat 1(1.05), lie 2(1.42), 
(B) 	17mm (2,10), (10,32), Leu 1(0.99), Tyr 1(0.81), Phe 1(0.99), His 1(1.00), 
(27,43) Lys 1(1.01). 20hrs. 
58 Hichrom C18 RPC18 Asp 2(2.07), Giu 1(1.19), Vat 1(1.02), lie 2(1.38), 
(B) 	18mm (2,10), (10,32), Leu 1(1.00), Tyr 1(0.81), Phe 1(1.00), His 1(0.99), 
(26,42) Lys 1(1.01). 20hrs. 
57 Hichrom C18 RPC18 Asp 2(2.13), Giu 1(1.20), Vat 1(1.04), lie 2(1.40), 
(B) 	18mm (2,10), (10,28), Leu 1(0.99), Tyr 1(0.87), Phe 1(1.01), His 1(0.99), 
(26,38) Lys 1(1.00). 20hrs. 
70 Hichrom C18 VydacC18(D) Asp 2(2.04), Giu 1(1.24), Val 1(1.02), lie 2(1.35), 
(B) 	22mm (2,10), (10,32), Leu 1(0.98), Tyr 1(0.93), Phe 1(1.02), His 1(1.00), 
(28,45) Lys 1(1.01). 20hrs. 
71 Hichrom C18 RPC18(C) Asp 2(2.08), Giu 1(1.22), Vat 1(1.03), lie 2(1.46), 
(B) 	24mm (2,10), (10,28), Leu 1(1.00), Tyr 1(0.84), Phe 1(1.02), His 1(0.99), 
(26,40) Lys 1(1.01). 20hrs. 
30 RP C18(A) RPC18(C) Asp 1(0.99), Giu 1(1.11), Cys 1(0.83), Val 1(1.01), 
17mm (2,10), (10,25), lie 2(1.32), Leu 1(0.96), Tyr 1(0.82), Phe 1(0.98), 
(24,36) His 1(0.99), Lys 1(0.99). 20hrs. 
29 RP C18(A) "C18(C) Asp 1(1.04), Giu 1(1.11), Cys 1(0.78), Val 1(0.96), 
17mm (2,10), (10,25), Ile 2(1.35), Leu 1(0.97), Tyr 1(0.83), Phe 1(0.95), 
(25,38) His 1(0.95). 20hrs. 
28 RP C18(A) RPCI8(C) Asp 1(0.98), Cys 1(0.93), Vat 1(0.97), lie 2(1.39), 
17mm (2,10), (10,28), Leu 1(1.01), Tyr 1(0.83), Phe 1(1.00), His 1(1.00). 
(26,40). 20hrs. 
35A Vydac C18(B) RPC18(C) Asp 1(0.98), Cys 1(0.76), Val 1(1.04), lie 2(1.45), 
22min (2,10), (10,28), Leu 1(0.99), Tyr 1(0.88), Phe 1(1.01), His 1(0.99). 
(30,40). 20hrs. 
Notes: a. Analytical column and retention time; 
b. Gradient in (t,B%) 
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Appendix V 
HPLC conditions and amino acid analysis data for the BigET-1 analogues 
Pept. IIPLC BIPLC Amino Acid Analysis 
No. Analytical- Preparative 6M HCl, 110°C 
45 PP C8 RP C18 Asp 3(2.73), Thr 1(0.98), Set 5(3.83), Glu 2(2.18), 
16mm (2,10), (10,30), Pro 3(3.25), Gly 2(2.14), Cys 4(2.59), Val 4(4.33), 
Vydac C18 (28, 40). Met 1(0.64), lie 2(1.53), Leu 3(2.96), Tyr 2(0.92), 
17min Phe 1(1.03), His 2(1.98), Lys 1(1.00), Arg 1(0.99). 
48hrs. 
045 RP C8 PP C8 Asp 3(3.23), Thr 1(1.02), Set 5(4.13), Giu 2(2.15), 
(BET) 16mm (60,2), (120, 60) Pro 3(3.20), Gly 2(2.10), Cys 4(2.45), Val 4(4.24), 
Vydac C18 Repurified: Met 1(0.71), lie 2(1.49), Leu 3(2.98), Tyr 2(1.01), 
l7min PP C8 Phe 1(1.06), His 2(2.01), Lys 1(1.01), Arg 1(1.00). 
(2,10), (6,25), 48hrs. 
(20, 38).  
5 PP C8(A) RPC18(C) Asp 3(2.79), Thr 1(0.97), Ser 5(3.57), Giu 2(2.03), 
18mm (2,10), (10,33), Pro 3(3.32), Gly 2(2.16), Cys 4(2.29), Val 4(4.41), 
(22,43). Met 1(0.69), lie 2(1.63), Leu 4(3.86), Tyr 2(0.87), 
Phe 1(1.12), His 2(1.99), Lys 1(0.99), Arg 1(0.99). 
48hrs. 
18 PP C18(A) RPC18(C) Asp 3(2.98), Thr 1(0.93), Ser 5(3.62), Glu 2(2.35), 
18mm (2,10), (38,50). Pro 3(3.36), Giy 2(1.99), Cys 4(1.98), Val 3(2.97), 
PP C8(A) Met 1(0.78), lie 2(1.39), Leu 3(2.94), Tyr 2(0.77), 
16min Phe 1(1.09), His 2(1.98), Lys 1(1.01), Arg 1(1.06). 
48hrs. 
018 PP C18 RP C18 Asp 3(2.92), Thr 1(0.95), Ser 5(3.78), Glu 2(2.33), 
17mm (60, 0), (110, 60). Pro 3(3.21), Gly 2(1.99), Cys 4(1.90), Val 3(3.02), 
PP C8 Repurified: Met 1(0.86), lie 2(1.19), Leu 3(2.89), Tyr 2(0.47), 
16niin RP C18 Phe 1(1.21), His 2(1.91), Lys 1(1.01), Arg 1(1.08). 
(2,10), (40,55). 48hrs. 
7 PP C18(A) RPC18(C) Asp 2(1.89), Thr 1(0.94), Ser 2(1.73), Glu 1(1.12), 
17mm (2,10), (10,30), Pro 3(3.34), Giy2(2.00), Cys 1(0.31), Val 3(2.70), 
(26,42). lie 2 (1.26), Leu 2(2.00), Tyr 2(1.64), Phe 1(1.01), 
His 2(1.99), Arg 1(1.09). 20hrs. 
6 RP C18(A) RPC18(C) Asp 1(0.94), Thr 1(0.98), Ser 2(1.79), Glu 1(1.17), 
16mm (2,10), (10,25), Pro 3(3.84), Giy 2(2.10), Val 2(1.76), lie 2(0.96), 
(25,40). Leu 1(1.07), Tyr 1(1.05), His 1(1.03), Arg 1(0.97). 
20hrs. 
16 PP C18(A) RPC18(C) Asp 1(0.99), Thr 1(0.92), Set 2(1.63), Giu 1(1.06), 
14mm (2,10), (26,35). Pro 3(2.71), Giy 2(2.04), Val 3(2.73), lie 2(l.31), 
Leu 1(1.02), Tyr 1(0.98), His 1(1.01), Arg 1(0.97). 
30hrs. 
17 PP C18(A) RPC18(C) Asp 1(1.09), Thr 1(0.94), Ser 2(1.78), Gin 1(1.00), 
14mm (2,10), (26,35). Pro 3(2.98), Giy 2(2.21), Val 2(1.99), lie 2(1.04), 
Leu 1(1.02), Tyr 1(0.90), His 1(1.05), Arg 1(0.96). 
30hrs. 
S17 RPC18(A) RPC18(C) 
14mm (2,10), (30,40). as pept. 17, not tested 
3 PP C18(A) RPC18(C) Asp 1(0.99), Thr 1(0.83), Ser 2(1.28), G!u 1(1.19), 
14mm (2,10), (28,42). Pro 3(3.57), Giy 2(1.92), Val 3(2.81), Leu 2(1.96), 
 Tyr 1(0.89), His 1(0.99), Arg 1(0.99). 20hrs. 
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Pept. HPLC IIPLC Amino Acid Analysis 
No. Analytical' Preparative" 6M HCI, 110 °C 
83 Hichrom C18 RPC18(C) Asp 2(1.89), Thr 1(0.97), Ser 2(1.87), Glu 1(1.13), 
(B) 	20mm (2,10), (10,28), Pro 3(3.32), Gly 2(2.06), Val 3(3.21), lie 2(1.63), 
(25,40). Leu 2(1.89), Tyr 1(0.47), His 2(1.99), Arg 1(0.99). 
48hrs. 
84 Hichrom C18 Vydac C18(D) Asp 2(1.91), Thr 1(0.98), Glu 1(1.12), Pro 2(2.12), 
(B) 	16mm (2,10), (10,30), Gly 2(2.07), Val 3(3.12), Ile 2(1.63), Leu 2(1.91), 
(20,38). Tyr 1(0.54), His 2(1.99). 40hrs. 
79 Hichrom C18 RPC18(C) Asp 2(1.98), Thr 1(0.97), Glu 1(1.15), Pro 2(2.05), 
(B) 	18mm (2,10), (10,25), Gly 2(2.04), Cys 1(0.76), Val 2(1.97), lie 2(1.59), 
(21,33). Leu 2(1.97), Tyr 1(0.89), His 2(1.98). 24hrs. 
80 Hichrom C18 RPC18(C) Asp 2(2.02), Thr 1(0.98), Glu 1(1.21), Pro 2(2.10), 
16mm (2,10), (10,25), Gly 2(2.08), Cys 1(0.65), Val 2(1.98), lie 2(1.56), 
(22,31). Leu 2(1.98), Tyr 1(0.87), His 2(1.98). 24hrs. 
81 Hichrom C18 RPC18(C) Asp 2(2.04), Thr 1(0.97), Glu 1(1.23), Pro 2(2.11), 
(B) 	19mm (2,10), (10,25), Gly 2(2.06), Val 2(2.02), lie 2(1.48), Leu 2(1.98), 
(20,33). Tyr 1(0.83), His 2(1.99). 24hrs. 
82 IlichromCl8 RPC18(C) - 
(B) 	20mm (60,2), (72,30), as pept. 81, not tested 
(82,38).  
27 PP C18(A) RPC18(C) Asp 1(0.99), Thr 1(0.97), Glu 1(1.10), Pro 2(1.98), 
(B) 	18mm (2,10), (10,28), Gly 2(2.07), Val 3(2.89), lie 2(1.74), Leu 1(1.06), 
(16,33). Tyr 1(1.04), His 1(0.97). 30hrs. 
76 Hichrom C18 RPC18(C) Asp 1(1.02), Thr 1(0.98), Glu 1(1.18), Pro 2(2.01), 
(B) 	18mm (2,10), (8,22), Gly 2(2.06), Cys 1(0.68), Val 2(1.98), lie 2(1.54),  
(24,31). Leu 1(1.02), Tyr 1(0.96), His 1(0.99). 24hrs. 
75 Hichrom C18 RPC18(C) Asp 1(0.98), Thr 1(0.97), Giu 1(1.13), Pro 2(2.01), 
(B) 	18mm (2,10), (8,22), Giy 2(2.05), Cys 1(0.76), Val 2(1.97), lie 2(1.64),  
(24,31). Leu 1(1.02), Tyr 1(0.97), His 1(0.98). 24hrs. 
77 Hichrom C18 RPC18(C) Asp 1(1.06), Thr 1(0.92), Glu 1(1.19), Pro 2(2.13), 
(B) 	18mm (2,10), (8,22), Gly 2(2.05), Val 2(1.98), Ile 2(1.47), Leu 1(1.02), 
(28,33). Tyr 1(0.91), His 1(1.00). 24hrs. 
78 Hichrom C18 RPC18(C) 
(B) 	16mm (60,2), (68,28), as pept 77, not tested 
(83,42).  
9 PP C18 RPC18(C) Asp 1(1.01), Thr 1(1.02), Glu 1(1.00), Pro 2(1.67), 
18mm (2,10), (28,50). Gly 1(1.12), Val 3(2.89), lie 2(1.54), Leu 2(2.06), 
Tyr 1(0.97), His 1(1.09). 20hrs. 
10 PP C18(A) RPC18 Asp 1(1.03), Thr 1(0.95), Glu 1(0.74), Pro 2(1.68), 
18mm (2,10), (28,50). Val 3(3.14), Ile 2(1.70), Leu 3(3.14), Tyr 1(0.99), 
His 1(1.01). 20hrs. 
8 RP C18(A) RPC18(C) Glu 1(1.09), Pro 1(0.96), Gly 1(1.07), Val 2(1.96), 
15mm (2,10), (28,35). Leu 2(2.06), Tyr 1(0.86), His 1(1.06). 20hrs. 
Notes: a. Analytical column and retention time; 
b. Gradient in (t,B%) 
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